Treatment of warts

Standardized Candida albicans-based compositions for intralesional injections address the variability in wart treatments by ensuring effective wart elimination and recurrence prevention through controlled dosages, achieving significant wart reduction and sustained disappearance.

JP2024164177AActive Publication Date: 2024-11-26NIELSEN BIOSCIENCES INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024143365
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-07-31
Filing Date
2024-08-23
Publication Date
2024-11-26
Estimated Expiration
2039-08-05

AI Technical Summary

Technical Problem

Current treatments for common warts, such as topical salicylic acid, cryotherapy, and immunotherapy using Candida albicans antigens, vary in effectiveness and often result in recurrence due to inconsistent dosages and sources of Candida antigen, lacking standardized potency.

Method used

Development of pharmaceutical compositions comprising filtered extracts of Candida albicans and secreted antigens with standardized potency for intralesional injections to treat common warts, administered in specific cumulative doses to achieve complete or partial disappearance, reduce wart diameter, or delay recurrence.

Benefits of technology

The compositions effectively eliminate or reduce warts and delay their recurrence by standardized doses, reducing wart diameter by at least 50% and lowering inflammatory cytokine levels like IL-23, IL-7, and IP-10, with complete disappearance maintained for at least 20 weeks post-treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024164177000001_ABST
    Figure 2024164177000001_ABST
Patent Text Reader

Abstract

To provide therapeutics having a standardized potency for the complete resolution of common warts and for the prevention of recurrence of common warts, and therapeutic methods.SOLUTION: The present invention provides a method for administering, to a subject in need of common wart treatment, a pharmaceutical composition comprising a filtered extract of Candida albicans and secreted antigens at a cumulative dose of 2.5 units of potency through one or more intralesional injections.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 62 / 714,942, filed August 6, 2018, and U.S. Provisional Application No. 62 / 880,742, filed July 31, 2019, each of which is incorporated by reference in its entirety. [Technical field]

[0002] The present disclosure relates to a treatment with standardized potency for the complete disappearance of common warts and for the prevention of recurrence of common warts. [Background technology]

[0003] Common warts are infections of the skin caused by the human papillomavirus (HPV). The virus initially targets the epidermal basal cells, inducing hyperplasia and hyperkeratosis, which clinically manifest as warts. Common warts are not life-threatening, but can cause both physical discomfort and embarrassment to patients.

[0004] The overall prevalence of common warts in the United States is estimated to be 2-20%. However, current treatment options for common warts vary in effectiveness and frequently result in recurrence. Treatments including topical salicylic acid, topical imiquimod, bleomycin injections, cryotherapy, excision, electrocautery, and laser vaporization are used with variable results and side effects.

[0005] Immunotherapy with Candida albicans antigens has also been studied; however, variable response levels have been reported (see Aldahan AS et al., “Efficacy of intralesional immunotherapy for the treatment of warts: A review of the literature,” Dermatologic Therapy 2016;29:197-207, Table 1; and Alikhan A et al., “Use of Candida antigen injections for the treatment of verruca vulgaris: A two-year mayo clinic experience,” Journal of Dermatological Treatment 2016;27(4):355-58, 355, Table 2). The inconsistent results may be due to the use of different sources of Candida antigens in these studies, with apparently different concentrations and potencies. For example, two studies used Candida antigens obtained from Hollister-Stier (Alikan et al. at 355 and Perman M et al., “The painful purple digit: an alarming complication of Candida albicans antigen treatment of recalcitrant warts,” Dermatitis: Contact, Atopic, Occupational, Drug 2005;16(1):38-40 (cited in Aldahan et al.)), and another study used Candida antigens obtained from Bayer (Johnson et al., “Intralesional injection of mumps or candida skin test antigens: a novel immunotherapy for warts,” Arch Dematol. 2001;137:451-55 (Aldahan et al. and Alikhan et al., cited in Aldahan et al. and Alikhan et al.), another study used Candida antigen obtained from Creative Drug Industries (Majid I and Imran S, “Immunotherapy with Intralesional Candida Albicans Antigen in Resistant or Recurrent Warts: A Study,” Indian Journal of Dermatology 2013:58(5):360-65 (cited in Aldahan et al. and Alikhan et al.), and another study used Candin® manufactured by Allermed Laboratories (Kim KH et al., “Phase 1 clinical trial of intralesional injection of Candida antigen for the treatment of warts,” Arch Dematol 2010,146(12):1431-33; Pfenninger JL and Fowler GC, “Procedures for Primary Care,” Third Edition, Elsevier 2010,639-43; Signor RJ, “Candida albicans Intralesional Injection Immunotherapy of Warts,” Cutis 2002;70:185-92 (cited in Alikhan et al.); Phillips RC et al., “Treatment of Warts with Candida Antigen Injection,” Arch Dematol 2001,136(10):1274-5; Wong A and Crawford RI, “Intralesional Candida antigen for common warts in people with HIV,” J Cutan Med Surg. 2013;17(5):313-15 (cited in Aldahan et al.)). Some studies did not report the source of Candida antigen. Summers P et al.,“Treatment of recalcitrant verruca vulgaris with Candida antigen in patient with human immunodeficiency virus,”J Drugs Dermatol 2009;8(3): 268-69(cited in Aldahan et al.);“Warts Refractory to Conventional Therapy Yield to Candida Antigen,”American Academy of Family Practice 90 Clinical Perspectives 1990;Harada S, “Clinical Application of Fungus Extracts and its Culture filtrate in the Treatment of Skin Diseases: (3) Candida Vaccine in the Treatment of Warts,” Japanese Journal of Dermatology 1979;89(6), 397-402. .

[0006] Therefore, given the variety of sources that have been studied, doses reported in volume and weight / volume (v / w) dilutions do not provide the practitioner with sufficient information to achieve consistent wart cure rates. At best, U.S. Patent No. 6,350,451 to Horn teaches administration of antigen based on an early delayed-type hypersensitivity (DTH) response. See the Examples in the '451 patent. Therefore, a Candida antigen composition with standardized potency for the treatment of warts is desirable. Summary of the Invention

[0007] The present disclosure provides and includes compositions having standardized strengths for use in treating one or more common or non-common warts. The present disclosure also provides and includes methods for treating one or more common or non-common warts.

[0008] In one aspect, the disclosure provides and includes a method for treating common warts in a subject in need thereof comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective for complete disappearance of the common warts at a cumulative dose of 2.5 unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and secretory antigens.

[0009] In one aspect, the disclosure provides and includes a method for treating common warts in a subject in need thereof, comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount sufficient to effect complete disappearance of the common warts at a cumulative dose of 2.5 unit potency, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens.

[0010] In one aspect, the disclosure provides and includes a method for treating common warts in a subject in need thereof comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective to partially clear the common warts, at a cumulative dose of 5 unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and secretory antigens.

[0011] In one aspect, the disclosure provides and includes a method for treating common warts in a subject in need thereof comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount sufficient to effect partial disappearance of the common warts at a cumulative dose of 5 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens.

[0012] In one aspect, the disclosure provides and includes a method for treating a plurality of common warts in a subject in need thereof comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective for partial disappearance of the plurality of common warts, at a cumulative dose of 5 unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and a secretory antigen.

[0013] In one aspect, the disclosure provides and includes a method for treating a plurality of common warts in a subject in need thereof comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount sufficient to effect partial disappearance of the plurality of common warts at a cumulative dose of 5 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and a secretory antigen.

[0014] In one aspect, the disclosure provides and includes a method for treating a plurality of common warts in a subject in need thereof, comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective to reduce the diameter of each of the plurality of common warts by at least 50%, at a cumulative dose of one unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and a secretory antigen.

[0015] In one aspect, the disclosure provides and includes a method for treating a plurality of common warts in a subject in need thereof comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount capable of reducing the diameter of each of the plurality of common warts by at least 50% at a cumulative dose of one unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and a secretory antigen.

[0016] In one aspect, the disclosure provides and includes a method for treating non-common warts in a subject in need thereof, the subject having one or more common warts, comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective for complete disappearance of the non-common warts, at a cumulative dose of 5 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens.

[0017] In one aspect, the disclosure provides and includes a method for treating non-common warts in a subject in need thereof, the subject having one or more common warts, the method comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount sufficient to effect complete disappearance of the non-common warts, at a cumulative dose of 5 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens.

[0018] In one aspect, the disclosure provides and includes a method for treating a previously treated common wart in a subject in need of treatment comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective for complete clearance of the previously treated common wart, at a cumulative dose of 5 unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and secretory antigens.

[0019] In one aspect, the disclosure provides and includes a method for treating a previously treated common wart in a subject in need of treatment comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount sufficient to effect complete clearance of the previously treated common wart at a cumulative dose of 5 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens.

[0020] In one aspect, the disclosure provides and includes a method for delaying the recurrence of common warts in a subject in need thereof, comprising administering to the subject, upon clearance of the common warts, one or more intralesional injections of a pharmaceutical composition in an amount effective to delay the reappearance of the common warts at a cumulative dose of 2.5 unit potency, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and secretory antigens.

[0021] In one aspect, the disclosure provides and includes a method for delaying the recurrence of common warts in a subject in need thereof comprising administering to the subject one or more intralesional injections of a pharmaceutical composition at a cumulative dose of 2.5 unit potency, in an amount capable of delaying the reappearance of the common warts upon disappearance of the common warts, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and secretory antigens.

[0022] In one aspect, the disclosure provides and includes a pharmaceutical product comprising a filtered extract of Candida albicans and secretory antigens, formulated to completely eradicate common warts at a cumulative dose of 2.5 unit strength.

[0023] In one aspect, the disclosure provides and includes a pharmaceutical product comprising a filtered extract of Candida albicans and secretory antigens, formulated to partially clear common warts at a cumulative dose of 5 unit strength.

[0024] In one aspect, the disclosure provides and includes a pharmaceutical product comprising a filtered extract of Candida albicans and secretory antigens, formulated to reduce the diameter of common warts by at least 50% at a cumulative dose of 1 unit strength.

[0025] In one aspect, the disclosure provides and includes a pharmaceutical product comprising a filtered extract of Candida albicans and secretory antigens, formulated to partially clear multiple common warts at a cumulative dose of 5 unit strength.

[0026] In one aspect, the disclosure provides and includes a pharmaceutical product comprising a filtered extract of Candida albicans and secretory antigens, formulated to reduce the diameter of multiple common warts by at least 50% at a cumulative dose of 1 unit strength.

[0027] In one aspect, the disclosure provides and includes a pharmaceutical product comprising a filtered extract of Candida albicans and secretory antigens, formulated to completely clear non-common warts at a cumulative dose of 5 unit strength.

[0028] In one aspect, the disclosure provides and includes a pharmaceutical product comprising a filtered extract of Candida albicans and secretory antigens, formulated to completely clear previously treated common warts at a cumulative dose of 5 unit strength.

[0029] In one aspect, the disclosure provides and includes a pharmaceutical product comprising a filtered extract of Candida albicans and secretory antigens, formulated to delay the reappearance of common warts upon disappearance of the common warts at a cumulative dose of 2.5 unit strength.

[0030] In one embodiment, the present disclosure provides and includes a method for reducing the level of IL-23 in a subject in need thereof, comprising administering to the subject one or more intralesional injections of an amount of a pharmaceutical composition at a cumulative dose of one unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens. In one embodiment, the subject has been diagnosed with at least one common wart. In one embodiment, the method of the present disclosure reduces the level of IL-23 in the subject by at least about 15% when receiving a cumulative dose of the pharmaceutical composition of the present disclosure, compared to the level of IL-23 measured in the subject before the administering step. In one embodiment, the method of the present disclosure reduces the level of IL-23 in the subject by at least about 35% when receiving a cumulative dose of the pharmaceutical composition of the present disclosure, compared to the level of IL-23 measured in the subject before the administering step.

[0031] In one embodiment, the present disclosure provides and includes a method for completely eradicating a common wart in a subject in need of such a method, comprising reducing the level of IL-23 by at least about 15% in the subject in need of such a method.In one embodiment, the present disclosure provides and includes a method for completely eradicating a common wart in a subject in need of such a method, comprising reducing the level of IL-23 by at least about 35% in the subject in need of such a method.In one embodiment, the method of the present disclosure reduces the level of IL-23 by administering to the subject one or more intralesional injections of an amount of a pharmaceutical composition at a cumulative dose of 3 unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and secretory antigens.

[0032] In one embodiment, the present disclosure provides and includes a method for reducing the level of IL-7 in a subject in need thereof, comprising administering to the subject one or more intralesional injections of an amount of a pharmaceutical composition at a cumulative dose of 0.6 unit potency, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens. In one embodiment, the subject is diagnosed with at least one common wart. In one embodiment, the method of the present disclosure reduces the level of IL-7 in the subject by at least about 10% when receiving one cumulative dose of the pharmaceutical composition of the present disclosure, compared to the level of IL-7 measured in the subject before the administration step.

[0033] In one embodiment, the present disclosure provides and includes a method for reducing the level of IL-7 in a subject in need thereof, comprising administering to the subject one or more intralesional injections of an amount of a pharmaceutical composition at a cumulative dose of 3 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens. In one embodiment, the subject is diagnosed with at least one common wart. In one embodiment, the method of the present disclosure reduces the level of IL-7 in the subject by at least about 20% when receiving one cumulative dose of the pharmaceutical composition of the present disclosure, compared to the level of IL-7 measured in the subject before the administration step.

[0034] In one embodiment, the present disclosure provides and includes a method for reducing the level of IP-10 in a subject in need thereof, comprising administering to the subject one or more intralesional injections of an amount of a pharmaceutical composition at a cumulative dose of 3 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens. In one embodiment, the subject is diagnosed with at least one common wart. In one embodiment, the method of the present disclosure reduces the level of IP-10 in the subject by at least about 5% when receiving one cumulative dose of the pharmaceutical composition of the present disclosure, compared to the level of IP-10 measured in the subject before the administration step.

[0035] In one embodiment, the present disclosure provides and includes a pharmaceutical product comprising a filtered extract of Candida albicans and secretor antigens for use in reducing the level of IL-23 in a subject in need thereof. In one embodiment, the subject has been diagnosed with at least one common wart.

[0036] In one embodiment, the present disclosure provides and includes a pharmaceutical product comprising a filtered extract of Candida albicans and secretory antigens, which is used to completely eliminate common warts in a subject in need of complete disappearance of common warts by reducing the level of IL-23 by at least about 35% in the subject in need of complete disappearance of common warts.In one embodiment, the present disclosure provides and includes a pharmaceutical product comprising a filtered extract of Candida albicans and secretory antigens, which is used to completely eliminate common warts in a subject in need of complete disappearance of common warts by reducing the level of IL-23 by at least about 15% in the subject in need of complete disappearance of common warts.

[0037] In one embodiment, the present disclosure provides and includes a pharmaceutical product comprising a filtered extract of Candida albicans and secretor antigens for use in reducing levels of IL-7 in a subject in need thereof. In one embodiment, the subject has been diagnosed with at least one common wart.

[0038] In one embodiment, the present disclosure provides and includes a pharmaceutical product comprising a filtered extract of Candida albicans and secretor antigens for use in reducing levels of IP-10 in a subject in need thereof. In one embodiment, the subject has been diagnosed with at least one common wart.

[0039] The present disclosure is disclosed with reference to the accompanying drawings. [Brief description of the drawings]

[0040] [Figure 1] FIG. 1 shows the characteristic morphology of isolated colonies of the first strain of Candida albicans deposited under ATCC Accession No. PTA-126019 in accordance with the present disclosure. [Diagram 2] FIG. 2 shows the characteristic morphology of isolated colonies of a second strain of Candida albicans deposited under ATCC Accession No. PTA-126020 in accordance with the present disclosure. [Diagram 3] FIG. 3 shows a typical appearance of a Candida albicans budding yeast cell according to the present disclosure. [Figure 4] FIG. 4 shows a typical appearance of Candida albicans pseudohyphae according to the present disclosure. [Diagram 5] FIG. 5 shows an example of a track grid on the back of a guinea pig in accordance with the present disclosure. [Figure 6] FIG. 6 shows the preferred location for intralesional injection. [Figure 7A]7A, 7B, and 7C show a comparison of changes in biomarker levels of IL-7, IP-10, and IL-23, respectively, within treatment groups according to the present disclosure and the placebo group. [Figure 7B] 7A, 7B, and 7C show a comparison of changes in biomarker levels of IL-7, IP-10, and IL-23, respectively, within treatment groups according to the present disclosure and the placebo group. [Figure 7C] 7A, 7B, and 7C show a comparison of changes in biomarker levels of IL-7, IP-10, and IL-23, respectively, within treatment groups according to the present disclosure and the placebo group. Description of the Invention

[0041] The present disclosure provides and includes pharmaceutical compositions having standardized strengths for use in the treatment of one or more common warts or non-vulgaris warts. In one embodiment, the treatment of one or more common warts or non-vulgaris warts refers to the therapeutic treatment of these warts. In one embodiment, the treatment of one or more common warts or non-vulgaris warts refers to the prophylactic or preventative measures against the occurrence of warts. In one embodiment, the pharmaceutical composition of the present disclosure allows for the complete disappearance of one or more common warts and non-vulgaris warts by the cumulative dose provided by the unit strength according to the present disclosure. In one embodiment, the pharmaceutical composition of the present disclosure allows for the partial disappearance of one or more common warts by the cumulative dose provided by the unit strength according to the present disclosure. In one embodiment, the pharmaceutical compositions of the present disclosure are capable of delaying the reappearance of one or more common warts upon the disappearance of one or more common warts by cumulative doses provided in a unit strength according to the present disclosure.

[0042] The present disclosure also provides and includes a method for treating one or more common warts or non-common warts with the pharmaceutical composition described herein.In one embodiment, a method for completely eradicating one or more common warts or non-common warts is provided.In one embodiment, a method for partially eradicating one or more common warts is provided.In one embodiment, a method for treating previously treated common warts is provided.In one embodiment, a method for delaying the reappearance of common warts is provided.

[0043] Unless otherwise defined herein, terms shall be understood according to conventional usage by those skilled in the relevant art. Where a term is provided in the singular, the inventors also contemplate aspects of the present disclosure described by the plural of that term. In the event of a conflict with terms and definitions used in references incorporated by reference, the terms used in this application shall have the definitions provided herein. Other technical terms used have their ordinary meaning in the art in which they are used, as exemplified by various field-specific dictionaries (e.g., "The American Heritage® Science Dictionary" (Editors of the American Heritage Dictionaries, 2011, Houghton Mifflin Harcourt, Boston and New York); the "McGraw-Hill Dictionary of Scientific and Technical Terms" (6th edition, 2002, McGraw-Hill, New York); or the "Oxford Dictionary of Biology" (6th edition, 2008, Oxford University Press, Oxford and New York)).

[0044] All publications, patents, and patent applications mentioned in this disclosure are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

[0045] The term "and / or," when used in a list of two or more items, means that any one or more of the listed items may be used alone or in combination with any one or more of the listed items. For example, the phrase "A and / or B" is intended to mean both or either A and B, i.e., A only, B only, or a combination of A and B. The phrase "A, B, and / or C" is intended to mean A only, B only, C only, a combination of A and B, a combination of A and C, a combination of B and C, or a combination of A, B, and C.

[0046] As used herein, singular words and forms such as "a," "an," and "the" include plural referents unless the content clearly dictates otherwise.

[0047] When a range of values ​​is stated, it is understood that each value between the upper and lower limits of that range, and any other stated or intervening value in that stated range, is included in the disclosure. The upper and lower limits of these smaller ranges may be independently included in the smaller ranges, which are also encompassed in the disclosure, subject to any specifically excluded limitations in the stated range. Whenever a stated range includes one or both of the upper and lower limits, ranges excluding either or both of the included limits are also included in the disclosure. Whenever the phrase "comprising" is used, variations such as "consisting essentially of" and "consisting of" are also contemplated.

[0048] As used herein, the term "about" is intended to soften the numerical value it modifies, and to present such value as a variable within a margin of error. When no specific margin of error (e.g., standard deviation relative to the mean) is given, the term "about" should be understood to mean a range that includes the given value, or a range that includes the given value by rounding up or down to take into account significant digits.

[0049] As used herein, a "pharmaceutical composition" of the present disclosure may be an antigen described herein or a solvate thereof.

[0050] As used herein, "excipient" refers to a substance that is formulated with the active ingredient of a pharmaceutical. Excipients can be used for long-term stabilization or to provide therapeutic enhancement to the active ingredient in the final dosage form, for example, to promote absorption, reduce viscosity, or enhance solubility of the active ingredient. Excipients can also be useful in the manufacturing process, for example, to aid in the handling of the active ingredient of interest by promoting the flowability or non-stickiness of the powder, in addition to aiding in vitro stability (e.g., preventing denaturation or aggregation over the expected shelf life).

[0051] As used herein, "pharmaceutical acceptable carriers" include any solvents, dispersion media, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharma- ceutical active substances is well known in the art. Any conventional media or agent is contemplated for use in the pharmaceutical compositions, except insofar as it is incompatible with the pharmaceutical composition. As used herein, the phrase "pharmaceutical, pharmacologically, or physiologically acceptable" refers to molecular entities and compositions that do not produce adverse, allergic, or other side effects when administered to animals or humans. Pharmaceutically acceptable carriers can be liquid (e.g., saline), gel, or solid form diluents, adjuvants, excipients, or acid-resistant encapsulating components. Suitable diluents and excipients include pharmaceutical grade saline, dextrose, glycerol, mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like, and combinations thereof.

[0052] As used herein, the term "pharmaceutical acceptable solvate" refers to an association of one or more solvent molecules with a compound of the present disclosure. Examples of solvents that form pharmaceutical acceptable solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.

[0053] As used herein, the term "treat" means (i) completely or partially inhibiting a disease, disorder, or condition, e.g., arresting its onset; (ii) completely or partially alleviating a disease, disorder, or condition, e.g., causing a remission of the disease, disorder, and / or condition; or (iii) completely or partially preventing a disease, disorder, or condition from occurring in a patient who may be predisposed to, but has not yet been diagnosed with, the disease, disorder, and / or condition. Similarly, "treatment" means both therapeutic treatment and prophylactic or preventative measures. For example, the methods or compositions provided herein can be used to delay the progression of a condition (e.g., warts). As used herein, "delaying" the progression of a condition means to postpone, hinder, slow, delay, stabilize, and / or postpone the onset of the condition. This delay can be of different lengths of time depending on the history of the condition and / or the individual being treated.

[0054] As used herein, the term "wart" means a growth on the skin caused by the human papilloma virus.

[0055] As used herein, the term "anatomical region" refers to any one of the following regions of a subject's body: left arm, right arm, left hand, right hand, left lower leg, right lower leg, left foot, right foot, and torso. As used herein, the arm region includes the shoulder, upper arm and forearm, wrist, and half of the armpit. As used herein, the hand region starts distal to the wrist and excludes periungual warts. As used herein, the foot starts distal to the ankle and excludes the sole. As used herein, the lower leg region includes the upper leg, lower leg, and ankle. As used herein, the torso region includes the neck, back, chest, abdomen, buttocks, and pelvic region.

[0056] As used herein, the term "refractory warts" refers to warts that have not been successfully treated by prior treatments, excluding OTC medications. As used herein, the term "OTC medications" refers to medicines sold directly to consumers without a prescription from a medical professional.

[0057] As used herein, the term "margin" means the peripheral edge of the wart.

[0058] As used herein, the term "recurrence" means the growth of a wart in the same location where a previously regressed wart was present.

[0059] As used herein, the term "complete disappearance" refers to the sustained disappearance of the wart, as reflected by no observed recurrence of the wart at least 20 weeks after administration of the first intralesional injection.

[0060] As used herein, the term "partial disappearance" means any reduction in the diameter of the wart compared to the diameter observed before the first intralesional injection.

[0061] As used herein, the terms "administration," "administering," or "administration" with respect to the dosage forms of the present disclosure refer to the act of introducing the dosage form into the system of a subject in need of treatment. When the dosage forms of the present disclosure are indicated in combination with one or more other active agents (in each dosage form), "administration" and variations thereof should each be understood to include simultaneous and / or chronological introduction of the dosage form and the other active agents. Administration of any of the described dosage forms includes simultaneous (concurrent) administration, chronological (stepwise) administration, co-administration, or separate administration, where the therapeutic agents are administered separately at about the same time, e.g., within about seconds to hours of each other.

[0062] As used herein, the term "pharmaceutical product" means a substance used in the treatment of a disease.

[0063] As used herein, the term "molecular weight" refers to the average mass of a molecule of interest relative to one-twelfth the mass of carbon-12. Molecular weight is given in units of Daltons (Da). Molecular weight is measured by a method using a stacked 12-column method calibrated with dextran standards having molecular weights between 1 kilodalton and 512 kilodaltons.

[0064] As used herein, the term "IL-23" means interleukin 23, which is a heterodimeric cytokine having p19 and p40 subunits.

[0065] As used herein, the term "IL-7" means interleukin 7, which is a cytokine important in B and T cell development.

[0066] As used herein, the term "IP-10" means interferon gamma-inducible protein, which is also known as CXCL10.

[0067] A. Manufacturing Processes for Pharmaceutical Compositions In one embodiment, the pharmaceutical composition of the present disclosure comprising a filtered extract of Candida albicans and secreted antigens can be prepared by a series of steps including growing two or more strains of Candida albicans separately, pooling cultures of two or more strains of Candida albicans and dialyzing the mixture, heating the mixture, lyophilizing the heated dialyzed material, producing a dry powder, extracting the dry powder, filtering the extract, and producing a master lot filtered solution. In one embodiment, the pharmaceutical composition of the present disclosure can be produced by the protocol outlined in Example 1.

[0068] In one embodiment, the pharmaceutical composition of the present disclosure can be prepared using two or more strains of Candida albicans, for example, using two, three, four, five, six, seven, eight, nine, or ten strains. In one embodiment, the pharmaceutical composition of the present disclosure is prepared using two strains of Candida albicans. In one embodiment, the pharmaceutical composition of the present disclosure is prepared using a strain of Candida albicans as shown in Hasenclever HF and Mitchell WO, "Antigenic Studies of Candida," Journal of Bacteriology 1961;82:578-581. In one embodiment, the pharmaceutical compositions of the present disclosure are prepared using two strains of Candida albicans, where a representative sample of the first strain has been deposited with the ATCC under ATCC Accession No. PTA-126019 and a representative sample of the second strain has been deposited with the ATCC under ATCC Accession No. PTA-126020. In one embodiment, a representative sample of the first strain has been deposited with the ATCC under ATCC Accession No. ATCC-10231.

[0069] In one embodiment, the master lot filtered solution can be diluted with a diluent at a volume ratio of about 2:998 to form a pharmaceutical composition, which means that 2 ml of the master lot filtered solution is diluted with 988 ml of the diluent. In one embodiment, the master lot filtered solution can be diluted with a diluent at a volume ratio of about 2:998 to about 1:1, for example, about 2:998 to about 10:990, about 10:990 to about 20:980, about 20:980 to about 30:970, about 30:970 to about 40:960, about 40:960 to about 50:950, about 50:950 to about 60:940. , about 60:940 to about 70:930, about 70:930 to about 80:920, about 80:920 to about 90:910, about 90:910 to about 1:9, about 1:9 to about 1:8, about 1:8 to about 1:7, about 1:7 to about 1:6, about 1:6 to about 1:5, about 1:5 to about 1:4, about 1:4 to about 1:3, about 1:3 to about 1:2, about 1:2 to about 1:1. In one embodiment, the master lot filtrate solution is not diluted in the pharmaceutical composition.

[0070] In one embodiment, the disclosure provides a resulting pharmaceutical composition comprising at least 80% mannose, e.g., 80% mannose to 85% mannose, 85% mannose to 90% mannose, or 80% to 90% mannose. In one embodiment, the disclosure provides a resulting pharmaceutical composition comprising at least 8% glucose, e.g., 8% glucose to 10% glucose, 10% glucose to 12% glucose, or 8% glucose to 12% glucose. In one embodiment, the disclosure provides a resulting pharmaceutical composition comprising at least 1% galactose, e.g., 1% galactose to 2.5% galactose, 2.5% galactose to 5% galactose, or 1% to 5% galactose.

[0071] In one embodiment, the disclosure provides a resulting pharmaceutical composition comprising an antigen having a molecular weight of about 167 kilodaltons, e.g., a molecular weight of 157 kilodaltons to 177 kilodaltons. In one embodiment, the molecular weight is measured by a stacked 12-column method calibrated with dextran standards having molecular weights between 1 kilodalton and 512 kilodaltons.

[0072] B. Relative Potency Test The unit potency according to the present disclosure is defined by the relative potency (RP) compared to the reference standard Candida albicans extract. Compounds that are determined to have a relative potency of 1 compared to the standard are assigned to have a unit potency of 1 per mL. Relative potency is determined in the female IAF hairless guinea pig (Crl:HA-HO) model and compared to the standard Candida albicans extract that can induce a 5 mm or greater induration reaction in immunologically competent humans 48 hours after injection of 0.1 mL. In one embodiment, the reference standard is established by skin test titration in humans with delayed hypersensitivity to Candida albicans.

[0073] Female IAF hairless guinea pigs are selected to be as uniform in age and weight as possible. In one embodiment, no more than 20 female IAF hairless guinea pigs may be used in the study. Hairless guinea pigs are generally 4-6 months old and weigh approximately 0.6-0.8 kilograms at the start of treatment. All experimental animals are acclimated to their designated housing for at least 14 days prior to the first day of use.

[0074] At week 0, all experimental animals are sensitized with a 1:1 mixture of complete Freund's adjuvant (CFA) mixed with antigen solution. In one embodiment, the antigen solution is a 10-fold dilution of a standard Candida albicans extract with non-preserved saline. In another embodiment, the antigen solution can be a 100-fold dilution of a standard Candida albicans extract with non-preserved saline. In one embodiment, Adjulite CFA (Pacific Immunology) or any other commercially available CFA can be used in this assay. The animals are injected with up to four subcutaneous injections of 0.1 ml of the prepared mixture (i.e., a total of 0.4 ml) using a needle. In one embodiment, the needle can be a 21 g, 22 g, or 23 g needle. These injections can be administered in the neck region (either across the neck or shoulder), buttocks (up to two injections at each location, once on each side), and / or groin region (up to 0.1 mL can be administered in each groin region). Any one of the injection regimens containing CFA can be administered to each guinea pig under study.

[0075] At week 4±1, four serial dilutions of each test sample and standard are prepared separately in phenolized saline. For example, a set of serial dilutions can be prepared at 1:1, 1:4, 1:16, and 1:64. To ensure proper placement, the animals are sedated for intradermal injections. Injections are administered in a volume of 0.1 mL with a 27 g intradermal beveled needle on the back of the sensitized guinea pig. Injection locations are separated at least 3 cm apart on a grid on the back of the guinea pig. For example, four "tracks" can be drawn on the back of the guinea pig for injection of the standard (track 1) and the three test samples (tracks 2-4). Each of the "tracks" can be positioned such that the dilutions increase from the last diluted (located cranially) to the most diluted (located caudally), with all "tracks" parallel to the spine. See Figure 5 for an example of a track grid on the back of a guinea pig.

[0076] At 24 hours ± 4 hours after injection, the animals are manually restrained and the induration is marked and measured using a modified Mantoux procedure: with a ruler, the longest possible diameter (mm) of the indurated area and its midpoint orthogonal diameter (mm) are recorded. The reaction (response) at each test site is quantified by averaging the longest and orthogonal axis measurements. Alternatively, a calibrated caliper may be used. Optionally, the above measurements can be repeated at 48 hours ± 4 hours.

[0077] In one embodiment, for each guinea pig, the responses of tracks 2, 3, and 4 relative to track 1 are plotted against their corresponding dilutions and analyzed using the parallel line method. First, the response data of Track 2 and Track 1 versus log(dilution) are plotted on the same graph to test the linearity of the response in each track data, and then a test for parallelism of the two lines is performed. If the two lines are parallel, RP2 is calculated using the following equation:

number

[0078] In one embodiment, for each guinea pig, the responses of tracks 2, 3, and 4 relative to track 1 are plotted against their corresponding dilutions and analyzed using the slope ratio method. First, the response data of track 2 and track 1 versus dilution are plotted on the same graph, and the linearity of the response in each track's data is tested with a regression model E(Y)=α+βD, where α denotes the common intercept Y-intercept shared by the two plots, and β t denotes the slope of the test line (e.g., track 2), and β rindicates the slope of the reference line (e.g., track 1). Before using the slope ratio method of analysis, two validity criteria must be met: (1) the slopes of the two tracks are significantly different from 0 at an alpha level of 0.05, and (2) the intercepts of the test and reference lines are statistically equal (this means that the 90% confidence interval of the difference in intercepts includes 0). If the above criteria are met, the estimate of relative potency, RP2, is given by RP2 = (β t ) / (β r The same calculations are repeated for tracks 3 and 4 relative to track 1 to obtain RP3 and RP4, respectively, using the same formulas above but replacing α2 with α3 or α4.

[0079] After obtaining RP2, RP3, and RP4, they are plotted against the RP of track 1. A regression analysis is performed to obtain R 2 We obtain the coefficient of determination, R 2 is targeted to be 0.85 or greater. RP2, RP3, and RP4 are each the relative titers of the respective samples in that track.

[0080] A relative potency of 1 indicates that the potency of the test sample is equal to that of the reference standard.

[0081] C. Preparation One or more components of the pharmaceutical composition of the present disclosure can be formulated in admixture with conventional excipients, carriers, buffers, etc. In one embodiment, an excipient is a substance that is formulated with the active ingredient of a pharmaceutical. Typical carriers include, but are not limited to, water; salt solutions; alcohol; gum arabic; vegetable oils; benzyl alcohol; polyethylene glycol; gelatin; carbohydrates such as lactose, amylose, or starch; magnesium stearate; talc; silicic acid; paraffin; flavor oils; fatty acid esters; hydroxymethylcellulose; polyvinylpyrrolidone, etc. In one embodiment, the carrier includes any solvent, dispersion medium, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc.

[0082] One or more of the components of the pharmaceutical compositions of the present disclosure can be sterilized and, if desired, mixed with auxiliary agents, such as, for example, lubricants; preservatives; disintegrating agents; stabilizers, such as cyclodextrins; wetting agents; emulsifying agents; salts; buffers; natural or artificial colorants; natural or artificial flavors; or aromatic substances.

[0083] One or more components of the pharmaceutical compositions of the present disclosure may also include one or more of the following agents: acetylated monoglycerides, aspartame, beta carotene, calcium stearate, carnauba wax, cellulose acetate phthalate, citric acid, anhydrous citric acid, colloidal silicon dioxide, powdered sugar, crospovidone, sodium docusate, ethyl alcohol, ferric oxide, fructose, gelatin, glycerin, glyceryl monostearate (e.g., glyceryl monostearate 40-50), glyceryl triacetate, HPMC (hydroxypropyl methylcellulose), hydroxypropyl cellulose, hypromellose, iron oxide, isopropyl alcohol, lactose monohydrate, low substituted hydroxypropyl cellulose, magnesium carbonate, sucrose, glyceryl monostearate ... Magnesium tearate, maltol, mannitol, methacrylic acid, methacrylic acid copolymers (e.g., methacrylic acid copolymer type C), methylcellulose, microcrystalline cellulose, monoammonium glycyrrhizinate, n-butyl alcohol, paraffin, pectin propylene glycol alginate, polyacrylates, polyethylene glycols (e.g., polyethylene glycol 6000), polysorbate 80, polyvinylpyrrolidone, povidone, propylene glycol, shellac, silicon dioxide, sodium carbonate, sodium citrate, sodium hydroxide, sodium lauryl sulfate, sodium stearyl fumarate, sorbitol, starch, sucrose, sugar spheres, talc, titanium dioxide, triethyl citrate, and xanthan gum.

[0084] In one embodiment, the pharmaceutical compositions described herein include active compounds prepared for administration as an aqueous solution of free base or pharmacologically acceptable salt suitably mixed with a surfactant such as hydroxypropylcellulose. Pharmaceutically acceptable base addition salts can be formed with metals or amines, such as alkali and alkaline earth metals, or organic amines. Pharmaceutically acceptable salts of compounds can also be prepared with pharma-ceutically acceptable cations. Suitable pharma-ceutically acceptable cations are well known to those skilled in the art and include alkali cations, alkaline earth cations, ammonium cations, and quaternary ammonium cations. Carbonates or bicarbonates are also possible. Examples of metals used as cations include sodium, potassium, magnesium, ammonium, calcium, or ferric iron. Examples of suitable amines include isopropylamine, trimethylamine, histidine, N,N' dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N methylglucamine, and procaine.

[0085] Pharmaceutically acceptable acid addition salts include inorganic acid salts or organic acid salts. Examples of suitable acid salts include hydrochloride, acetate, citrate, salicylate, nitrate, and phosphate. Other suitable pharma- ceutically acceptable salts are well known to those skilled in the art, and include, for example, acetic acid, citric acid, oxalic acid, tartaric acid, or mandelic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, or phosphoric acid; organic carboxylic acid, sulfonic acid, sulfoacid, or phosphoric acid, or N-substituted sulfamic acid, such as acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4 aminosalicylic acid, 2 phenoxybenzoic acid, 2 acetoxybenzoic acid, ene acid, phenylalanine ... amino acids, such as the 20 alpha amino acids involved in the synthesis of natural proteins, such as glutamic acid or aspartic acid, as well as phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglyceric acid, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamate), or salts with other acid organic compounds, such as ascorbic acid.

[0086] In one embodiment, the pharmaceutical composition of the present disclosure comprises NaCl, NaHCO3, human albumin, polysorbate 80, and phenol. In one embodiment, the pharmaceutical composition of the present disclosure comprises 0.5% NaCl, 0.25% NaHCO3, 0.03% human albumin, 8 ppm polysorbate 80, and 0.4% phenol.

[0087] In one embodiment, the pharmaceutical compositions of the present disclosure described herein can be administered to a subject in need of the pharmaceutical composition via any route, including, but not limited to, sublingual, sacral, dental, intracervical, enteral, epidural, extracorporeal, intravenous, implantation, infiltration, intra-amniotic, intra-arterial, intra-articular, intra-buccal, intracardiac, intrasacral, intracavitary, intradermal, intradiscal, intralesional, intralymphatic, intraocular, intraperitoneal, intrapleural, intraspinal, intrasynovial, intrathecal, intratracheal, intratumoral, intratympanic, intrauterine, intravascular, intravitreal, iontophoretic, irrigation, intranasal, parenteral, transdermal, periarticular, peridural, periodontal, photophoretic, retrobulbar, subarachnoid, subconjunctival, submucosal, transdermal, ureteral, and urethral. In one embodiment, the pharmaceutical composition of the present disclosure is administered intralesionally to a subject in need of the pharmaceutical composition. In one embodiment, administration is performed by the action of introducing a dosage form into the system of the subject in need of treatment.

[0088] In one embodiment, the pharmaceutical composition of the present disclosure described herein can be administered via a form selected from the group consisting of oral, buccal, sublingual, topical, injection, infusion, inhalation, rectal, intravenous, intramuscular, and subcutaneous forms.For example, the pharmaceutical composition of the present disclosure described herein can be administered as a transdermal patch, with a microneedle, as a mist, as a suppository, as a gel, as a cream, as a pill, or as a spray, using methods known in the art.In one embodiment, the pharmaceutical composition of the present disclosure described herein is administered by an injectable form.

[0089] The pharmaceutical compositions provided herein can be prepared in a pharmaceutical form suitable for injectable use. In one embodiment, such compositions include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and fluid to the extent that ease of injection is ensured. The form must be stable under the conditions of manufacture and storage and preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium, for example, a solvent or dispersion medium containing water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, etc.), suitable mixtures thereof, and vegetable oils. In one embodiment, the solvent is a pharma-ceutically acceptable solvate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by maintaining the required particle size in the case of dispersion, and by the use of surfactants. The action of microorganisms can be prevented by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include an isotonic agent, for example, sugar or sodium chloride. Prolonged absorption of injectable compositions can be achieved by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

[0090] In one embodiment, sterile injectable solution is prepared by incorporating the required amount of active compound in a suitable solvent together with various other components listed above as necessary, and then sterilizing by filtration.In general, dispersion is prepared by incorporating various sterilized active components into a sterile vehicle that contains basic dispersion medium and the other components listed above as required.For the case of sterile powder for preparing sterile injectable solution, the preferred preparation method is vacuum drying and freeze-drying technology, which can be used to obtain powder containing active component and any additional desired component from the solution that has been previously sterilized and filtered.

[0091] In one embodiment, the pharmaceutical composition disclosed herein comprises human serum albumin. In one embodiment, the pharmaceutical composition disclosed herein comprises polysorbate 80.

[0092] In one embodiment, the pharmaceutical composition disclosed herein can be formulated as a sterile stabilized filtered extract of Candida albicans. In one embodiment, the pharmaceutical composition can be formulated in a single dose vial. In one embodiment, the pharmaceutical composition can be formulated in a single non-preserved vial. In one embodiment, the pharmaceutical composition can be formulated in a multi-dose vial. In one embodiment, the pharmaceutical composition can be formulated in a multi-dose preserved vial. In one embodiment, the pharmaceutical composition can be formulated as a pre-filled syringe or device, with or without an attached needle. In one embodiment, the pharmaceutical composition can be formulated in a container selected from the group consisting of a needle, a vial, and an ampoule. In one embodiment, the container can be a glass container or a plastic container. In one embodiment, the container has a volume of about 0.25 ml, about 0.5 ml, about 0.75 ml, about 1.0 ml, about 1.5 ml, about 2.0 ml, about 2.5 ml, about 3.0 ml, about 3.5 ml, about 4.0 ml, about 4.5 ml, about 5 ml, about 6 ml, about 7 ml, about 8 ml, about 9 ml, or about 10 ml.

[0093] In one embodiment, a pharmaceutical product comprising a filtered extract of Candida albicans and secretory antigens is provided in a cumulative dosage provided by the present disclosure for use in treating warts according to the present disclosure. In one embodiment, the treatment of warts is selected from the group consisting of complete disappearance of common warts, partial disappearance of common warts, reduction in diameter of common warts, partial disappearance of multiple common warts, at least a 50% reduction in diameter of multiple common warts, complete disappearance of non-common warts, complete disappearance of previously treated common warts, and delay in reappearance of common warts upon disappearance. In one embodiment, the medicament provides treatment of warts at a cumulative dose of less than about 0.5 unit potency, less than about 1 unit potency, less than about 2 unit potency, less than about 3 unit potency, less than about 4 unit potency, less than about 5 unit potency, less than about 6 unit potency, less than about 7 unit potency, less than about 8 unit potency, less than about 9 unit potency, or less than about 10 unit potency.In one embodiment, the medicament is formulated for administration to a subject by injection.In one embodiment, the injection is provided as an intralesional injection.

[0094] In one embodiment, a pharmaceutical product is provided that includes a filtered extract of Candida albicans and secretory antigens, the pharmaceutical product being formulated to completely eliminate common warts at a cumulative dose of 2.5 unit potency. In one embodiment, the disclosure provides a pharmaceutical product that includes a filtered extract of Candida albicans and secretory antigens, the pharmaceutical product being formulated to completely eliminate common warts at a cumulative dose of less than about 0.5 unit potency, less than about 1 unit potency, less than about 2 unit potency, less than about 3 unit potency, less than about 4 unit potency, less than about 5 unit potency, less than about 6 unit potency, less than about 7 unit potency, less than about 8 unit potency, less than about 9 unit potency, or less than about 10 unit potency.

[0095] In one embodiment, a pharmaceutical product is provided that includes a filtered extract of Candida albicans and secretory antigens, formulated to partially clear common warts at a cumulative dose of 5 unit potency. In one embodiment, the disclosure provides a pharmaceutical product that includes a filtered extract of Candida albicans and secretory antigens, formulated to partially clear common warts at a cumulative dose of less than about 0.5 unit potency, less than about 1 unit potency, less than about 2 unit potency, less than about 3 unit potency, less than about 4 unit potency, less than about 5 unit potency, less than about 6 unit potency, less than about 7 unit potency, less than about 8 unit potency, less than about 9 unit potency, or less than about 10 unit potency.

[0096] In one embodiment, a pharmaceutical product is provided that includes a filtered extract of Candida albicans and secretory antigens, formulated to reduce the diameter of common warts by at least 50% at a cumulative dose of 1 unit potency. In one embodiment, the disclosure provides a pharmaceutical product that includes a filtered extract of Candida albicans and secretory antigens, formulated to reduce the diameter of common warts by at least 50% at a cumulative dose of less than about 0.5 unit potency, less than about 1 unit potency, less than about 2 unit potency, less than about 3 unit potency, less than about 4 unit potency, less than about 5 unit potency, less than about 6 unit potency, less than about 7 unit potency, less than about 8 unit potency, less than about 9 unit potency, or less than about 10 unit potency.

[0097] In one embodiment, a pharmaceutical product is provided that includes a filtered extract of Candida albicans and secretory antigens, the pharmaceutical product being formulated to partially clear multiple common warts at a cumulative dose of 5 unit potency. In one embodiment, the disclosure provides a pharmaceutical product that includes a filtered extract of Candida albicans and secretory antigens, the pharmaceutical product being formulated to partially clear multiple common warts at a cumulative dose of less than about 0.5 unit potency, less than about 1 unit potency, less than about 2 unit potency, less than about 3 unit potency, less than about 4 unit potency, less than about 5 unit potency, less than about 6 unit potency, less than about 7 unit potency, less than about 8 unit potency, less than about 9 unit potency, or less than about 10 unit potency.

[0098] In one embodiment, a pharmaceutical product is provided that includes a filtered extract of Candida albicans and secretory antigens, the pharmaceutical product being formulated to reduce the diameter of a plurality of common warts by at least 50% at a cumulative dose of 1 unit potency. In one embodiment, the disclosure provides a pharmaceutical product that includes a filtered extract of Candida albicans and secretory antigens, the pharmaceutical product being formulated to reduce the diameter of a plurality of common warts by at least 50% at a cumulative dose of less than about 0.5 unit potency, less than about 1 unit potency, less than about 2 unit potency, less than about 3 unit potency, less than about 4 unit potency, less than about 5 unit potency, less than about 6 unit potency, less than about 7 unit potency, less than about 8 unit potency, less than about 9 unit potency, or less than about 10 unit potency.

[0099] In one embodiment, a pharmaceutical product is provided that includes a filtered extract of Candida albicans and secretor antigens, formulated to completely eliminate non-common warts at a cumulative dose of 5 unit potency. In one embodiment, the disclosure provides a pharmaceutical product that includes a filtered extract of Candida albicans and secretor antigens, formulated to completely eliminate non-common warts at a cumulative dose of less than about 0.5 unit potency, less than about 1 unit potency, less than about 2 unit potency, less than about 3 unit potency, less than about 4 unit potency, less than about 5 unit potency, less than about 6 unit potency, less than about 7 unit potency, less than about 8 unit potency, less than about 9 unit potency, or less than about 10 unit potency.

[0100] In one embodiment, a pharmaceutical product is provided that includes a filtered extract of Candida albicans and secretor antigens, the pharmaceutical product being formulated to completely eliminate previously treated common warts at a cumulative dose of 5 unit potency. In one embodiment, the disclosure provides a pharmaceutical product that includes a filtered extract of Candida albicans and secretor antigens, the pharmaceutical product being formulated to completely eliminate previously treated common warts at a cumulative dose of less than about 0.5 unit potency, less than about 1 unit potency, less than about 2 unit potency, less than about 3 unit potency, less than about 4 unit potency, less than about 5 unit potency, less than about 6 unit potency, less than about 7 unit potency, less than about 8 unit potency, less than about 9 unit potency, or less than about 10 unit potency.

[0101] In one embodiment, a pharmaceutical product is provided that includes a filtered extract of Candida albicans and secretory antigens, formulated to delay the reappearance of common warts upon their disappearance at a cumulative dose of 2.5 unit potency. In one embodiment, the disclosure provides a pharmaceutical product that includes a filtered extract of Candida albicans and secretory antigens, formulated to delay the reappearance of common warts upon their disappearance at a cumulative dose of less than about 0.5 unit potency, less than about 1 unit potency, less than about 2 unit potency, less than about 3 unit potency, less than about 4 unit potency, less than about 5 unit potency, less than about 6 unit potency, less than about 7 unit potency, less than about 8 unit potency, less than about 9 unit potency, or less than about 10 unit potency.

[0102] In one embodiment, a pharmaceutical product is provided that includes a filtered extract of Candida albicans and secretory antigens, the pharmaceutical product being used to reduce the level of a cytokine biomarker in a subject diagnosed with common warts. In one embodiment, the cytokine biomarker is a proinflammatory cytokine. In one embodiment, the cytokine biomarker is selected from the group consisting of IL-23, IL-7, and IP-10. In one embodiment, the level of a cytokine biomarker in a subject is reduced upon administration of a pharmaceutical product that includes a filtered extract of Candida albicans and secretory antigens at a cumulative dose of less than about 0.5 unit potency, less than about 1 unit potency, less than about 2 unit potency, less than about 3 unit potency, less than about 4 unit potency, less than about 5 unit potency, less than about 6 unit potency, less than about 7 unit potency, less than about 8 unit potency, less than about 9 unit potency, or less than about 10 unit potency. In one embodiment, the level of a cytokine biomarker in a subject is reduced upon administration of a pharmaceutical preparation comprising a filtered extract of Candida albicans and secreted antigens at a cumulative dose of at least about 0.5 unit potency, at least about 1 unit potency, at least about 2 unit potency, at least about 3 unit potency, at least about 4 unit potency, at least about 5 unit potency, at least about 6 unit potency, at least about 7 unit potency, at least about 8 unit potency, at least about 9 unit potency, or at least about 10 unit potency. In one embodiment, the level of a cytokine biomarker in a subject is reduced upon administration of a pharmaceutical preparation comprising a filtered extract of Candida albicans and secreted antigens at a cumulative dose of at least about 0.5 unit potency to 10 unit potency, e.g., 0.5 unit potency to 9.5 unit potency, about 1 unit potency to 9.5 unit potency, about 1.5 unit potency to about 9 unit potency, about 2 unit potency to about 9 unit potency, about 2 unit potency to about 8.5 unit potency, about 2.5 unit potency to about 8.5 unit potency, about 2.5 unit potency to about 8 unit potency, or about 2.5 unit potency to about 8 unit potency. The clinical efficacy of the present invention is reduced when a pharmaceutical preparation comprising a filtered extract of Candida albicans and secretory antigens is administered at a cumulative dose of about 100 mg / kg / day, about 3 unit potency to about 8 unit potency, about 3 unit potency to about 7.5 unit potency, about 3.5 unit potency to about 7.5 unit potency, about 3.5 unit potency to about 7 unit potency, about 4 unit potency to about 7 unit potency, about 4 unit potency to about 6.5 unit potency, about 4.5 unit potency to about 6.5 unit potency, about 4.5 unit potency to about 6 unit potency, or about 5 unit potency to about 6 unit potency.In one embodiment, the level of a cytokine biomarker is reduced in a subject by up to 99.9% upon administration of one cumulative dose of a pharmaceutical agent, e.g., by up to 99.5%, up to 99%, up to 98%, up to 95%, up to 90%, up to 85%, up to 80%, up to 75%, up to 70%, up to 65%, up to 60%, up to 55%, up to 50%, up to 45%, up to 40%, up to 35%, up to 30%, up to 25%, up to 20%, up to 15%, up to 10%, or up to 5%. In one embodiment, the level of a cytokine biomarker is reduced in a subject by about 5% to about 99.9% upon administration of one cumulative dose of a pharmaceutical agent, e.g., by about 5% to about 99.8%, about 5% to about 99.5%, about 5% to about 99%, about 5% to about 98%, about 5% to about 95%, about 10% to about 95%, about 10% to about 90%, about 15% to about 90%, or about 16% to about 90%. %, about 15% to about 85%, about 20% to about 85%, about 20% to about 80%, about 25% to about 80%, about 25% to about 75%, about 30% to about 75%, about 30% to about 70%, about 35% to about 70%, about 35% to about 65%, about 40% to about 65%, about 40% to about 60%, about 45% to about 60%, about 45% to about 55%, or about 50% to about 55%.

[0103] In one embodiment, a pharmaceutical product is provided comprising a filtered extract of Candida albicans and secretor antigens for use in reducing levels of IL-23 in a subject in need thereof. In one embodiment, the subject has been diagnosed with at least one common wart.

[0104] In one embodiment, a pharmaceutical product is provided that includes a filtered extract of Candida albicans and secretory antigens, which is used to completely eliminate common warts in a subject in need thereof by reducing the level of IL-23 by at least about 35% in the subject in need thereof.In one embodiment, a pharmaceutical product is provided that includes a filtered extract of Candida albicans and secretory antigens, which is used to completely eliminate common warts in a subject in need thereof by reducing the level of IL-23 by at least about 15% in the subject in need thereof.

[0105] In one embodiment, a pharmaceutical product is provided comprising a filtered extract of Candida albicans and secretor antigens for use in reducing levels of IL-7 in a subject in need thereof. In one embodiment, the subject has been diagnosed with at least one common wart.

[0106] In one embodiment, a pharmaceutical product is provided comprising a filtered extract of Candida albicans and secretor antigens for use in reducing levels of IP-10 in a subject in need thereof. In one embodiment, the subject has been diagnosed with at least one common wart.

[0107] In one embodiment, a medicament is provided for use in completely eradicating common warts, the medicament comprising a filtered extract of two strains of Candida albicans and secretor antigens, a representative sample of the first strain being deposited with the ATCC under ATCC Accession No. PTA-126019 and a representative sample of the second strain being deposited with the ATCC under ATCC Accession No. PTA-126020. In one embodiment, a representative sample of the first strain being deposited with the ATCC under ATCC Accession No. ATCC-10231.

[0108] In one embodiment, a medicament is provided for use in partially eradicating common warts, the medicament comprising a filtered extract of two strains of Candida albicans and secretor antigens, a representative sample of the first strain being deposited with the ATCC under ATCC Accession No. PTA-126019 and a representative sample of the second strain being deposited with the ATCC under ATCC Accession No. PTA-126020. In one embodiment, a representative sample of the first strain being deposited with the ATCC under ATCC Accession No. ATCC-10231.

[0109] In one embodiment, a medicament is provided for use in reducing the diameter of a common wart by at least 50%, wherein the medicament comprises a filtered extract of two strains of Candida albicans and secretor antigens, a representative sample of the first strain being deposited with the ATCC under ATCC Accession No. PTA-126019 and a representative sample of the second strain being deposited with the ATCC under ATCC Accession No. PTA-126020. In one embodiment, a representative sample of the first strain being deposited with the ATCC under ATCC Accession No. ATCC-10231.

[0110] In one embodiment, a medicament is provided for use in partially eradicating multiple common warts, the medicament comprising a filtered extract of two strains of Candida albicans and secretor antigens, a representative sample of the first strain being deposited with the ATCC under ATCC Accession No. PTA-126019 and a representative sample of the second strain being deposited with the ATCC under ATCC Accession No. PTA-126020. In one embodiment, a representative sample of the first strain being deposited with the ATCC under ATCC Accession No. ATCC-10231.

[0111] In one embodiment, a medicament is provided for use in reducing the diameter of a plurality of common warts by at least 50%, wherein the medicament comprises a filtered extract of two strains of Candida albicans and secretor antigens, a representative sample of the first strain being deposited with the ATCC under ATCC Accession No. PTA-126019 and a representative sample of the second strain being deposited with the ATCC under ATCC Accession No. PTA-126020. In one embodiment, a representative sample of the first strain being deposited with the ATCC under ATCC Accession No. ATCC-10231.

[0112] In one embodiment, a medicament is provided for use in completely eradicating non-common warts, the medicament comprising a filtered extract of two strains of Candida albicans and secretor antigens, a representative sample of the first strain being deposited with the ATCC under ATCC Accession No. PTA-126019 and a representative sample of the second strain being deposited with the ATCC under ATCC Accession No. PTA-126020. In one embodiment, a representative sample of the first strain being deposited with the ATCC under ATCC Accession No. ATCC-10231.

[0113] In one embodiment, a medicament is provided for use in completely eradicating previously treated common warts, the medicament comprising a filtered extract of two strains of Candida albicans and secretor antigens, a representative sample of the first strain being deposited with the ATCC under ATCC Accession No. PTA-126019 and a representative sample of the second strain being deposited with the ATCC under ATCC Accession No. PTA-126020. In one embodiment, a representative sample of the first strain being deposited with the ATCC under ATCC Accession No. ATCC-10231.

[0114] In one embodiment, a medicament is provided for use in delaying the reappearance of common warts, the medicament comprising a filtered extract of two strains of Candida albicans and secretor antigens, a representative sample of the first strain being deposited with the ATCC under ATCC Accession No. PTA-126019 and a representative sample of the second strain being deposited with the ATCC under ATCC Accession No. PTA-126020. In one embodiment, a representative sample of the first strain being deposited with the ATCC under ATCC Accession No. ATCC-10231.

[0115] In one embodiment, a pharmaceutical product is provided that includes a filtered extract of Candida albicans and secretor antigens for use in reducing the level of IL-23 in a subject in need thereof, the pharmaceutical product comprising a filtered extract of Candida albicans and secretor antigens of two strains, a representative sample of the first strain being deposited with ATCC under ATCC Accession No. PTA-126019 and a representative sample of the second strain being deposited with ATCC under ATCC Accession No. PTA-126020. In one embodiment, the subject is diagnosed with at least one common wart. In one embodiment, a representative sample of the first strain being deposited with ATCC under ATCC Accession No. ATCC-10231.

[0116] In one embodiment, a medicament is provided comprising a filtered extract of Candida albicans and secretor antigens for use in completely eradicating common warts in a subject in need thereof, the medicament reducing the level of IL-23 by at least about 35% in the subject in need thereof, the medicament comprising a filtered extract of Candida albicans and secretor antigens of two strains, a representative sample of the first strain being deposited with the ATCC under ATCC Accession No. PTA-126019 and a representative sample of the second strain being deposited with the ATCC under ATCC Accession No. PTA-126020. In one embodiment, a representative sample of the first strain being deposited with the ATCC under ATCC Accession No. ATCC-10231.

[0117] In one embodiment, a pharmaceutical product is provided that includes a filtered extract of Candida albicans and secretory antigens for use in reducing the level of IL-7 in a subject in need thereof, the pharmaceutical product comprising a filtered extract of Candida albicans and secretory antigens of two strains, a representative sample of the first strain being deposited with ATCC under ATCC Accession No. PTA-126019 and a representative sample of the second strain being deposited with ATCC under ATCC Accession No. PTA-126020. In one embodiment, the subject is diagnosed with at least one common wart. In one embodiment, a representative sample of the first strain being deposited with ATCC under ATCC Accession No. ATCC-10231.

[0118] In one embodiment, a pharmaceutical product is provided that includes a filtered extract of Candida albicans and secretor antigens for use in reducing IP-10 levels in a subject in need thereof, the pharmaceutical product comprising a filtered extract of Candida albicans and secretor antigens of two strains, a representative sample of the first strain being deposited with ATCC under ATCC Accession No. PTA-126019 and a representative sample of the second strain being deposited with ATCC under ATCC Accession No. PTA-126020. In one embodiment, the subject is diagnosed with at least one common wart. In one embodiment, a representative sample of the first strain being deposited with ATCC under ATCC Accession No. ATCC-10231.

[0119] In one embodiment, the pharmaceutical preparation comprising a filtered extract of Candida albicans and secretor antigens is formulated to have at least 1 unit potency per ml, e.g., at least about 2 unit potency per ml, at least about 3 unit potency per ml, at least about 4 unit potency per ml, at least about 5 unit potency per ml, at least about 6 unit potency per ml, at least about 7 unit potency per ml, at least about 8 unit potency per ml, at least about 9 unit potency per ml, at least about 10 unit potency per ml, at least about 15 unit potency per ml, at least about 16 unit potency per ml, at least about 18 unit potency per ml, at least about 19 unit potency per ml, at least about 20 unit potency per ml, at least about 21 unit potency per ml, at least about 22 unit potency per ml, at least about 23 unit potency per ml, at least about 24 unit potency per ml, at least about 25 unit potency per ml, at least about 26 unit potency per ml, at least about 27 unit potency per ml, at least about 28 unit potency per ml, at least about 29 unit potency per ml, at least about 30 unit potency per ml, at least about 31 unit potency per ml, at least about 32 unit potency per ml, at least about 33 unit potency per ml, at least about 34 unit potency per ml, at least about 35 unit potency per ml, at least about 36 unit potency per ml, at least about 37 unit potency per ml, at least about 38 unit potency per ml, at least about 39 unit potency per ml, at least about 40 unit potency per ml, at least about 40 unit potency per ml, at least about 41 unit potency per ml, at least about 42 unit potency per ml, at least about 43 unit potency per ml, at least about 44 unit potency per ml, at least about 45 unit pot Also, the composition may be formulated to have a potency of about 20 units, at least about 25 units per ml, at least about 30 units per ml, at least about 40 units per ml, at least about 50 units per ml, at least about 30 units per ml, at least about 40 units per ml, at least about 50 units per ml, at least about 60 units per ml, at least about 70 units per ml, at least about 80 units per ml, at least about 90 units per ml, or at least about 100 units per ml.

[0120] D. Treatment method In one embodiment, a method for treating warts in a subject in need thereof is provided, comprising administering to the subject in need thereof one or more doses of a pharmaceutical composition of the present disclosure. In one embodiment, the growth on the skin is caused by human papillomavirus. In one embodiment, the pharmaceutical composition comprises a filtered extract of Candida albicans and secretory antigens. In one embodiment, the method of the present disclosure completely or partially inhibits the development of warts. In one embodiment, the method of the present disclosure completely or partially alleviates warts. In one embodiment, the method of the present disclosure causes the regression of warts. In one embodiment, the method of the present disclosure completely or partially prevents the development of warts in a patient who may be susceptible to developing warts. In one embodiment, the treatment of warts is selected from the group consisting of complete disappearance of common warts, partial disappearance of common warts, reduction in diameter of common warts, partial disappearance of multiple common warts, at least 50% reduction in diameter of multiple common warts, complete disappearance of non-common warts, complete disappearance of previously treated common warts, and delay in reappearance of common warts when disappeared.In one embodiment, the method for treating warts achieves its therapeutic goal with a cumulative dose of less than about 0.5 unit potency, less than about 1 unit potency, less than about 2 unit potency, less than about 3 unit potency, less than about 4 unit potency, less than about 5 unit potency, less than about 6 unit potency, less than about 7 unit potency, less than about 8 unit potency, less than about 9 unit potency, or less than about 10 unit potency.In one embodiment, each dose is administered to the subject by injection. In one embodiment, the injection is provided as an intralesional injection.

[0121] In one embodiment, a method for treating common warts in a subject in need of treatment is provided, the method comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective for complete disappearance of the common warts, at a cumulative dose of 2.5 unit potency, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and a secretor antigen.In one embodiment, a method for treating common warts in a subject in need of treatment is provided, the method comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective for complete disappearance of the common warts, at a cumulative dose of 2.5 unit potency, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and a secretor antigen.

[0122] In one embodiment, complete disappearance of a common wart is identified by observation of no recurrence of the common wart at the same site at least 20 weeks after administration of the first intralesional injection, for example, about 20 weeks, about 25 weeks, about 30 weeks, about 35 weeks, about 40 weeks, about 45 weeks, about 50 weeks, about 55 weeks, about 60 weeks, about 70 weeks, about 80 weeks, about 90 weeks, or about 100 weeks after administration of the first intralesional injection. In one embodiment, recurrence of a common wart is defined by the growth of a wart at the same location where a previously regressed wart was present.

[0123] In one embodiment, complete disappearance of the wart is accompanied by the absence of a scar at the location of the common wart. In one embodiment, complete disappearance of the wart is accompanied by a low level of depigmentation at the location of the common wart (eg, less than 3% of all disappeared common warts).

[0124] In one embodiment, a method for treating common warts in a subject in need thereof is provided, comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective for partial disappearance of the common warts at a cumulative dose of 5 unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and secretory antigens. In one embodiment, the pharmaceutical composition effective for partial disappearance of common warts at a cumulative dose of 5 unit strength is also effective for at least 50% reduction in the diameter of the common warts at a cumulative dose of 1 unit strength. In one embodiment, partial disappearance of the wart is identified by any reduction in the diameter of the wart compared to the diameter observed before the first intralesional injection.

[0125] In one embodiment, a method for treating common warts in a subject in need thereof is provided, the method comprising administering to the subject one or more intralesional injections of a pharmaceutical composition effective for partial disappearance of the common warts at a cumulative dose of 5 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens. In one embodiment, a pharmaceutical composition effective for partial disappearance of common warts at a cumulative dose of 5 unit strength is also capable of reducing the diameter of the common warts by at least 50% at a cumulative dose of 1 unit strength.

[0126] In one embodiment, a method is provided for treating a plurality of common warts in a subject in need of treatment, the method comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective for partial disappearance of the plurality of common warts, at a cumulative dose of 5 unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and a secretor antigen.In one embodiment, a method is provided for treating a plurality of common warts in a subject in need of treatment, the method comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective for partial disappearance of the plurality of common warts, at a cumulative dose of 5 unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and a secretor antigen.

[0127] In one embodiment, a method is provided for treating a plurality of common warts in a subject in need of treatment, the method comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective to reduce the diameter of each of the plurality of common warts by at least 50% at a cumulative dose of one unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and a secretor antigen.In one embodiment, a method is provided for treating a plurality of common warts in a subject in need of treatment, the method comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective to reduce the diameter of each of the plurality of common warts by at least 50% at a cumulative dose of one unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and a secretor antigen.

[0128] In one embodiment, the plurality of common warts comprises 2-20 common warts, e.g., 2-20 common warts, 2-19 common warts, 3-19 common warts, 3-18 common warts, 4-18 common warts, 4-17 common warts, 5-17 common warts, 5-16 common warts, 6-1 The number of common warts may include 6 common warts, 6-15 common warts, 7-15 common warts, 7-14 common warts, 8-14 common warts, 8-13 common warts, 9-13 common warts, 9-12 common warts, 10-12 common warts, 10-11 common warts, or 11-12 common warts. In one embodiment, the plurality of common warts are in the same anatomical location of the subject. In one embodiment, the plurality of common warts are in different anatomical locations of the subject. In one embodiment, the anatomical location is selected from one of the following regions of the subject's body: left arm, right arm, left hand, right hand, left lower leg, right lower leg, left foot, right foot, and torso. In one embodiment, the arm region includes the shoulder, upper and lower arms, wrist, and half of the armpit. In one embodiment, the hand region starts distal to the wrist and excludes periungual warts. In one embodiment, the foot region starts distal to the ankle and excludes the sole. In one embodiment, the lower leg region includes the upper leg, lower leg, and ankle. In one embodiment, the torso region includes the neck, back, chest, abdomen, buttocks, and pelvic region.

[0129] In one embodiment, a method is provided for treating non-vulgaris warts in a subject having one or more common warts in need of such treatment, the method comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective for complete disappearance of the non-vulgaris warts, at a cumulative dose of 5 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and a secretor antigen.In one embodiment, a method is provided for treating non-vulgaris warts in a subject having one or more common warts in need of such treatment, the method comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective for complete disappearance of the non-vulgaris warts, at a cumulative dose of 5 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and a secretor antigen.

[0130] In one embodiment, the non-vulgaris wart is a plantar wart. In one embodiment, the non-vulgaris wart is a genital wart. In one embodiment, the non-vulgaris wart is a facial wart. In one embodiment, the non-vulgaris wart is a flat wart. In one embodiment, the non-vulgaris wart is a periungual wart. In one embodiment, the non-vulgaris wart is in the same anatomical region as one or more vulgaris warts.

[0131] In one embodiment, complete disappearance of a non-common wart is identified by observation of no recurrence of the non-common wart at the same site at least 20 weeks after administration of the first intralesional injection, for example, about 20 weeks, about 25 weeks, about 30 weeks, about 35 weeks, about 40 weeks, about 45 weeks, about 50 weeks, about 55 weeks, about 60 weeks, about 70 weeks, about 80 weeks, about 90 weeks, or about 100 weeks after administration of the first intralesional injection. In one embodiment, recurrence of a common wart is defined by the growth of a wart at the same location where a previously regressed wart was present.

[0132] In one embodiment, a method is provided for treating previously treated common warts in a subject in need of treatment, the method comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective for complete disappearance of the previously treated common warts, at a cumulative dose of 5 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and a secretor antigen.In one embodiment, a method is provided for treating previously treated common warts in a subject in need of treatment, the method comprises administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective for complete disappearance of the previously treated common warts, at a cumulative dose of 5 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and a secretor antigen.

[0133] In one embodiment, the previously treated common wart is a common wart previously treated with cryotherapy. In one embodiment, the previously treated common wart did not respond to cryotherapy. In one embodiment, cryotherapy did not completely eradicate the previously treated common wart.

[0134] In one embodiment, the previously treated common wart is a common wart that has been previously treated with salicylic acid or related acid. In one embodiment, the related acid is trichloroacetic acid or bichloroacetic acid. In one embodiment, the previously treated common wart did not respond to salicylic acid or related acid. In one embodiment, salicylic acid or related acid did not completely eradicate the previously treated common wart.

[0135] In one embodiment, the previously treated common wart is a previously treated common wart selected from the group consisting of liquid nitrogen, carbon dioxide, cantharidin, simple occlusion, wart gel, apple cider vinegar, surgery, laser, tea tree oil, cryowart spray, wart curettage, electrodesiccation, lavender and oregano essential oils, and imiquimod.In one embodiment, the previously treated common wart did not respond to the previous treatment.In one embodiment, the previous treatment did not completely eliminate the previously treated common wart.

[0136] In one embodiment, complete disappearance of a previously treated common wart is identified by no recurrence of the previously treated common wart at the same site at least 20 weeks after administration of the first intralesional injection, for example, about 20 weeks, about 25 weeks, about 30 weeks, about 35 weeks, about 40 weeks, about 45 weeks, about 50 weeks, about 55 weeks, about 60 weeks, about 70 weeks, about 80 weeks, about 90 weeks, or about 100 weeks after administration of the first intralesional injection. In one embodiment, recurrence of a common wart is defined by the growth of a wart at the same location where a previously regressed wart was present.

[0137] In one embodiment, the complete disappearance of a previously treated common wart is accompanied by an absence of scarring at the location of the common wart. In one embodiment, the complete disappearance of a previously treated common wart is accompanied by a low level of depigmentation at the location of the common wart (e.g., less than 3% of all disappeared common warts).

[0138] In one embodiment, a method is provided for delaying the recurrence of common warts in a subject in need thereof, the method comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective to delay the reappearance of the common warts upon disappearance of the common warts, at a cumulative dose of 2.5 unit potency, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and a secretor antigen.In one embodiment, a method is provided for delaying the recurrence of common warts in a subject in need thereof, the method comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective to delay the reappearance of the common warts upon disappearance of the common warts, at a cumulative dose of 2.5 unit potency, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and a secretor antigen. In one embodiment, delaying the reappearance of common warts means postponing, preventing, slowing, retarding, stabilizing, and / or postponing the onset of the condition at the same location where the previously regressed wart was present. In one embodiment, the delay may be for a different length of time depending on the history of the condition and / or the individual being treated. In one embodiment, the subject does not develop any new common warts within at least 16 weeks after the last injection of the treatment regimen, for example, at least 18 weeks, at least 20 weeks, at least 25 weeks, at least 30 weeks, at least 35 weeks, at least 40 weeks, at least 45 weeks, at least 50 weeks, at least 55 weeks, at least 60 weeks, at least 65 weeks, at least 70 weeks, at least 80 weeks, at least 90 weeks, or at least 100 weeks after the last injection of the treatment regimen. In one embodiment, the subject does not develop any new common warts in the same anatomical area as the disappeared common warts.In one embodiment, the subject does not develop any new common warts in the same location as the disappeared common warts.

[0139] In one embodiment, a method is provided for reducing the level of a cytokine biomarker in a subject in need thereof, the method comprising administering to the subject one or more intralesional injections of an amount of a pharmaceutical composition at a cumulative dose of about 0.5 unit potency to about 10 unit potency, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and secreted antigens. In one embodiment, the cytokine biomarker is an inflammatory cytokine. In one embodiment, the subject has been diagnosed with at least one common wart. In one embodiment, the cytokine biomarker is selected from the group consisting of IL-23, IL-7, and IP-10. In one embodiment, the level of a cytokine biomarker in a subject is reduced upon administration of a pharmaceutical composition of the present disclosure at a cumulative dose of less than about 0.5 unit potency, less than about 1 unit potency, less than about 2 unit potency, less than about 3 unit potency, less than about 4 unit potency, less than about 5 unit potency, less than about 6 unit potency, less than about 7 unit potency, less than about 8 unit potency, less than about 9 unit potency, or less than about 10 unit potency. In one embodiment, the level of a cytokine biomarker in a subject is reduced upon administration of a pharmaceutical composition of the present disclosure at a cumulative dose of at least about 0.5 unit potency, at least about 1 unit potency, at least about 2 unit potency, at least about 3 unit potency, at least about 4 unit potency, at least about 5 unit potency, at least about 6 unit potency, at least about 7 unit potency, at least about 8 unit potency, at least about 9 unit potency, or at least about 10 unit potency.In one embodiment, the level of the cytokine biomarker in the subject is at a cumulative dose of about 0.5 unit titer to about 10 unit titer, e.g., about 0.5 unit titer to about 9.5 unit titer, about 1 unit titer to about 9.5 unit titer, about 1.5 unit titer to about 9 unit titer, about 2 unit titer to about 9 unit titer, about 2 unit titer to about 8.5 unit titer, about 2.5 unit titer to about 8.5 unit titer, about 2.5 unit titer to about 8 unit titer, is decreased when a pharmaceutical composition of the present disclosure is administered at a cumulative dose of about 3 unit potency to about 8 unit potency, about 3 unit potency to about 7.5 unit potency, about 3.5 unit potency to about 7.5 unit potency, about 3.5 unit potency to about 7 unit potency, about 4 unit potency to about 7 unit potency, about 4 unit potency to about 6.5 unit potency, about 4.5 unit potency to about 6.5 unit potency, about 4.5 unit potency to about 6 unit potency, or about 5 unit potency to about 6 unit potency. In one embodiment, the level of a cytokine biomarker is reduced in a subject by up to 99.9% upon administration of one cumulative dose of a pharmaceutical composition of the disclosure, e.g., by up to 99.5%, up to 99%, up to 98%, up to 95%, up to 90%, up to 85%, up to 80%, up to 75%, up to 70%, up to 65%, up to 60%, up to 55%, up to 50%, up to 45%, up to 40%, up to 35%, up to 30%, up to 25%, up to 20%, up to 15%, up to 10%, or up to 5%. In one embodiment, the level of a cytokine biomarker is reduced in a subject by about 5% to about 99.9% upon administration of one cumulative dose of a pharmaceutical composition of the present disclosure, e.g., by about 5% to about 99.8%, about 5% to about 99.5%, about 5% to about 99%, about 5% to about 98%, about 5% to about 95%, about 10% to about 95%, about 10% to about 90%, about 15% to about A decrease of 90%, about 15% to about 85%, about 20% to about 85%, about 20% to about 80%, about 25% to about 80%, about 25% to about 75%, about 30% to about 75%, about 30% to about 70%, about 35% to about 70%, about 35% to about 65%, about 40% to about 65%, about 40% to about 60%, about 45% to about 60%, about 45% to about 55%, or about 50% to about 55%.

[0140] In one embodiment, a method for reducing IL-23 levels in a subject in need thereof is provided, the method comprising administering to the subject one or more intralesional injections of an amount of a pharmaceutical composition at a cumulative dose of one unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and secretory antigens. In one embodiment, the subject has been diagnosed with at least one common wart. In one embodiment, the method of the present disclosure reduces the level of IL-23 in the subject by at least about 15% when receiving a cumulative dose of the pharmaceutical composition of the present disclosure, compared to the level of IL-23 measured in the subject before the administering step. In one embodiment, the method of the present disclosure reduces the level of IL-23 in the subject by at least about 35% when receiving a cumulative dose of the pharmaceutical composition of the present disclosure, compared to the level of IL-23 measured in the subject before the administering step.

[0141] In one embodiment, a method for completely eradicating a common wart in a subject in need thereof is provided, the method comprising reducing the level of IL-23 by at least about 35% in the subject in need thereof. In one embodiment, a method for completely eradicating a common wart in a subject in need thereof is provided, the method comprising reducing the level of IL-23 by at least about 15% in the subject in need thereof. In one embodiment, the method of the present disclosure reduces the level of IL-23 by administering to the subject one or more intralesional injections of an amount of a pharmaceutical composition at a cumulative dose of 3 unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and secretory antigens.

[0142] In one embodiment, a method for reducing the level of IL-7 in a subject in need thereof is provided, the method comprising administering to the subject one or more intralesional injections of an amount of a pharmaceutical composition at a cumulative dose of 0.6 unit potency, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens. In one embodiment, the subject is diagnosed with at least one common wart. In one embodiment, the method of the present disclosure reduces the level of IL-7 in the subject by at least about 10% when receiving one cumulative dose of the pharmaceutical composition of the present disclosure, compared to the level of IL-7 measured in the subject before the administration step.

[0143] In one embodiment, a method for reducing the level of IL-7 in a subject in need thereof is provided, the method comprising administering to the subject one or more intralesional injections of an amount of a pharmaceutical composition at a cumulative dose of 3 unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and secretory antigens. In one embodiment, the subject is diagnosed with at least one common wart. In one embodiment, the method of the present disclosure reduces the level of IL-7 in the subject by at least about 20% when receiving one cumulative dose of the pharmaceutical composition of the present disclosure, compared to the level of IL-7 measured in the subject before the administration step.

[0144] In one embodiment, a method for reducing IP-10 levels in a subject in need thereof is provided, the method comprising administering to the subject one or more intralesional injections of an amount of a pharmaceutical composition at a cumulative dose of 3 unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and secretory antigens. In one embodiment, the subject is diagnosed with at least one common wart. In one embodiment, the method of the present disclosure reduces the level of IP-10 in the subject by at least about 5% when receiving a cumulative dose of the pharmaceutical composition of the present disclosure, compared to the level of IP-10 measured in the subject before the administration step.

[0145] In one embodiment, the disclosed method is effective in achieving a therapeutic goal at a cumulative dose of less than about 0.5 unit potency, less than about 1 unit potency, less than about 2 unit potency, less than about 3 unit potency, less than about 4 unit potency, less than about 5 unit potency, less than about 6 unit potency, less than about 7 unit potency, less than about 8 unit potency, less than about 9 unit potency, or less than about 10 unit potency. In one embodiment, the disclosed method is capable of achieving a therapeutic goal at a cumulative dose of less than about 0.5 unit potency, less than about 1 unit potency, less than about 2 unit potency, less than about 3 unit potency, less than about 4 unit potency, less than about 5 unit potency, less than about 6 unit potency, less than about 7 unit potency, less than about 8 unit potency, less than about 9 unit potency, or less than about 10 unit potency.

[0146] In one embodiment, the disclosed method is effective in achieving a therapeutic goal at a cumulative dose of at least about 0.5 unit potency, at least about 1 unit potency, at least about 2 unit potency, at least about 3 unit potency, at least about 4 unit potency, at least about 5 unit potency, at least about 6 unit potency, at least about 7 unit potency, at least about 8 unit potency, at least about 9 unit potency, or at least about 10 unit potency. In one embodiment, the disclosed method is capable of achieving a therapeutic goal at a cumulative dose of at least about 0.5 unit potency, at least about 1 unit potency, at least about 2 unit potency, at least about 3 unit potency, at least about 4 unit potency, at least about 5 unit potency, at least about 6 unit potency, at least about 7 unit potency, at least about 8 unit potency, at least about 9 unit potency, or at least about 10 unit potency.

[0147] In one embodiment, the method of the disclosure provides a cumulative dose of about 0.5 unit potency to about 10 unit potency, e.g., about 0.5 unit potency to about 9.5 unit potency, about 1 unit potency to about 9.5 unit potency, about 1.5 unit potency to about 9 unit potency, about 2 unit potency to about 9 unit potency, about 2 unit potency to about 8.5 unit potency, about 2.5 unit potency to about 8.5 unit potency, about 2.5 unit potency to about 8 unit potency, about 3 unit potency to about 3.5 unit potency, about 4 unit potency to about 4.5 unit potency, about 5 unit potency to about 5.5 unit potency, about 6 unit potency to about 6.5 unit potency, about 7 unit potency to about 7.5 unit potency, about 8 unit potency to about 8.5 unit potency, about 9 unit potency to about 9 unit potency, about 10 unit potency to about 10 unit potency, e.g. ... A cumulative dose of from about 1 unit potency to about 8 unit potency, from about 3 unit potency to about 7.5 unit potency, from about 3.5 unit potency to about 7.5 unit potency, from about 3.5 unit potency to about 7 unit potency, from about 4 unit potency to about 7 unit potency, from about 4 unit potency to about 6.5 unit potency, from about 4.5 unit potency to about 6.5 unit potency, from about 4.5 unit potency to about 6 unit potency, or from about 5 unit potency to about 6 unit potency is effective in achieving the therapeutic goal. In one embodiment, the method of the disclosure provides a cumulative dose of about 0.5 unit potency to about 10 unit potency, e.g., about 0.5 unit potency to about 9.5 unit potency, about 1 unit potency to about 9.5 unit potency, about 1.5 unit potency to about 9 unit potency, about 2 unit potency to about 9 unit potency, about 2 unit potency to about 8.5 unit potency, about 2.5 unit potency to about 8.5 unit potency, about 2.5 unit potency to about 8 unit potency, about 3 unit potency to about 9 unit potency, about 4 unit potency to about 9 unit potency, about 5 unit potency to about 9 unit potency, about 6 unit potency to about 9 unit potency, about 7 unit potency to about 10 unit potency, about 8 unit potency to about 10 unit potency, about 9 unit potency to about 10 unit potency, about 10 ... It is possible to achieve therapeutic goals with a cumulative dose of from about 1 unit potency to about 8 unit potency, from about 3 unit potency to about 7.5 unit potency, from about 3.5 unit potency to about 7.5 unit potency, from about 3.5 unit potency to about 7 unit potency, from about 4 unit potency to about 7 unit potency, from about 4 unit potency to about 6.5 unit potency, from about 4.5 unit potency to about 6.5 unit potency, from about 4.5 unit potency to about 6 unit potency, or from about 5 unit potency to about 6 unit potency.

[0148] In one embodiment, each dose administered in the method of the present disclosure can be administered via a form selected from the group consisting of oral, buccal, sublingual, topical, injection, infusion, inhalation, rectal, intravenous, intramuscular, and subcutaneous forms.In one embodiment, two or more intralesional injections are provided to a subject in need thereof over a period of time.In one embodiment, the potency of each dose is at least 0.3 unit potency.In one embodiment, the potency of each dose is at least 0.5 unit potency. In one embodiment, each dose is administered at a dose of at least about 0.1 unit potency to about 1 unit potency, such as from about 0.1 unit potency to about 0.9 unit potency, such as from about 0.2 unit potency to about 1 unit potency, such as from about 0.2 unit potency to about 0.8 unit potency, such as from about 0.2 unit potency to about 0.5 unit potency, such as from about 0.2 unit potency to about 0.4 unit potency, such as from about 0.3 unit potency to about 0.7 unit potency, or such as from about 0.4 unit potency to about 0.6 unit potency. In one embodiment, each dose has a volume of about 5 μL to about 500 μL, e.g., about 5 μL to about 450 μL, about 5 μL to about 400 μL, about 5 μL to about 350 μL, about 5 μL to about 300 μL, about 5 μL to about 250 μL, about 5 μL to about 200 μL, about 5 μL to about 150 μL, about 5 μL to about 100 μL, about 5 μL to about 50 μL, about 5 μL to about 40 μL, about 5 μL to about 30 μL, about 5 μL to about 20 μL, about 5 μL to about 10 μL. , about 50 μL to about 500 μL, about 50 μL to about 450 μL, about 50 μL to about 400 μL, about 50 μL to about 350 μL, about 50 μL to about 300 μL, about 50 μL to about 250 μL, about 50 μL to about 200 μL, about 50 μL to about 150 μL, about 50 μL to about 100 μL, about 100 μL to about 500 μL, about 150 μL to about 450 μL, about 200 μL to about 400 μL, or about 250 μL to about 350 μL. In one embodiment, a pair of doses is provided to a subject in need thereof about two weeks apart, e.g., 10, 11, 12, 13, 14, 15, 16, 17, or 18 days apart. In one embodiment, a pair of doses is provided to a subject in need thereof about three weeks apart, for example, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days apart.In one embodiment, the dose administered by the method is provided to a subject in need thereof for about 2 weeks to about 27 weeks, such as for about 2 weeks to about 26 weeks, such as for about 2 weeks to about 25 weeks, such as for about 2 weeks to about 24 weeks, such as for about 2 weeks to about 23 weeks, such as for about 2 weeks to about 22 weeks, such as for about 2 weeks to about 21 weeks, such as for about 2 weeks to about 20 weeks, such as for about 2 weeks to about 19 weeks, such as for about 2 weeks to about 18 weeks, such as for about 2 weeks to about 17 weeks, such as for about 2 weeks to about 27 weeks, such as for about 2 weeks to about 28 weeks, such as for about 2 weeks to about 29 weeks, such as for about 3 weeks to about 31 weeks, such as for about 3 weeks to about 32 weeks, such as for about 3 weeks to about 33 weeks, such as for about 3 weeks to about 34 weeks, such as for about 3 weeks to about 35 weeks, such as for about 3 weeks to about 36 weeks, such as for about 3 weeks to about 37 weeks, such as for about 3 weeks to about 38 weeks, such as for about 3 weeks to about 39 weeks, such as for about 3 weeks to about 40 weeks, such as for about 3 weeks to about 41 weeks, such as for about 3 weeks to about 42 weeks, such as for about 3 weeks to about 43 weeks, such as for about 3 weeks to about 44 weeks, such as for about 3 weeks to about 45 weeks, such as for about 3 weeks to about 46 weeks, such as for about 3 weeks to about 47 weeks, such as for about 3 weeks to about 48 weeks, such as for about 3 weeks to about 49 weeks, such as for about 3 weeks to about 50 weeks, such as for about 3 weeks to about 51 weeks, such as for about The vaccine is provided for about 2 weeks to about 16 weeks, for example, about 2 weeks to about 15 weeks, for example, about 2 weeks to about 14 weeks, for example, about 2 weeks to about 13 weeks, for example, about 2 weeks to about 12 weeks, for example, about 2 weeks to about 11 weeks, for example, about 2 weeks to about 10 weeks, for example, about 2 weeks to about 9 weeks, for example, about 2 weeks to about 8 weeks, for example, about 2 weeks to about 7 weeks, for example, about 2 weeks to about 6 weeks, for example, about 2 weeks to about 5 weeks, for example, about 2 weeks to about 4 weeks, or for example, about 2 weeks to about 3 weeks. In one embodiment, the dose administered by the method is provided to a subject in need thereof for a period of about 3 weeks to about 27 weeks, e.g., about 4 weeks to about 27 weeks, about 5 weeks to about 27 weeks, about 6 weeks to about 27 weeks, about 7 weeks to about 27 weeks, about 8 weeks to about 27 weeks, about 9 weeks to about 27 weeks, about 10 weeks to about 27 weeks, about 11 weeks to about 27 weeks, about 12 weeks to about 27 weeks, about 13 weeks to about 27 weeks. , for a period of about 14 weeks to about 27 weeks, about 15 weeks to about 27 weeks, about 16 weeks to about 27 weeks, about 17 weeks to about 27 weeks, about 18 weeks to about 27 weeks, about 19 weeks to about 27 weeks, about 20 weeks to about 27 weeks, about 21 weeks to about 27 weeks, about 22 weeks to about 27 weeks, about 23 weeks to about 27 weeks, about 24 weeks to about 27 weeks, about 25 weeks to about 27 weeks, or about 26 weeks to about 27 weeks. In one embodiment, the doses administered in the method are provided to a subject in need thereof for a period of about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 21 weeks, about 22 weeks, about 23 weeks, about 24 weeks, about 25 weeks, about 26 weeks, or about 27 weeks.

[0149] In one embodiment, intralesional injection is provided to a subject in need thereof. In one embodiment, intralesional injection is provided to the margin of the common wart to be treated. In one embodiment, intralesional injection is provided near the margin of the common wart to be treated. In one embodiment, intralesional injection is provided at a position about 5 mm or less from the margin of the common wart to be treated, for example, about 4 mm or less, about 3 mm or less, about 2 mm or less, or about 1 mm or less from the margin of the common wart. In one embodiment, the margin is defined by the margin of the wart. In one embodiment, intralesional injection is provided to the common wart to be treated. In one embodiment, intralesional injection is provided to the largest common wart in an anatomical region in the presence of multiple common warts in the same anatomical region. In one embodiment, the intralesional injection is provided to the largest common wart in an anatomical region in the presence of multiple common and non-common warts in the same anatomical region, hi one embodiment, the largest common wart is determined by selecting the common wart in the anatomical region that has the largest diameter.

[0150] In one embodiment, the subject has a common wart vulgaris measuring between about 3 mm and about 20 mm prior to the initiation of a treatment of the present disclosure, e.g., between about 3 mm and about 19 mm, between about 4 mm and about 20 mm, between about 4 mm and about 19 mm, between about 5 mm and about 19 mm, between about 5 mm and about 18 mm, between about 6 mm and about 18 mm, between about 6 mm and about 17 mm, between about 7 mm and about 16 mm, between about 7 mm and about 15 mm, between about 8 mm and about 15 mm, between about 8 mm and about 14 mm, between about 9 mm and about 14 mm, between about 9 mm and about 13 mm, between about 10 mm and about 13 mm, between about 10 mm and about 12 mm, or between about 11 mm and about 12 mm. In one embodiment, the subject has a common wart vulgaris with a dimension between about 20mm and about 1cm, such as between about 20mm and about 95mm, such as between 25mm and about 1cm, such as between about 20mm and about 90mm, such as between about 25mm and about 95mm, such as between about 25mm and about 90mm, such as between about 30mm and about 90mm, such as between about 30cm and about 85mm, such as between about 35mm and about 85mm, such as between about 35mm and about 80mm, such as between about 40mm and about 80mm, such as between about 40mm and about 75mm, such as between about 45mm and about 75mm, such as between about 45mm and about 60mm, such as between about 50mm and about 70mm, such as between about 50mm and about 65mm, such as between about 55mm and about 65mm, or such as between about 55mm and about 60mm.In one embodiment, the subject has a common wart measuring between about 1 cm and about 100 cm, e.g., between about 1 cm and about 95 cm, between about 5 cm and about 100 cm, between about 5 cm and about 95 cm, between about 10 cm and about 95 cm, between about 10 cm and about 90 cm, between about 15 cm and about 90 cm, between about 15 cm and about 85 cm, between about 20 cm and about 85 cm, between about 20 cm and about 80 cm, between about 25 cm and about 50 cm, between about 30 cm and about 55 cm, between about 35 cm and about 50 cm, between about 35 ...0 cm, between about 35 cm and about 50 cm, between about 35 cm and about 50 cm, between about 35 cm and about 50 cm, between about 35 cm and about 50 cm, between about common warts measuring between about 25 cm and about 80 cm, between about 25 cm and about 75 cm, between about 30 cm and about 75 cm, between about 30 cm and about 70 cm, between about 35 cm and about 70 cm, between about 35 cm and about 65 cm, between about 40 cm and about 65 cm, between about 40 cm and about 60 cm, between about 45 cm and about 60 cm, between about 45 cm and about 55 cm, or between about 50 cm and about 55 cm.

[0151] In one embodiment, two or more intralesional injections are provided to a subject in need thereof over a period of time. In one embodiment, each of the two or more intralesional injections is provided at a dose of at least 0.5 unit potency. In one embodiment, each of the two or more intralesional injections is administered at a dose of at least about 0.1 unit potency to about 1 unit potency, such as about 0.1 unit potency to about 0.9 unit potency, such as about 0.2 unit potency to about 1 unit potency, such as about 0.2 unit potency to about 0.8 unit potency, such as about 0.3 unit potency to about 0.7 unit potency, or such as about 0.4 unit potency to about 0.6 unit potency. In one embodiment, each of the two or more intralesional injections is in a volume of about 5 μL to about 500 μL, e.g., about 5 μL to about 450 μL, about 5 μL to about 400 μL, about 5 μL to about 350 μL, about 5 μL to about 300 μL, about 5 μL to about 250 μL, about 5 μL to about 200 μL, about 5 μL to about 150 μL, about 5 μL to about 100 μL, about 5 μL to about 50 μL, about 5 μL to about 40 μL, about 5 μL to about 30 μL, about 5 μL to about 20 μL, about 5 μL to about 50 μL, It is provided in a volume of about 10 μL, about 50 μL to about 500 μL, about 50 μL to about 450 μL, about 50 μL to about 400 μL, about 50 μL to about 350 μL, about 50 μL to about 300 μL, about 50 μL to about 250 μL, about 50 μL to about 200 μL, about 50 μL to about 150 μL, about 50 μL to about 100 μL, about 100 μL to about 500 μL, about 150 μL to about 450 μL, about 200 μL to about 400 μL, or about 250 μL to about 350 μL.

[0152] In one embodiment, a pair of intralesional injections of the two or more intralesional injections are provided to a subject in need thereof about two weeks apart, for example, 10, 11, 12, 13, 14, 15, 16, 17, or 18 days apart. In one embodiment, a pair of intralesional injections of the two or more intralesional injections are provided to a subject in need thereof about three weeks apart, for example, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days apart.

[0153] In one embodiment, the two or more intralesional injections are provided to a subject in need thereof over a period of about 2 weeks to about 27 weeks, such as from about 2 weeks to about 26 weeks, for example, from about 2 weeks to about 25 weeks, for example, from about 2 weeks to about 24 weeks, for example, from about 2 weeks to about 23 weeks, for example, from about 2 weeks to about 22 weeks, for example, from about 2 weeks to about 21 weeks, for example, from about 2 weeks to about 20 weeks, for example, from about 2 weeks to about 19 weeks, for example, from about 2 weeks to about 18 weeks, for example, from about 2 weeks to about 17 weeks, for example, The vaccine is provided for 2 weeks to about 16 weeks, for example, for about 2 weeks to about 15 weeks, for example, for about 2 weeks to about 14 weeks, for example, for about 2 weeks to about 13 weeks, for example, for about 2 weeks to about 12 weeks, for example, for about 2 weeks to about 11 weeks, for example, for about 2 weeks to about 10 weeks, for example, for about 2 weeks to about 9 weeks, for example, for about 2 weeks to about 8 weeks, for example, for about 2 weeks to about 7 weeks, for example, for about 2 weeks to about 6 weeks, for example, for about 2 weeks to about 5 weeks, for example, for about 2 weeks to about 4 weeks, or for example, for about 2 weeks to about 3 weeks. In one embodiment, the two or more intralesional injections are provided to a subject in need thereof over a period of about 3 weeks to about 27 weeks, e.g., about 4 weeks to about 27 weeks, about 5 weeks to about 27 weeks, about 6 weeks to about 27 weeks, about 7 weeks to about 27 weeks, about 8 weeks to about 27 weeks, about 9 weeks to about 27 weeks, about 10 weeks to about 27 weeks, about 11 weeks to about 27 weeks, about 12 weeks to about 27 weeks, about 13 weeks to about 27 weeks, The vaccine may be provided for a period of about 14 weeks to about 27 weeks, about 15 weeks to about 27 weeks, about 16 weeks to about 27 weeks, about 17 weeks to about 27 weeks, about 18 weeks to about 27 weeks, about 19 weeks to about 27 weeks, about 20 weeks to about 27 weeks, about 21 weeks to about 27 weeks, about 22 weeks to about 27 weeks, about 23 weeks to about 27 weeks, about 24 weeks to about 27 weeks, about 25 weeks to about 27 weeks, or about 26 weeks to about 27 weeks. In one embodiment, two or more intralesional injections are provided to a subject in need thereof over a period of about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 21 weeks, about 22 weeks, about 23 weeks, about 24 weeks, about 25 weeks, about 26 weeks, or about 27 weeks.

[0154] In one embodiment, two or more intralesional injections are provided to a subject in need thereof in subgroups of two or more intralesional injections over a period of time. In one embodiment, each of the two or more subgroups is provided at a dose of at least 0.5 unit potency. In one embodiment, each of the two or more subgroups is provided at a dose of at least about 0.1 unit potency to about 1 unit potency, such as about 0.1 unit potency to about 0.9 unit potency, such as about 0.2 unit potency to about 1 unit potency, such as about 0.2 unit potency to about 0.8 unit potency, such as about 0.3 unit potency to about 0.7 unit potency, or about 0.4 unit potency to about 0.6 unit potency. In one embodiment, each of the two or more subgroups is provided in a volume of about 5 μL to about 500 μL, e.g., about 5 μL to about 450 μL, about 5 μL to about 400 μL, about 5 μL to about 350 μL, about 5 μL to about 300 μL, about 5 μL to about 250 μL, about 5 μL to about 200 μL, about 5 μL to about 150 μL, about 5 μL to about 100 μL, about 5 μL to about 50 μL, about 5 μL to about 40 μL, about 5 μL to about 5 ... The solution may be provided in a volume of about 30 μL, about 5 μL to about 20 μL, about 5 μL to about 10 μL, about 50 μL to about 500 μL, about 50 μL to about 450 μL, about 50 μL to about 400 μL, about 50 μL to about 350 μL, about 50 μL to about 300 μL, about 50 μL to about 250 μL, about 50 μL to about 200 μL, about 50 μL to about 150 μL, about 50 μL to about 100 μL, about 100 μL to about 500 μL, about 150 μL to about 450 μL, about 200 μL to about 400 μL, or about 250 μL to about 350 μL.

[0155] In one embodiment, a pair of subgroups within the two or more intralesional injection subgroups are provided to a subject in need thereof about two weeks apart, e.g., 10, 11, 12, 13, 14, 15, 16, 17, or 18 days apart. In one embodiment, a pair of subgroups within the two or more intralesional injection subgroups are provided to a subject in need thereof about three weeks apart, e.g., 17, 18, 19, 20, 21, 22, 23, 24, or 25 days apart.

[0156] In one embodiment, a subgroup of intralesional injections includes at least two intralesional injections, e.g., two intralesional injections, three intralesional injections, four intralesional injections, five intralesional injections, six intralesional injections, seven intralesional injections, eight intralesional injections, nine intralesional injections, or ten intralesional injections.

[0157] In one embodiment, the intralesional injections within a subgroup of intralesional injections are administered at about the same time, e.g., within about 1 minute, within about 2 minutes, within about 3 minutes, within about 4 minutes, within about 5 minutes, etc. In one embodiment, the intralesional injections within a subgroup of intralesional injections are administered within a 24 hour period, e.g., within about 18 hours, within about 12 hours, within about 6 hours, within about 5 hours, within about 4 hours, within about 3 hours, within about 2 hours, or within about 1 hour.

[0158] In one embodiment, the intralesional injections in the subgroup of intralesional injections are provided around the periphery of the wart to be treated. In one embodiment, the intralesional injections in the subgroup of intralesional injections are equally spaced around the periphery of the wart to be treated. In one embodiment, each of the intralesional injections in the subgroup of intralesional injections is provided at a position not greater than about 5 mm from the periphery of the wart to be treated, for example, not greater than about 4 mm, not greater than about 3 mm, not greater than about 2 mm, or not greater than about 1 mm from the periphery of the wart. In one embodiment, the intralesional injections in the subgroup of intralesional injections are equally spaced around the periphery of the wart to be treated. In one embodiment, the periphery is defined by the periphery of the wart.

[0159] In one embodiment, the pharmaceutical composition administered by the methods of the present disclosure comprises a filtered extract of two strains of Candida albicans and secreted antigens, where a representative sample of the first strain is deposited with the ATCC under ATCC Accession No. PTA-126019 and a representative sample of the second strain is deposited with the ATCC under ATCC Accession No. PTA-126020. In one embodiment, a representative sample of the first strain is deposited with the ATCC under ATCC Accession No. ATCC-10231.

[0160] In one embodiment, the subject treated with the method of the present disclosure is between 18 and 65 years old, for example, between 20 and 60 years old, between 18 and 30 years old, between 25 and 50 years old, between 30 and 40 years old, between 40 and 50 years old, or between 50 and 65 years old. In one embodiment, the subject treated with the method of the present disclosure is a pediatric patient. In one embodiment, the pediatric patient is a premature newborn. In one embodiment, the pediatric patient is in the neonatal stage. In one embodiment, the pediatric patient is a newborn. In one embodiment, the pediatric patient is an infant. In one embodiment, the pediatric patient is a toddler. In one embodiment, the pediatric patient is a young child. In one embodiment, the pediatric patient is a child. In one embodiment, the pediatric patient is an adolescent. In one embodiment, the pediatric patient is a child patient less than about 18, 15, 12, 10, 8, 6, 4, 3, 2, or 1 year old. In one embodiment, the subject treated with the method of the present disclosure has been diagnosed with a first common wart at least 12 weeks prior to receiving one or more intralesional injections, for example, between 12 and 100 weeks, between 15 and 90 weeks, between 20 and 80 weeks, between 25 and 75 weeks, between 30 and 70 weeks, between 35 and 65 weeks, between 40 and 60 weeks, between 45 and 55 weeks, or between 50 and 55 weeks. In one embodiment, the subject treated by the method of the present disclosure has not been diagnosed with refractory warts.In one embodiment, refractory warts are warts that have not been successfully treated by previous treatments, except OTC drugs.In one embodiment, refractory warts are warts that have not been successfully treated by one or more types of previous treatments, for example, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more types of previous treatments.In one embodiment, OTC drugs are medicines that are sold directly to consumers without prescription from medical professionals.

[0161] In one embodiment, subjects treated with the disclosed method have a baseline result of between 5 mm and 25 mm for delayed type hypersensitivity (DTH) testing. In one embodiment, the DTH test is performed by administering a single intradermal injection of CANDIN® (0.1 mL; Allermed / Nielsen Biosciences) on the palmar aspect of the forearm or the lateral aspect of the upper arm at least 2 cm away from any primary injectable wart. Before applying the skin test, the skin is wiped with 70% alcohol. The intradermal injection is performed as superficially as possible, which results in a clear, well-defined bleb. The test is read 48±4 hours after the DTH challenge injection by visually inspecting the test site and palpating the area of ​​induration. Measurements are taken at two diameters. The average of the longest and midpoint perpendicular diameters of the area of ​​induration is reported as the DTH response.

[0162] In one embodiment, the subject treated with the method of the present disclosure has not been diagnosed with a systemic disease that impairs immune function. In one embodiment, the subject treated with the method of the present disclosure has not been diagnosed with a localized disease that impairs immune function. In one embodiment, the subject treated with the method of the present disclosure has not been diagnosed with a systemic condition that impairs immune function. In one embodiment, the subject treated with the method of the present disclosure has not been diagnosed with a localized condition that impairs immune function. In one embodiment, the subject treated with the method of the present disclosure has not been diagnosed with psoriasis. In one embodiment, the subject treated with the method of the present disclosure has not been treated to cause an immune-compromised condition.

[0163] In one embodiment, the subject treated with the methods of the present disclosure has not been diagnosed with diabetes. In one embodiment, the subject treated by the method of the present disclosure does not have a history of keloid formation.In one embodiment, the subject treated by the method of the present disclosure does not have a pre-existing dermatological condition in the same anatomical area as the wart being treated.In one embodiment, the subject treated by the method of the present disclosure does not have an underlying inflammatory condition.In one embodiment, the underlying inflammatory condition is an arthritic joint.

[0164] In one embodiment, the subject treated with the method of the present disclosure has not received one or more treatments selected from the group consisting of liquid nitrogen, carbon dioxide, electrodesiccation, laser, surgery, simple occlusion (e.g., duct tape), salicylic acid or related acids (including trichloroacetic acid and bichloroacetic acid), OTC drugs, and cantharidin within 4 weeks prior to the administration step. In one embodiment, the subject treated with the method of the present disclosure has not received one or more immunotherapies selected from the group consisting of diphenylcyclopropenone (DPCP), dinitrochlorobenzene (DNCB), imiquimod, 5-fluorouracil, bleomycin, and podophyllin within 12 weeks prior to the administration step. In one embodiment, the subject treated with the method of the present disclosure has not received one or more systemic therapies selected from the group consisting of cimetidine, zinc supplements at doses higher than 20 mg elemental zinc per day, azathioprine, 6-mercaptopurine, methotrexate, infliximab, adalimumab, etanercept, and steroids within 12 weeks prior to the administration step.In one embodiment, the subject treated with the method of the present disclosure has not received any investigational drug within 30 days prior to the administration step.In one embodiment, the subject treated with the method of the present disclosure has not received any of the above investigational drugs within 5 half-lives prior to the administration step. EXAMPLES

[0165] Example 1: Production of a composition containing sterile filtrates of Candida albicans and secretory antigens First, a preproduction culture is prepared by aseptically removing one loopful of stock culture of each of two strains of Candida albicans (ATCC accession numbers: PTA-126019 and PTA-126020) from the oil cover stock culture and placing it into animal component-free trypticase soy broth (ATSB; TechNova, Dartmouth, Nova Scotia). The preproduction culture is incubated at 20-25°C until a growth pellet is observed at the bottom of the tube (usually within 7-14 days). After evidence of fungal growth (e.g., milky yeast-like growth at the bottom of the tube) is observed, a portion of the growth is transferred to a plate of animal component-free trypticase soy agar (ATSA; TechNova, Dartmouth, Nova Scotia) and incubated at 20-25°C for 3-7 days. The growth from the ATSA plate is passaged onto a fresh ATSA plate and the plate is streaked to generate isolated colonies. Incubate the ATSA plates at 20-25 °C for 3-7 days.

[0166] From the ATSA plate, several isolated colonies with characteristic morphology (see Figures 1 and 2, which show the characteristic morphology of isolated colonies of the first and second strains, respectively) are transferred to an Erlenmeyer flask containing Chemically Defined Candida Medium (CDCM; TechNova, Dartmouth, Nova Scotia). CDCM consists of 3.6 g / L KH2PO4, 1.2 g / L Na2HPO4, 8.0 g / L (NH4)2SO4, 0.2 g / L MgSO4·7H2O, 0.01 g / L ZnSO4·7H2O, 8.0 g / L sucrose, and 0.01 g / L biotin. The Erlenmeyer flask is incubated at a temperature of 20-25 °C for 3-7 days on a shaker set at approximately 60 rpm. With reference to Figure 1, isolated colonies of the first strain, deposited under ATCC Accession No. PTA-126019, appear as a creamy paste with smooth edges. With reference to Figure 2, isolated colonies of the second strain, deposited under ATCC Accession No. PTA-126020, appear as a white-cream color with some roughness and irregular edges.

[0167] When the inoculum displays budding yeast pseudohyphae (see Figure 3 for a diagram of Candida albicans budding yeast cells and Figure 4 for Candida albicans pseudohyphae) and is free of bacteria, transfer each stock at an approximate 1:100 dilution to separate production flasks containing CDCM. For example, transfer approximately 1.0 mL of each stock to a separate production flask containing 100 mL of CDCM, or transfer approximately 10 mL of each stock to a separate production flask containing 1000 mL of CDCM. Incubate the production flasks at 20-25 °C for 7 days on a shaker set at 60 rotations or oscillations per minute.

[0168] Once incubation is complete, 1.0 mL of 1% phenol is added to each production flask. The flasks are stored at 20-25 °C for 7 days to kill the fungus. The contents of all production flasks that contain acceptable growth and are free of impurities are then pooled into a sterile glass bottle. The pooled material is cultured by adding 1.0 mL to each of three 40 mL tubes of Trypticase Soy Broth (TSB; TechNova, Dartmouth, Nova Scotia). Each TSB culture is further diluted 10-fold in TSB and incubated at 20-25 °C for 7 days to ensure no viables. The pooled production material is stored in a storage bottle at 20-25 °C for 7 days during the culture period.

[0169] The pooled cultures are dialyzed in USP grade Water for Injection (WFI; TechNova, Dartmouth, Nova Scotia) at 1-8 °C using Spectrapor 6,000-8,000 MWCO dialysis tubing (size 40 mm). Dialyze against 20 volumes of WFI and repeat the procedure twice with a 24-h interval. The dialyzed material is then uniformly heated in a water bath at 90-95 °C for 60 min.

[0170] Add 200 mL of the heat-treated dialyzed material to a 600 mL lyophilization flask and freeze-dry in a Labconco freeze-dryer. This procedure is repeated until the entire lot is lyophilized. The lyophilized material is then covered with petroleum ether for 6-8 hours at 20-25 °C and the supernatant is discarded by filtration. The resulting material is air-dried in a fume hood. This is the dry powder denoted as source material for further processing.

[0171] The source material is diluted with Coca's glycerol solution (0.25% NaCl, 0.125% NaHCO3, 53% glycerin; 47% WFI) with a pH ranging from 6 to 8.5 at the desired weight / volume extraction ratio. In one embodiment, the volumetric extraction ratio is 1:20 w / v, adding 20 mL of Coca's glycerol solution for every gram of source material. The extract is mixed intermittently on a magnetic stirrer at 1-8° C. for approximately 71 hours, until the source material appears homogenous throughout the mixture.

[0172] The extract is then centrifuged at approximately 4000 RPM for 20 minutes. The extract is then filtered by vacuum filtration using a Buchner funnel and Whatman No. 3 filter paper. The filtered extract is adjusted to have a final concentration of 0.4% phenol and returned to 1-8°C. The product is filtered through a sterile Sartorius 0.2 μm filter capsule (#5231307H) and under a class 100 laminar flow hood in a class 100,000 room.

[0173] In a sterile filtration room, sterile Sartorius "Sartobran" 0.45 / 0.2μm [5235307H7OOA (0.05m 2 ) or 5231307H5OOB(0.03m 2 Sterilize the product using 20 mL of 500 mL of diluent (100% ethanol). Collect the filtered solution in an appropriately sized sterile depyrogenated container and store the filtered solution at 1-8 °C. Finally, dilute 1.7 mL of this master lot filtered solution with 998.3 mL of diluent consisting of 5.0 g / L NaCl, 2.5 g / L NaHCO3, 4.5 mL / L phenol, 1.2 mL / L 20% solution human serum albumin, and 0.8 mL / L polysorbate 80.

[0174] Example 2: Intralesional injection for warts Intralesional injection of the pharmaceutical composition of the present disclosure into a wart is provided at the bottom of the common wart, in the interdigitated base region of the wart. FIG. 6 shows a preferred location for intralesional injection. Preferably, upon injection, blanching of the treated wart is observed. Without being limited by theory, the injection is performed slowly to aid in spreading the injected pharmaceutical composition along the dermo-epidermal junction. Most injections are performed with the bevel facing down. However, for particularly thick warts, injections may be performed with the needle bevel facing up. For particularly thin warts, injections may be performed with the needle bevel facing sideways. After injection, moderate pressure is applied to the injected wart.

[0175] In some cases, doses of the pharmaceutical composition may be injected via multiple injections into interdigitated bases of the warts.

[0176] Example 3: Injection treatment of a single wart To treat patients diagnosed with common warts, a 0.5 unit strength dose of the pharmaceutical composition of the present disclosure is provided for the largest common wart once every 2 weeks (14±2 days) for up to 10 intralesional injections. If the primary common wart shows a complete response, the next largest injectable common wart in all anatomical regions is injected with the same pharmaceutical composition at the same 0.5 unit strength dose. If an injected wart recurs after showing a complete response, that wart is reinjected in place of the non-primary wart injected at the previous visit. This injection strategy is repeated for up to 10 injections, or until all injectable common warts show a complete response before all 10 injections are used.

[0177] The treatment was effective in completely eradicating 85% of all primary injected warts at any given injection time, compared with 52% with placebo injections. Additionally, 75% of all warts mapped at baseline were completely cleared in subjects injected with the pharmaceutical composition of the present disclosure compared to 34% in subjects injected with placebo. The median number of injections required to completely clear the first injected wart was 5 injections compared with 10 injections for placebo. Furthermore, 4 months after the last injection, 50% of the first injected warts remained completely clear compared with 31% for placebo.

[0178] The treatment was also effective in clearing all common warts in 53% of 52 treated subjects, compared with 21% of subjects given a placebo. Of patients diagnosed with non-common warts, 75% showed disappearance of non-common warts, compared with 57% of those given a placebo.

[0179] Furthermore, the treatment was able to eliminate 47% of primary injected warts previously treated with cryotherapy, compared with 21% with placebo.

[0180] 10% of subjects receiving treatment showed scarring at the site of the cleared wart compared to 6% of subjects receiving placebo. 3% of subjects receiving treatment showed depigmentation at the site of the cleared wart compared to 0% of subjects receiving placebo.

[0181] Example 4: Injection treatment for multiple warts To treat patients diagnosed with common warts in at least two different anatomical regions, the pharmaceutical composition of the present disclosure is injected into the largest common wart (primary) in each anatomical region at a minimum of two and a maximum of four injections of 0.3 unit strength per visit every two weeks (14±2 days) for a maximum of ten injection visits. No more than one wart is injected per anatomical region at any one visit. If any primary injected wart shows a complete response, the next largest injectable common wart is injected with the same pharmaceutical composition at the same dose of 0.3 unit strength (maximum of four per visit), provided that the new injectable wart is not in the same anatomical region as any other wart currently being injected. If an injected wart shows a complete response and then recurs, it is reinjected in place of the non-primary wart injected at the previous visit. This injection strategy will be repeated for a total of up to 10 injection visits per subject, or if all injectable common warts show a complete response before the end of 10 injection visits.

[0182] The treatment was effective in completely eradicating 82% of the largest primary injected warts at any given injection number, compared to 52% with placebo injections. The median number of injections required to completely eradicate the largest primary injected wart was 4 injections, compared to 10 injections with placebo. Furthermore, 4 months after the last injection, 43% of the largest primary injected warts remained completely eradicated, compared to 31% with placebo injections.

[0183] 7% of subjects receiving treatment had scarring at the site of the cleared wart compared to 6% of subjects receiving placebo. 3% of subjects receiving treatment had depigmentation at the site of the cleared wart compared to 0% of subjects receiving placebo.

[0184] Example 5: Changes in cytokine biomarkers in wart patients A total of 58 subjects will be provided with intralesional injections to assess biomarker changes in wart patients. The pharmaceutical composition of the present disclosure will be provided to each of 43 subjects with up to 10 injections every 2 weeks into the largest wart (primary) lesion at a dose of 0.3 strength per injection, while placebo will be provided to each of 15 subjects with up to 10 injections every 2 weeks into the primary wart lesion.

[0185] If the primary wart shows a complete response, the same dose is used to treat the next larger wart. This strategy is repeated until all warts are gone or for 10 injections, whichever comes first. If an injected wart recurs after showing a complete response, it is re-treated in place of the wart injected at the previous visit.

[0186] Blood samples are collected at screening before treatment initiation (V1), after treatment injections but just prior to the third injection (V5), and at study completion, i.e., disappearance of all warts or after 10 injections (V13). Plasma separated from the blood is stored at -80°C until assayed for multiple protein biomarkers (45-plex cytokine / chemokine / growth factor panel) from BioAgilytix (Durham, NC).

[0187] Check individual sample results to ensure they fall within valid standards. Exclude results that are outside the valid range.

[0188] Table 1 shows summary statistics for treatment and placebo groups for study monitoring levels of IL-23, IL-7, and IP-10. Only p-values ​​less than 0.05 are included in the table. [Table 1]

[0189] In this study, when comparing treatment and placebo groups, the placebo group tended to have higher biomarker concentrations than the treatment group at all visits, including Visit 1, where blood samples were taken prior to any injections. P values ​​for comparing mean concentrations at each visit are reported when differences were considered significant (p<0.05). In each case, the mean concentrations in the placebo group were higher than the treatment group.

[0190] Additionally, this study compared changes in biomarker levels relative to baseline (V13-V1) between treatment groups. In general, a relative decrease in biomarker levels was observed in the active treatment group compared to the placebo group. Three biomarkers (IL7, IP-10, and IL-23) showed a statistically significant decrease after treatment compared to the placebo group. Figures 7A, 7B, and 7C show the comparison of changes in biomarker levels for IL-7, IP-10, and IL-23, respectively, using one-way ANOVA analysis. A indicates treatment group, P indicates placebo group, and changes in biomarker levels are reported in terms of pg / mL.

[0191] The active treatment group is subdivided into those who showed complete disappearance of all treated warts and those who showed less than 50% complete disappearance. Comparison of the mean changes after treatment between these two subgroups reveals a striking difference in the cytokine IL-23. The changes observed in the high-responder subgroup correspond to a 35% decrease from baseline values, while the low-responder subgroup shows a 5% decrease. In contrast, the placebo group shows, on average, a 35% increase in IL-23 concentrations. Example 6: Injection treatment of a single wart

[0192] To treat patients aged 12-65 years with between 3 and 20 common warts, a dose of 0.3 unit strength of the pharmaceutical composition of the present disclosure is provided for the largest common wart once every 2 weeks (14±2 days) for up to 6 intralesional injections. If the primary common wart shows a complete response, the next largest injectable common wart in all anatomical regions is injected with the same pharmaceutical composition at the same dose of 0.3 unit strength. If an injected wart recurs after showing a complete response, that wart is reinjected in place of the non-primary wart injected at the previous visit. This injection strategy is repeated for up to 6 injections, or until all injectable common warts show a complete response before all 6 injections are used. Complete clearance of the primary wart is determined 1 month after the last injection.

[0193] The treatment was effective in completely eradicating 66% of all primary injected warts at any given injection time, compared with 37% with placebo injections. The median number of injections required to completely clear the first injected wart was 5 injections compared with 10 injections for placebo. Furthermore, 4 months after the last injection, 46% of the first injected warts remained completely clear compared with 37% for placebo.

[0194] The treatment was also effective in clearing all common warts in 32% of 61 treated subjects, compared with 21% who received a placebo.

[0195] From the above, it will be appreciated that the present invention can be embodied in a variety of ways, including but not limited to the following.

[0196] Embodiment 1. A method for treating common warts in a subject in need thereof comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective for complete disappearance of the common warts, at a cumulative dose of 2.5 unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and a secretory antigen.

[0197] Embodiment 2. The method of embodiment 1, wherein the pharmaceutical composition is further effective at a cumulative dose of 1 unit strength to reduce the diameter of the common wart by at least 50%.

[0198] Embodiment 3. A method for treating common warts in a subject in need thereof comprising administering to the subject one or more intralesional injections of a pharmaceutical composition comprising a filtered extract of Candida albicans and a secretory antigen in an amount sufficient to effect complete disappearance of the common warts at a cumulative dose of 2.5 unit strength.

[0199] Embodiment 4. The method of embodiment 3, wherein the pharmaceutical composition is further capable of reducing the diameter of the common wart by at least 50% at a cumulative dose of 1 unit strength.

[0200] Embodiment 5. The method of embodiment 1 or 3, wherein said complete disappearance is identified by observing that said common wart does not recur at the same site at least 20 weeks after administration of the first intralesional injection.

[0201] Embodiment 6. The method of embodiment 1 or 3, wherein said complete disappearance is accompanied by the absence of scarring at the location of said common wart.

[0202] Embodiment 7. The method of embodiment 1 or 3, wherein said complete disappearance is accompanied by a low level of depigmentation at the location of said common wart.

[0203] Embodiment 8. The method of any one of embodiments 1-4, wherein prior to said administering, said common warts are between about 3 mm and about 20 mm in size.

[0204] Embodiment 9. The method of any one of embodiments 1 to 4, wherein said administering is providing an intralesional injection to said subject.

[0205] Embodiment 10. The method of embodiment 9, wherein said administering is providing an intralesional injection near the margins of said common wart.

[0206] Embodiment 11. The method of embodiment 9, wherein said administering is providing an intralesional injection at the margins of said common wart.

[0207] Embodiment 12 The method of embodiment 9, wherein said administering is providing an intralesional injection within said common wart.

[0208] Embodiment 13. The method of any one of embodiments 1 to 4, wherein said administering comprises providing two or more intralesional injections to said subject.

[0209] Embodiment 14. The method of embodiment 13, wherein each of said two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

[0210] Embodiment 15. The method of any one of embodiments 1-4, wherein the two or more intralesional injections are provided to the subject over a period of time.

[0211] Embodiment 16 The method of embodiment 15, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about two weeks apart.

[0212] Embodiment 17. The method of embodiment 15, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about three weeks apart.

[0213] Embodiment 18. The method of embodiment 15, wherein the two or more intralesional injections are provided to the subject over a period of at least about 8 weeks.

[0214] Embodiment 19. The method of embodiment 13, wherein the two or more intralesional injections are provided in subgroups of two or more intralesional injections over a period of time.

[0215] Embodiment 20. The method of embodiment 19, wherein a subgroup within said two or more intralesional injection subgroups provides a total dose of at least 0.5 unit strength.

[0216] Embodiment 21. The method of embodiment 19 or 20, wherein a pair of subgroups within said two or more intralesional injection subgroups is provided to said subject about two weeks apart.

[0217] Embodiment 22. The method of embodiment 19 or 20, wherein a pair of subgroups of the two or more intralesional injections is provided to the subject about three weeks apart.

[0218] Embodiment 23 The method of embodiment 19 or 20, wherein said subgroups of two or more intralesional injections are provided to said subject over a period of at least about 8 weeks.

[0219] Embodiment 24 The method of embodiment 19 or 20, wherein a subgroup within said two or more subgroups comprises two intralesional injections around said common wart.

[0220] Embodiment 25. The method of embodiment 19 or 20, wherein a subgroup within said two or more subgroups comprises three intralesional injections around said common wart.

[0221] Embodiment 26 The method of embodiment 19 or 20, wherein a subgroup within said two or more subgroups comprises four intralesional injections around said common wart.

[0222] Embodiment 27 The method of embodiment 19 or 20, wherein a subgroup within said two or more subgroups comprises five injections around said common wart.

[0223] Embodiment 28. The method of embodiment 19 or 20, wherein a subgroup within said two or more subgroups comprises six intralesional injections around said common wart.

[0224] Embodiment 29. The method of any one of embodiments 24-28, wherein the intralesional injections within said subgroups are approximately equally spaced about the margins of the common wart.

[0225] Embodiment 30. The method of any one of embodiments 24-28, wherein the intralesional injections within said subgroups are approximately equally spaced around the margins of the common wart.

[0226] Embodiment 31 The method of any one of embodiments 24-28, wherein said intralesional injections within said subgroups are administered approximately simultaneously.

[0227] Embodiment 32. A method for treating common warts in a subject in need thereof, comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective to partially clear the common warts, at a cumulative dose of 5 unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and secretory antigens.

[0228] Embodiment 33. The method of embodiment 32, wherein the pharmaceutical composition is further effective at a cumulative dose of 1 unit strength to reduce the diameter of the common wart by at least 50%.

[0229] Embodiment 34. A method for treating common warts in a subject in need thereof, comprising administering to the subject one or more intralesional injections of a pharmaceutical composition capable of partial disappearance of the common warts at a cumulative dose of 5 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens.

[0230] Embodiment 35. The method of embodiment 34, wherein the pharmaceutical composition is further capable of reducing the diameter of the common wart by at least 50% at a cumulative dose of 1 unit strength.

[0231] Embodiment 36 The method of embodiment 32 or 34, wherein said partial disappearance is identified by a reduction in wart diameter.

[0232] Embodiment 37. The method of any one of embodiments 32-35, wherein prior to said administering, said common wart has a dimension between about 3 mm and about 20 mm.

[0233] Embodiment 38. The method of any one of embodiments 32 to 35, wherein said administering comprises providing an intralesional injection to said subject.

[0234] Embodiment 39. The method of embodiment 38, wherein said administering is providing an intralesional injection near the margins of said common wart.

[0235] Embodiment 40 The method of embodiment 38, wherein said administering comprises providing an intralesional injection at the margins of said common wart.

[0236] Embodiment 41 The method of embodiment 38, wherein said administering is providing an intralesional injection within said common wart.

[0237] Embodiment 42. The method of any one of embodiments 32-35, wherein said administering comprises providing two or more intralesional injections to said subject.

[0238] Embodiment 43. The method of embodiment 42, wherein each of the two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

[0239] Embodiment 44. The method of any one of embodiments 32-35, wherein the two or more intralesional injections are provided to the subject over a period of time.

[0240] Embodiment 45. The method of embodiment 44, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about two weeks apart.

[0241] Embodiment 46 The method of embodiment 44, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about three weeks apart.

[0242] Embodiment 47. The method of embodiment 44, wherein the two or more intralesional injections are provided to the subject over a period of at least about 18 weeks.

[0243] Embodiment 48. The method of embodiment 42, wherein the two or more intralesional injections are provided in subgroups of two or more intralesional injections over a period of time.

[0244] Embodiment 49. The method of embodiment 48, wherein a subgroup within said two or more intralesional injection subgroups provides a total dose of at least 0.5 unit strength.

[0245] Embodiment 50. The method of embodiment 48 or 49, wherein a pair of subgroups within the two or more intralesional injection subgroups is provided to the subject about two weeks apart.

[0246] Embodiment 51. The method of embodiment 48 or 49, wherein a pair of subgroups within the two or more intralesional injection subgroups is provided to the subject about three weeks apart.

[0247] Embodiment 52. The method of embodiment 48 or 49, wherein said subgroups of two or more intralesional injections are provided to said subject over a period of at least about 18 weeks.

[0248] Embodiment 53. The method of embodiment 48 or 49, wherein a subgroup within the two or more subgroups comprises two intralesional injections around the common wart.

[0249] Embodiment 54. The method of embodiment 48 or 49, wherein a subgroup within said two or more subgroups comprises three intralesional injections around said common wart.

[0250] Embodiment 55. The method of embodiment 48 or 49, wherein a subgroup within said two or more subgroups comprises four intralesional injections around said common wart.

[0251] Embodiment 56 The method of embodiment 48 or 49, wherein a subgroup within the two or more subgroups comprises five injections around the common wart.

[0252] Embodiment 57. The method of embodiment 48 or 49, wherein a subgroup within said two or more subgroups comprises six intralesional injections around said common wart.

[0253] Embodiment 58. The method of any one of embodiments 52-57, wherein the intralesional injections within the subgroup are approximately equally spaced about the margins of the common wart.

[0254] Embodiment 59. The method of any one of embodiments 52-57, wherein the intralesional injections within said subgroups are approximately equally spaced around the margins of the common wart.

[0255] Embodiment 60. The method of any one of embodiments 52-57, wherein said intralesional injections within said subgroups are administered approximately simultaneously.

[0256] Embodiment 61. A method for treating a plurality of common warts in a subject in need thereof, comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective for partial disappearance of the plurality of common warts, at a cumulative dose of 5 unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and a secretory antigen.

[0257] Embodiment 62. A method for treating a plurality of common warts in a subject in need thereof, comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount sufficient to effect partial disappearance of the plurality of common warts at a cumulative dose of 5 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and a secretory antigen.

[0258] Embodiment 63. The method of embodiment 61 or 62, wherein said partial disappearance is identified by a reduction in wart diameter.

[0259] Embodiment 64. The method of embodiment 61 or 62, wherein the plurality of common warts comprises 3 to 20 common warts.

[0260] Embodiment 65. The method of embodiment 61 or 62, wherein the multiple common warts are in the same anatomical location in the subject.

[0261] Embodiment 66 The method of embodiment 61 or 62, wherein said administering is providing an intralesional injection to said subject.

[0262] Embodiment 67. The method of embodiment 61 or 62, wherein said administering comprises providing two or more intralesional injections to said subject.

[0263] Embodiment 68. The method of embodiment 67, wherein the two or more intralesional injections are provided to the subject over a period of time.

[0264] Embodiment 69. The method of embodiment 68, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about two weeks apart.

[0265] Embodiment 70. The method of embodiment 68, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about three weeks apart.

[0266] Embodiment 71. The method of embodiment 68, wherein the two or more intralesional injections are provided to the subject over a period of at least about 18 weeks.

[0267] Embodiment 72. The method of embodiment 67, wherein each of the two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

[0268] Embodiment 73. The method of embodiment 61 or 62, further comprising identifying the largest common wart within said plurality of common warts.

[0269] Embodiment 74. The method of embodiment 73, wherein prior to said administering, said largest common wart measures between about 3 mm and about 20 mm.

[0270] Embodiment 75. The method of embodiment 73, wherein said administering is providing an intralesional injection at the margins of said largest common warts.

[0271] Embodiment 76 The method of embodiment 73, wherein said administering is providing an intralesional injection near the margins of the largest common wart.

[0272] Embodiment 77. The method of embodiment 73, wherein said administering is providing an intralesional injection within said largest common wart.

[0273] Embodiment 78. The method of embodiment 73, wherein said administering comprises providing two or more intralesional injections into said largest common wart.

[0274] Embodiment 79. The method of embodiment 78, wherein each of the two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

[0275] Embodiment 80. The method of embodiment 78 or 79, wherein the two or more intralesional injections are provided to the subject over a period of time.

[0276] Embodiment 81. The method of embodiment 80, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about two weeks apart.

[0277] Embodiment 82. The method of embodiment 80, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about three weeks apart.

[0278] Embodiment 83. The method of embodiment 80, wherein the two or more intralesional injections are provided to the subject over a period of at least about 18 weeks.

[0279] Embodiment 84. The method of embodiment 78, wherein the two or more intralesional injections are provided in subgroups of two or more intralesional injections over a period of time.

[0280] Embodiment 85. The method of embodiment 84, wherein a subgroup within said two or more intralesional injection subgroups provides a total dose of at least 0.5 unit strength.

[0281] Embodiment 86. The method of embodiment 84 or 85, wherein a pair of subgroups within the two or more intralesional injection subgroups is provided to the subject about two weeks apart.

[0282] Embodiment 87. The method of embodiment 84 or 85, wherein a pair of subgroups within the two or more intralesional injection subgroups is provided to the subject about three weeks apart.

[0283] Embodiment 88. The method of embodiment 84 or 85, wherein said subgroups of two or more intralesional injections are provided to said subject over a period of at least about 18 weeks.

[0284] Embodiment 89. The method of embodiment 84 or 85, wherein a subgroup within said two or more subgroups comprises two intralesional injections around said largest common wart.

[0285] Embodiment 90. The method of embodiment 84 or 85, wherein a subgroup within said two or more subgroups comprises three intralesional injections around said largest common wart.

[0286] Embodiment 91. The method of embodiment 84 or 85, wherein a subgroup within said two or more subgroups comprises four intralesional injections around said largest common wart.

[0287] Embodiment 92. The method of embodiment 84 or 85, wherein a subgroup within said two or more subgroups comprises five injections around said largest common wart.

[0288] Embodiment 93. The method of embodiment 84 or 85, wherein a subgroup within said two or more subgroups comprises six intralesional injections around said largest common wart.

[0289] Embodiment 94. The method of any one of embodiments 89-93, wherein the intralesional injections within the subgroup are approximately equally spaced about the margin of the largest common wart.

[0290] Embodiment 95. The method of any one of embodiments 89-93, wherein the intralesional injections within the subgroup are approximately equally spaced around the edge of the largest common wart.

[0291] Embodiment 96. The method of any one of embodiments 89 to 93, wherein said intralesional injections within said subgroups are administered approximately simultaneously.

[0292] Embodiment 97. A method for treating a plurality of common warts in a subject in need thereof, comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective to reduce the diameter of each of the plurality of common warts by at least 50%, at a cumulative dose of one unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and a secretory antigen.

[0293] Embodiment 98. A method for treating a plurality of common warts in a subject in need thereof, comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount capable of reducing the diameter of each of the plurality of common warts by at least 50% at a cumulative dose of one unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and a secretory antigen.

[0294] Embodiment 99. The method of embodiment 97 or 98, wherein the plurality of common warts comprises 3 to 20 common warts.

[0295] Embodiment 100. The method of embodiment 97 or 98, wherein the multiple common warts are in the same anatomical location in the subject.

[0296] Embodiment 101. The method of embodiment 97 or 98, wherein said administering is providing an intralesional injection to said subject.

[0297] Embodiment 102. The method of embodiment 97 or 98, wherein said administering comprises providing two or more intralesional injections to said subject.

[0298] Embodiment 103. The method of embodiment 102, wherein the two or more intralesional injections are provided to the subject over a period of time.

[0299] Embodiment 104. The method of embodiment 103, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about two weeks apart.

[0300] Embodiment 105. The method of embodiment 103, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about three weeks apart.

[0301] Embodiment 106. The method of embodiment 102, wherein each of the two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

[0302] Embodiment 107. The method of embodiment 97 or 98, further comprising identifying the largest common wart within said plurality of common warts.

[0303] Embodiment 108. The method of embodiment 107, wherein prior to said administering, said largest common wart measures between about 3 mm and about 20 mm.

[0304] Embodiment 109. The method of embodiment 107, wherein said administering is providing an intralesional injection at the margins of said largest common warts.

[0305] Embodiment 110. The method of embodiment 107, wherein said administering is providing an intralesional injection near the margins of the largest common wart.

[0306] Embodiment 111. The method of embodiment 107, wherein said administering is providing an intralesional injection within said largest common wart.

[0307] Embodiment 112. The method of embodiment 107, wherein said administering comprises providing two or more intralesional injections into said largest common wart.

[0308] Embodiment 113. The method of embodiment 112, wherein each of the two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

[0309] Embodiment 114. The method of embodiment 112 or 113, wherein the two or more intralesional injections are provided to the subject over a period of time.

[0310] Embodiment 115. The method of embodiment 114, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about two weeks apart.

[0311] Embodiment 116 The method of embodiment 114, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about three weeks apart.

[0312] Embodiment 117. The method of embodiment 112, wherein the two or more intralesional injections are provided in subgroups of two or more intralesional injections over a period of time.

[0313] Embodiment 118. The method of embodiment 117, wherein each of said two or more intralesional injection subgroups is provided in a total dose of at least 0.5 unit strength.

[0314] Embodiment 119. The method of embodiment 117 or 118, wherein a pair of subgroups within the two or more intralesional injection subgroups is provided to the subject about two weeks apart.

[0315] Embodiment 120. The method of embodiment 117 or 118, wherein a pair of subgroups within the two or more intralesional injection subgroups is provided to the subject about three weeks apart.

[0316] Embodiment 121. The method of embodiment 117 or 118, wherein said subgroups of two or more intralesional injections are provided to said subject over a period of at least about two weeks.

[0317] Embodiment 122. The method of embodiment 117 or 118, wherein a subgroup within said two or more subgroups comprises two intralesional injections around said largest common wart.

[0318] Embodiment 123. The method of embodiment 117 or 118, wherein a subgroup within said two or more subgroups comprises three intralesional injections around said largest common wart.

[0319] Embodiment 124. The method of embodiment 117 or 118, wherein a subgroup within said two or more subgroups comprises four intralesional injections around said largest common wart.

[0320] Embodiment 125. The method of embodiment 117 or 118, wherein a subgroup within said two or more subgroups comprises five injections around said largest common wart.

[0321] Embodiment 126. The method of embodiment 117 or 118, wherein a subgroup within said two or more subgroups comprises six intralesional injections around said largest common wart.

[0322] Embodiment 127. The method of any one of embodiments 122-126, wherein the intralesional injections within the subgroup are approximately equally spaced about the margin of the largest common wart.

[0323] Embodiment 128. The method of any one of embodiments 122 to 126, wherein the intralesional injections within the subgroup are approximately equally spaced around the edge of the largest common wart.

[0324] Embodiment 129. The method of any one of embodiments 122 to 126, wherein the intralesional injections within the subgroups are administered approximately simultaneously.

[0325] Embodiment 130. A method for treating non-vulgaris warts in a subject in need of treatment, the subject having one or more common warts, comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective for complete disappearance of the non-vulgaris warts, at a cumulative dose of 5 unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and secretory antigens.

[0326] Embodiment 131. A method for treating non-vulgaris warts in a subject in need thereof, the subject having one or more common warts, comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount sufficient to effect complete disappearance of the non-vulgaris warts at a cumulative dose of 5 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and a secretory antigen.

[0327] Embodiment 132. The method of embodiment 130 or 131, wherein the non-common wart is a plantar wart.

[0328] Embodiment 133. The method of embodiment 130 or 131, wherein the non-vulgar warts are genital warts.

[0329] Embodiment 134. The method of embodiment 130 or 131, wherein the non-common warts are facial warts.

[0330] Embodiment 135. The method of embodiment 130 or 131, wherein the non-common wart is a flat wart.

[0331] Embodiment 136. The method of embodiment 130 or 131, wherein the non-vulgar wart is a periungual wart.

[0332] Embodiment 137. The method of embodiment 130 or 131, wherein the non-common warts are in the same anatomical region as the one or more common warts.

[0333] Embodiment 138. The method of embodiment 130 or 131, wherein said complete disappearance is identified by observing that said non-vulgaris wart does not recur at the same site at least 20 weeks after administration of the first intralesional injection.

[0334] Embodiment 139. The method of embodiment 130 or 131, wherein said administering is providing an intralesional injection to said subject.

[0335] Embodiment 140. The method of embodiment 130 or 131, wherein said administering comprises providing two or more intralesional injections to said subject.

[0336] Embodiment 141. The method of embodiment 140, wherein the two or more intralesional injections are provided to the subject over a period of time.

[0337] Embodiment 142. The method of embodiment 141, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject two weeks apart.

[0338] Embodiment 143. The method of embodiment 141, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject three weeks apart.

[0339] Embodiment 144. The method of embodiment 141, wherein the two or more intralesional injections are provided to the subject over a period of 27 weeks.

[0340] Embodiment 145. The method of embodiment 140, wherein each of the two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

[0341] Embodiment 146. The method of embodiment 130 or 131, wherein the one or more common warts comprises 3 to 20 common warts.

[0342] Embodiment 147. The method of embodiment 130 or 131, further comprising identifying the largest common wart within the one or more common warts.

[0343] Embodiment 148. The method of embodiment 147, wherein prior to said administering, said largest common wart measures between about 3 mm and about 20 mm.

[0344] Embodiment 149. The method of embodiment 147, wherein said administering is providing an intralesional injection at the margin of said largest common wart.

[0345] Embodiment 150. The method of embodiment 147, wherein said administering is providing an intralesional injection near the margins of the largest common wart.

[0346] Embodiment 151. The method of embodiment 147, wherein said administering is providing an intralesional injection within said largest common wart.

[0347] Embodiment 152. The method of embodiment 147, wherein said administering comprises providing two or more intralesional injections into said largest common wart.

[0348] Embodiment 153. The method of embodiment 152, wherein each of the two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

[0349] Embodiment 154. The method of embodiment 152 or 153, wherein the two or more intralesional injections are provided to the subject over a period of time.

[0350] Embodiment 155. The method of embodiment 154, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about two weeks apart.

[0351] Embodiment 156. The method of embodiment 154, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about three weeks apart.

[0352] Embodiment 157. The method of embodiment 154, wherein the two or more intralesional injections are provided to the subject over a period of at least about 18 weeks.

[0353] Embodiment 158. The method of embodiment 152, wherein the two or more intralesional injections are provided in subgroups of two or more intralesional injections over a period of time.

[0354] Embodiment 159. The method of embodiment 158, wherein a subgroup within said two or more intralesional injection subgroups is provided with a total dose of at least 0.5 unit strength.

[0355] Embodiment 160. The method of embodiment 158 ​​or 159, wherein a pair of subgroups within the two or more intralesional injection subgroups is provided to the subject about two weeks apart.

[0356] Embodiment 161. The method of embodiment 158 ​​or 159, wherein a pair of subgroups within the two or more intralesional injection subgroups is provided to the subject about three weeks apart.

[0357] Embodiment 162. The method of embodiment 158 ​​or 159, wherein the subgroups of two or more intralesional injections are provided to the subject over a period of at least about 18 weeks.

[0358] Embodiment 163. The method of embodiment 158 ​​or 159, wherein a subgroup within said two or more subgroups comprises two intralesional injections around said largest common wart.

[0359] Embodiment 164. The method of embodiment 158 ​​or 159, wherein a subgroup within said two or more subgroups comprises three intralesional injections around said largest common wart.

[0360] Embodiment 165. The method of embodiment 158 ​​or 159, wherein a subgroup within said two or more subgroups comprises four intralesional injections around said largest common wart.

[0361] Embodiment 166. The method of embodiment 158 ​​or 159, wherein a subgroup within said two or more subgroups comprises five injections around said largest common wart.

[0362] Embodiment 167. The method of embodiment 158 ​​or 159, wherein a subgroup within said two or more subgroups comprises six intralesional injections around said largest common wart.

[0363] Embodiment 168. The method of any one of embodiments 163 to 167, wherein the intralesional injections within said subgroups are approximately equally spaced around the edge of the largest common wart.

[0364] Embodiment 169. The method of any one of embodiments 163 to 167, wherein the intralesional injections within the subgroup are approximately equally spaced about the edge of the largest common wart.

[0365] Embodiment 170. The method of any one of embodiments 163 to 167, wherein said intralesional injections within said subgroups are administered approximately simultaneously.

[0366] Embodiment 171. A method for treating a previously treated common wart in a subject in need of treatment comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective for complete disappearance of the previously treated common wart, at a cumulative dose of 5 unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and a secretory antigen.

[0367] Embodiment 172. A method for treating a previously treated common wart in a subject in need of treatment comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount sufficient to effect complete disappearance of the previously treated common wart at a cumulative dose of 5 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and a secretory antigen.

[0368] Embodiment 173. The method of embodiment 171 or 172, wherein the previously treated common wart is a common wart previously treated with cryotherapy.

[0369] Embodiment 174. The method of embodiment 173, wherein the previously treated common wart did not respond to the cryotherapy.

[0370] Embodiment 175. The method of embodiment 173, wherein the cryotherapy did not completely eradicate the previously treated common warts.

[0371] Embodiment 176. The method of embodiment 171 or 172, wherein the previously treated common wart is a common wart previously treated with salicylic acid or a related acid.

[0372] Embodiment 177. The method of embodiment 176, wherein the related acid is trichloroacetic acid or bichloroacetic acid.

[0373] Embodiment 178. The method of embodiment 176, wherein the previously treated common wart did not respond to the salicylic acid or related acid.

[0374] Embodiment 179. The method of embodiment 176, wherein the salicylic acid or related acid did not completely eliminate the previously treated common warts.

[0375] Embodiment 180. The method of embodiment 171 or 172, wherein the previously treated common wart is a common wart that has been previously treated with a treatment selected from the group consisting of liquid nitrogen, carbon dioxide, cantharidin, simple occlusion, wart gel, apple cider vinegar, surgery, laser, tea tree oil, cryowart spray, wart curettage, electrodesiccation, essential oils of lavender and oregano, and imiquimod.

[0376] Embodiment 181. The method of embodiment 180, wherein the previously treated common wart did not respond to the treatment.

[0377] Embodiment 182. The method of embodiment 180, wherein the treatment did not completely eradicate the previously treated common warts.

[0378] Embodiment 183. The method of any one of embodiments 171 to 182, wherein prior to said administration, said previously treated common warts measure between about 3 mm and about 20 mm.

[0379] Embodiment 184. The method of any one of embodiments 171-182, wherein said complete disappearance is identified by observing that said previously treated common wart does not recur at the same site at least 20 weeks after administration of the first intralesional injection.

[0380] Embodiment 185. The method of any one of embodiments 171 to 182, wherein the complete disappearance is accompanied by the absence of scarring at the location of the previously treated common wart.

[0381] Embodiment 186. The method of any one of embodiments 171 to 182, wherein said complete disappearance is accompanied by a low level of depigmentation at the location of said previously treated common warts.

[0382] Embodiment 187. The method of any one of embodiments 171 to 182, wherein the administering is providing an intralesional injection to the subject.

[0383] Embodiment 188. The method of embodiment 187, wherein said administering is providing an intralesional injection at the margins of said previously treated common wart.

[0384] Embodiment 189. The method of embodiment 187, wherein said administering is providing an intralesional injection near the margins of said previously treated common wart.

[0385] Embodiment 190. The method of embodiment 187, wherein said administering is providing an intralesional injection within said previously treated common wart.

[0386] Embodiment 191. The method of any one of embodiments 171 to 182, wherein said administering comprises providing two or more intralesional injections to said subject.

[0387] Embodiment 192. The method of embodiment 191, wherein each of the two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

[0388] Embodiment 193. The method of embodiment 191 or 192, wherein the two or more intralesional injections are provided to the subject over a period of time.

[0389] Embodiment 194. The method of embodiment 193, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about two weeks apart.

[0390] Embodiment 195. The method of embodiment 193, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about three weeks apart.

[0391] Embodiment 196. The method of embodiment 193, wherein the two or more intralesional injections are provided to the subject over a period of at least about 18 weeks.

[0392] Embodiment 197. The method of embodiment 191, wherein the two or more intralesional injections are provided in subgroups of two or more intralesional injections over a period of time.

[0393] Embodiment 198. The method of embodiment 197, wherein a subgroup within the two or more intralesional injection subgroups provides a total dose of at least 0.5 unit strength.

[0394] Embodiment 199. The method of embodiment 197 or 198, wherein a pair of subgroups within the two or more intralesional injection subgroups is provided to the subject about two weeks apart.

[0395] Embodiment 200. The method of embodiment 197 or 198, wherein a pair of subgroups within the two or more intralesional injection subgroups is provided to the subject about three weeks apart.

[0396] Embodiment 201. The method of embodiment 197 or 198, wherein said subgroups of two or more intralesional injections are provided to said subject over a period of at least about 18 weeks.

[0397] Embodiment 202. The method of embodiment 197 or 198, wherein a subgroup within the two or more subgroups comprises two intralesional injections around the previously treated common wart.

[0398] Embodiment 203. The method of embodiment 197 or 198, wherein a subgroup within said two or more subgroups comprises three intralesional injections around said previously treated common wart.

[0399] Embodiment 204. The method of embodiment 197 or 198, wherein a subgroup within said two or more subgroups comprises four intralesional injections around said previously treated common wart.

[0400] Embodiment 205. The method of embodiment 197 or 198, wherein a subgroup within the two or more subgroups comprises five injections around the previously treated common wart.

[0401] Embodiment 206. The method of embodiment 197 or 198, wherein a subgroup within said two or more subgroups comprises six intralesional injections around said previously treated common wart.

[0402] Embodiment 207. The method of any one of embodiments 202 to 206, wherein the intralesional injections within the subgroup are approximately equally spaced around the margins of the previously treated common warts.

[0403] Embodiment 208. The method of any one of embodiments 202 to 206, wherein the intralesional injections within the subgroup are approximately equally spaced about the margins of the previously treated common warts.

[0404] Embodiment 209. The method of any one of embodiments 202 to 206, wherein the intralesional injections within the subgroups are administered approximately simultaneously.

[0405] Embodiment 210. A method for delaying the recurrence of common warts in a subject in need thereof, comprising administering to the subject one or more intralesional injections of a pharmaceutical composition at the time of disappearance of the common warts, in an amount effective to delay the reappearance of the common warts, at a cumulative dose of 2.5 unit potency, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and secretory antigens.

[0406] Embodiment 211. A method for delaying the recurrence of common warts in a subject in need thereof, comprising administering to the subject one or more intralesional injections of a pharmaceutical composition at the time of disappearance of the common warts, in a cumulative dose of 2.5 unit potency, in an amount capable of delaying the reappearance of the common warts, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and secretory antigens.

[0407] Embodiment 212. The method of embodiment 210 or 211, wherein the subject does not develop any new common warts within at least 16 weeks after the last of the one or more intralesional injections.

[0408] Embodiment 213. The method of embodiment 210 or 211, wherein the subject does not develop any new common warts within the same anatomical region of the common wart.

[0409] Embodiment 214. The method of embodiment 210 or 211, wherein the subject does not develop any new common warts within the same site of the common wart.

[0410] Embodiment 215. The method of embodiment 210 or 211, wherein prior to said administration, said common wart has a dimension between about 3 mm and about 20 mm.

[0411] Embodiment 216 The method of embodiment 210 or 211, wherein said administering is providing an intralesional injection to said subject.

[0412] Embodiment 217. The method of embodiment 216, wherein said administering is providing an intralesional injection at the margin of said common wart.

[0413] Embodiment 218. The method of embodiment 216, wherein the administering is providing an intralesional injection near the margins of the common wart.

[0414] Embodiment 219. The method of embodiment 216, wherein said administering is providing an intralesional injection within said common wart.

[0415] Embodiment 220. The method of embodiment 210 or 211, wherein said administering comprises providing two or more intralesional injections to said subject.

[0416] Embodiment 221. The method of embodiment 220, wherein each of the two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

[0417] Embodiment 222. The method of embodiment 220 or 221, wherein the two or more intralesional injections are provided to the subject over a period of time.

[0418] Embodiment 223. The method of embodiment 222, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about two weeks apart.

[0419] Embodiment 224. The method of embodiment 222, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about three weeks apart.

[0420] Embodiment 225. The method of embodiment 222, wherein the two or more intralesional injections are provided to the subject over a period of at least about 8 weeks.

[0421] Embodiment 226. The method of embodiment 220, wherein the two or more intralesional injections are provided in subgroups of two or more intralesional injections over a period of time.

[0422] Embodiment 227. The method of embodiment 226, wherein a subgroup within the two or more intralesional injection subgroups provides a total dose of at least 0.5 unit strength.

[0423] Embodiment 228. The method of embodiment 226 or 227, wherein a pair of subgroups within the two or more intralesional injection subgroups is provided to the subject about two weeks apart.

[0424] Embodiment 229. The method of embodiment 226 or 227, wherein a pair of subgroups within the two or more intralesional injection subgroups is provided to the subject about three weeks apart.

[0425] Embodiment 230. The method of embodiment 226 or 227, wherein the subgroups of two or more intralesional injections are provided to the subject over a period of at least about 8 weeks.

[0426] Embodiment 231. The method of embodiment 226 or 227, wherein a subgroup within the two or more subgroups comprises two intralesional injections around the common wart.

[0427] Embodiment 232. The method of embodiment 226 or 227, wherein a subgroup within the two or more subgroups comprises three intralesional injections around the common wart.

[0428] Embodiment 233. The method of embodiment 226 or 227, wherein a subgroup within the two or more subgroups comprises four intralesional injections around the common wart.

[0429] Embodiment 234. The method of embodiment 226 or 227, wherein a subgroup within the two or more subgroups comprises five injections around the common wart.

[0430] Embodiment 235. The method of embodiment 226 or 227, wherein a subgroup within the two or more subgroups comprises six intralesional injections around the common wart.

[0431] Embodiment 236. The method of any one of embodiments 231 to 235, wherein the intralesional injections within said subgroups are approximately equally spaced around the edge of the common wart.

[0432] Embodiment 237. The method of any one of embodiments 231 to 235, wherein the intralesional injections within the subgroup are approximately equally spaced about the margins of the common wart.

[0433] Embodiment 238. The method of any one of embodiments 231 to 235, wherein the intralesional injections within the subgroups are administered approximately simultaneously.

[0434] Embodiment 239. The method of any one of embodiments 1 to 238, wherein the pharmaceutical composition comprises at least 80% mannose.

[0435] Embodiment 240. The method of any one of embodiments 1 to 239, wherein the pharmaceutical composition comprises at least 8% glucose.

[0436] Embodiment 241. The method of any one of embodiments 1 to 240, wherein the pharmaceutical composition comprises at least 1% galactose.

[0437] Embodiment 242. The method of any one of embodiments 1 to 240, wherein the antigen has a molecular weight of about 167 kilodaltons.

[0438] Embodiment 243. The method of any one of embodiments 1 to 241, wherein the subject is between 18 and 65 years of age.

[0439] Embodiment 244. The method of any one of embodiments 1 to 243, wherein the subject had been diagnosed with a first common wart at least 12 weeks prior to receiving the one or more intralesional injections.

[0440] Embodiment 245. The method of any one of embodiments 1 to 244, wherein the subject has not been diagnosed with refractory warts.

[0441] Embodiment 246. The method of any one of embodiments 1 to 245, wherein the subject has a baseline result of between 5 mm and 25 mm on a delayed type hypersensitivity test.

[0442] Embodiment 247. The method of any one of embodiments 1 to 246, wherein the subject has not been diagnosed with a systemic disease that impairs immune function.

[0443] Embodiment 248. The method of any one of embodiments 1 to 246, wherein the subject has not been diagnosed with a localized disease that impairs immune function.

[0444] Embodiment 249. The method of any one of embodiments 1 to 246, wherein the subject has not been diagnosed with a systemic condition that impairs immune function.

[0445] Embodiment 250. The method of any one of embodiments 1 to 246, wherein the subject has not been diagnosed with a localized condition that impairs immune function.

[0446] Embodiment 251. The method of any one of embodiments 1 to 246, wherein the subject has not been diagnosed with psoriasis.

[0447] Embodiment 252. The method of any one of embodiments 1 to 251, wherein the subject is not undergoing a treatment that results in an immunocompromised state.

[0448] Embodiment 253. The method of any one of embodiments 1 to 252, wherein the subject has not been diagnosed with diabetes.

[0449] Embodiment 254. The method of any one of embodiments 1 to 253, wherein the subject has no history of keloid formation.

[0450] Embodiment 255. The method of any one of embodiments 1 to 254, wherein the subject does not have an existing dermatological condition in the same anatomical region as the wart being treated.

[0451] Embodiment 256. The method of any one of embodiments 1 to 255, wherein the subject does not have an underlying inflammatory condition.

[0452] Embodiment 257. The method of embodiment 256, wherein the underlying inflammatory condition is an arthritic joint.

[0453] Embodiment 258. The method of any one of embodiments 1 to 257, wherein the subject has not received one or more therapies selected from the group consisting of liquid nitrogen, carbon dioxide, electrodesiccation, laser, surgery, simple occlusion, salicylic acid, trichloroacetic acid, bichloroacetic acid, OTC medications, and cantharidin within 4 weeks prior to said administration.

[0454] Embodiment 259. The method of any one of embodiments 1 to 258, wherein the subject has not received one or more immunotherapies selected from the group consisting of diphenylcyclopropenone (DPCP), dinitrochlorobenzene (DNCB), imiquimod, 5-fluorouracil, bleomycin, and podophyllin within 12 weeks prior to said administration.

[0455] Embodiment 260. The method of any one of embodiments 1 to 259, wherein the subject has not received one or more systemic therapies selected from the group consisting of cimetidine, zinc supplements at doses greater than 20 mg elemental zinc per day, azathioprine, 6-mercaptopurine, methotrexate, infliximab, adalimumab, etanercept, and steroids within 12 weeks prior to said administration.

[0456] Embodiment 261. The method of any one of embodiments 1 to 260, wherein the subject has not received any investigational drug within 30 days prior to said administration.

[0457] Embodiment 262. The method of any one of embodiments 1 to 260, wherein the subject has not received any investigational drug within 5 half-lives of the investigational drug prior to said administration.

[0458] Embodiment 263. A pharmaceutical comprising a filtered extract of Candida albicans and secretory antigens, formulated to completely eradicate common warts at a cumulative dose of 2.5 unit strength.

[0459] Embodiment 264. A pharmaceutical comprising a filtered extract of Candida albicans and secretory antigens, formulated to partially eradicate common warts at a cumulative dose of 5 unit strength.

[0460] Embodiment 265. A pharmaceutical comprising a filtered extract of Candida albicans and secretory antigens, formulated to reduce the diameter of common warts by at least 50% at a cumulative dose of one unit strength.

[0461] Embodiment 266. A pharmaceutical comprising a filtered extract of Candida albicans and secretory antigens, formulated for partial eradication of multiple common warts at a cumulative dose of 5 unit strength.

[0462] Embodiment 267. A pharmaceutical comprising a filtered extract of Candida albicans and secretory antigens, formulated to reduce the diameter of multiple common warts by at least 50% at a cumulative dose of one unit strength.

[0463] Embodiment 268. A pharmaceutical comprising a filtered extract of Candida albicans and secretory antigens, formulated to completely eradicate non-vulgaris warts at a cumulative dose of 5 unit strength.

[0464] Embodiment 269. A pharmaceutical comprising a filtered extract of Candida albicans and secretory antigens, formulated to achieve complete eradication of previously treated common warts at a cumulative dose of 5 unit strength.

[0465] Embodiment 270. A pharmaceutical comprising a filtered extract of Candida albicans and secretory antigens, at a cumulative dose of 2.5 unit strength, formulated to delay the reappearance of common warts upon their disappearance.

[0466] Embodiment 271. A pharmaceutical product according to any one of embodiments 263 to 270, wherein the pharmaceutical product contains at least 80% mannose.

[0467] Embodiment 272. A pharmaceutical product according to any one of embodiments 263 to 270, wherein the pharmaceutical product contains at least 8% glucose.

[0468] Embodiment 273. A pharmaceutical product according to any one of embodiments 263 to 270, wherein the pharmaceutical product contains at least 1% galactose.

[0469] Embodiment 274. A pharmaceutical product according to any one of embodiments 263 to 270, wherein the antigen has a molecular weight of about 167 kilodaltons.

[0470] Embodiment 275. A pharmaceutical product according to any one of embodiments 263 to 274, wherein the pharmaceutical product is formulated in a vial.

[0471] Embodiment 276. The pharmaceutical product of embodiment 275, wherein the vial is a multi-dose storage vial.

[0472] Embodiment 277. The pharmaceutical product of embodiment 275, wherein the vial is a single-dose, non-reserved vial.

[0473] Embodiment 278. The pharmaceutical product of embodiment 275, wherein the vial is a glass vial.

[0474] Embodiment 279. The pharmaceutical product of embodiment 278, wherein the glass vial is a 2 mL vial.

[0475] Embodiment 280. A pharmaceutical product according to any one of embodiments 263 to 273, wherein the pharmaceutical product is formulated in a prefilled syringe.

[0476] Embodiment 281. The pharmaceutical product of embodiment 280, wherein the prefilled syringe has a volume of 0.5 mL.

[0477] Embodiment 282. A method for reducing the level of IL-23 in a subject diagnosed with common warts, comprising administering to the subject one or more intralesional injections of a quantity of a pharmaceutical composition at a cumulative dose of one unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens.

[0478] Embodiment 283. The method of embodiment 282, wherein, upon receiving said cumulative doses, said level of IL-23 in said subject is reduced by at least about 15% compared to the level of IL-23 measured in said subject prior to said administration.

[0479] Embodiment 284. A method for completely eliminating common warts in a subject in need thereof, comprising reducing the level of IL-23 by at least about 35% in a subject in need thereof.

[0480] Embodiment 285. The method of embodiment 284, wherein the reduction is achieved by administering to the subject one or more intralesional injections of a quantity of a pharmaceutical composition at a cumulative dose of 3 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens.

[0481] Embodiment 286. The method of embodiment 284, wherein said complete disappearance is identified by observing that said common wart does not recur at the same site at least 20 weeks after said reduction.

[0482] Embodiment 287. A method for reducing the level of IL-7 in a subject diagnosed with common warts, comprising administering to the subject one or more intralesional injections of a quantity of a pharmaceutical composition at a cumulative dose of 0.6 unit potency, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens.

[0483] Embodiment 288. The method of embodiment 287, wherein, upon receiving said cumulative doses, said level of IL-7 in said subject is reduced by at least about 10% compared to the level of IL-7 measured in said subject prior to said administration.

[0484] Embodiment 289. A method for reducing the level of IL-7 in a subject diagnosed with common warts, comprising administering to the subject one or more intralesional injections of an amount of a pharmaceutical composition at a cumulative dose of 3 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens.

[0485] Embodiment 290. The method of embodiment 289, wherein, upon receiving said cumulative doses, said level of IL-7 in said subject is reduced by at least about 20% compared to the level of IL-7 measured in said subject prior to said administration.

[0486] Embodiment 291. A method for reducing the level of IP-10 in a subject diagnosed with common warts, comprising administering to the subject one or more intralesional injections of a quantity of a pharmaceutical composition at a cumulative dose of 3 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens.

[0487] Embodiment 292. The method of embodiment 291, wherein, upon receiving said cumulative doses, said level of IP-10 in said subject is reduced by at least about 5% compared to the level of IP-10 measured in said subject prior to said administration.

[0488] Embodiment 293. The method of any one of embodiments 282, 283, and 285 to 292, wherein the administering is providing an intralesional injection to the subject.

[0489] Embodiment 294. The method of embodiment 293, wherein the administering is providing an intralesional injection near the margins of the common wart.

[0490] Embodiment 295. The method of embodiment 293, wherein the administering is providing an intralesional injection at the margin of the common wart.

[0491] Embodiment 296. The method of embodiment 293, wherein the administering is providing an intralesional injection within the common wart.

[0492] Embodiment 297. The method of any one of embodiments 282, 283, and 285 to 292, wherein the administering comprises providing two or more intralesional injections to the subject.

[0493] Embodiment 298. The method of embodiment 297, wherein each of the two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

[0494] Embodiment 299. The method of any one of embodiments 282, 283, and 285 to 292, wherein the two or more intralesional injections are provided to the subject over a period of time.

[0495] Embodiment 300. The method of embodiment 299, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about two weeks apart.

[0496] Embodiment 301. The method of embodiment 299, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about three weeks apart.

[0497] Embodiment 302. The method of embodiment 299, wherein the two or more intralesional injections are provided to the subject over a period of at least about 8 weeks.

[0498] Embodiment 303. The method of embodiment 297, wherein the two or more intralesional injections are provided in subgroups of two or more intralesional injections over a period of time.

[0499] Embodiment 304. The method of embodiment 303, wherein a subgroup within the two or more intralesional injection subgroups provides a total dose of at least 0.5 unit strength.

[0500] Embodiment 305. The method of embodiment 303 or 304, wherein a pair of subgroups within the two or more intralesional injection subgroups is provided to the subject about two weeks apart.

[0501] Embodiment 306. The method of embodiment 303 or 304, wherein a pair of subgroups within the two or more intralesional injection subgroups is provided to the subject about three weeks apart.

[0502] Embodiment 307. The method of embodiment 303 or 304, wherein the subgroups of two or more intralesional injections are provided to the subject over a period of at least about 8 weeks.

[0503] Embodiment 308. The method of embodiment 303 or 304, wherein a subgroup within the two or more subgroups comprises two intralesional injections around the common wart.

[0504] Embodiment 309. The method of embodiment 303 or 304, wherein a subgroup within the two or more subgroups comprises three intralesional injections around the common wart.

[0505] Embodiment 310. The method of embodiment 303 or 304, wherein a subgroup within the two or more subgroups comprises four intralesional injections around the common wart.

[0506] Embodiment 311. The method of embodiment 303 or 304, wherein a subgroup within the two or more subgroups comprises five injections around the common wart.

[0507] Embodiment 312. The method of embodiment 303 or 304, wherein a subgroup within the two or more subgroups comprises six intralesional injections around the common wart.

[0508] Embodiment 313. The method of any one of embodiments 308 to 312, wherein the intralesional injections within the subgroup are approximately equally spaced about the margins of the common wart.

[0509] Embodiment 314. The method of any one of embodiments 308 to 312, wherein the intralesional injections within the subgroup are approximately equally spaced around the edge of the common wart.

[0510] Embodiment 315. The method of any one of embodiments 308 to 312, wherein said intralesional injections within said subgroups are administered approximately simultaneously.

[0511] Embodiment 316. The method according to any one of embodiments 1 to 262 and 282 to 315, wherein the pharmaceutical composition comprises a filtered extract of two strains of Candida albicans and secretory antigens.

[0512] Embodiment 317. The method of embodiment 316, wherein a representative sample of the first of the two strains of Candida albicans has been deposited with the ATCC under ATCC Accession No. PTA-126019.

[0513] Embodiment 318. The method of embodiment 316, wherein a representative sample of the first of the two strains of Candida albicans has been deposited with the ATCC under ATCC Accession No. ATCC-10231.

[0514] Embodiment 319. The method of any one of embodiments 316 to 318, wherein a representative sample of the second of the two strains of Candida albicans has been deposited with the ATCC under ATCC Accession No. PTA-126020.

[0515] Embodiment 320. A pharmaceutical according to any one of embodiments 263 to 281, wherein the aforementioned filtered extract of Candida albicans contains two strains of Candida albicans.

[0516] Embodiment 321. The pharmaceutical product of embodiment 320, wherein a representative sample of the first of the two strains of Candida albicans has been deposited with the ATCC under ATCC Accession No. PTA-126019.

[0517] Embodiment 322. The pharmaceutical product of embodiment 320, wherein a representative sample of the first of the two strains of Candida albicans has been deposited with the ATCC under ATCC Accession No. ATCC-10231.

[0518] Embodiment 323. A pharmaceutical product according to any one of embodiments 320 to 322, wherein a representative sample of the second of the two strains of Candida albicans has been deposited with the ATCC under ATCC Accession No. PTA-126020.

[0519] Although the present disclosure has been described with reference to specific embodiments, those skilled in the art will recognize that various modifications may be made and equivalents may be substituted for elements of the present disclosure to accommodate particular situations without departing from the scope of the present disclosure. Therefore, it is intended that the disclosure not be limited to the particular embodiment disclosed as the best mode contemplated for carrying out the disclosure, but that the disclosure will include all embodiments falling within the spirit and scope of the appended claims.

Claims

1. 1. A method for treating common warts in a subject in need of treatment comprising administering to said subject one or more intralesional injections of a pharmaceutical composition in an amount effective for the complete disappearance of said common warts at a cumulative dose of 2.5 unit strength, said pharmaceutical composition comprising a filtered extract of Candida albicans and a secretory antigen.

2. 10. The method of claim 1, wherein the pharmaceutical composition is further effective to reduce the diameter of the common wart by at least 50% at a cumulative dose of one unit strength.

3. 1. A method for treating common warts in a subject in need of treatment comprising administering to said subject one or more intralesional injections of a pharmaceutical composition in an amount sufficient to effect complete disappearance of said common warts at a cumulative dose of 2.5 unit strength, said pharmaceutical composition comprising a filtered extract of Candida albicans and a secretory antigen.

4. 4. The method of claim 3, wherein the pharmaceutical composition is further capable of reducing the diameter of the common wart by at least 50% at a cumulative dose of one unit strength.

5. 4. The method of claim 1 or 3, wherein the complete disappearance is identified by observing that the common wart does not recur at the same site at least 20 weeks after administration of the first intralesional injection.

6. 4. The method of claim 1 or 3, wherein the complete disappearance is accompanied by the absence of a scar at the location of the common wart.

7. 4. The method of claim 1 or 3, wherein the complete disappearance is accompanied by a low level of depigmentation at the location of the common wart.

8. 5. The method of any one of claims 1 to 4, wherein prior to said administering, said common wart is between about 3 mm and about 20 mm in size.

9. The method of any one of claims 1 to 4, wherein said administering comprises providing an intralesional injection to said subject.

10. 10. The method of claim 9, wherein the administering is providing an intralesional injection near the margins of the common wart.

11. 10. The method of claim 9, wherein said administering comprises providing an intralesional injection to the margins of said common wart.

12. 10. The method of claim 9, wherein said administering is providing an intralesional injection within said common wart.

13. The method of any one of claims 1 to 4, wherein said administering comprises providing two or more intralesional injections to said subject.

14. 14. The method of claim 13, wherein each of the two or more intralesional injections is provided at a dose of at least 0.5 unit strength.

15. The method of any one of claims 1 to 4, wherein the two or more intralesional injections are administered to the subject over a period of time.

16. 16. The method of claim 15, wherein a pair of intralesional injections of the two or more intralesional injections are provided to the subject about two weeks apart.

17. 16. The method of claim 15, wherein a pair of intralesional injections of the two or more intralesional injections are administered to the subject about three weeks apart.

18. 16. The method of claim 15, wherein the two or more intralesional injections are administered to the subject over a period of at least about eight weeks.

19. 14. The method of claim 13, wherein the two or more intralesional injections are provided in subgroups of two or more intralesional injections over a period of time.

20. 20. The method of claim 19, wherein a subgroup within the two or more intralesional injection subgroups provides a total dose of at least 0.5 unit strength.

21. 21. The method of claim 19 or 20, wherein a pair of subgroups of the two or more intralesional injections is provided to the subject about two weeks apart.

22. 21. The method of claim 19 or 20, wherein a pair of subgroups of the two or more intralesional injections is provided to the subject about three weeks apart.

23. 21. The method of claim 19 or 20, wherein said subgroups of two or more intralesional injections are administered to said subject over a period of at least about eight weeks.

24. 21. The method of claim 19 or 20, wherein a subgroup in the two or more subgroups comprises two intralesional injections around the common wart.

25. 21. The method of claim 19 or 20, wherein a subgroup in said two or more subgroups comprises three intralesional injections around said common wart.

26. 21. The method of claim 19 or 20, wherein a subgroup in said two or more subgroups comprises four intralesional injections around said common wart.

27. 21. The method of claim 19 or 20, wherein a subgroup in the two or more subgroups comprises five injections around the common wart.

28. 21. The method of claim 19 or 20, wherein a subgroup in said two or more subgroups comprises six intralesional injections around said common wart.

29. 29. The method of any one of claims 24 to 28, wherein the intralesional injections within the subgroups are approximately equally spaced about the margin of the common wart.

30. 29. The method of any one of claims 24 to 28, wherein the intralesional injections within the subgroups are approximately equally spaced around the margin of the common wart.

31. 29. The method of any one of claims 24 to 28, wherein said intralesional injections within said subgroups are administered approximately simultaneously.

32. 1. A method for treating common warts in a subject in need of treatment comprising administering to said subject one or more intralesional injections of a pharmaceutical composition in an amount effective to cause partial disappearance of said common warts, at a cumulative dose of 5 unit strength, said pharmaceutical composition comprising a filtered extract of Candida albicans and a secretory antigen.

33. 33. The method of claim 32, wherein said pharmaceutical composition is further effective at a cumulative dose of one unit strength to reduce the diameter of said common warts by at least 50%.

34. 1. A method for treating common warts in a subject in need of treatment comprising administering to said subject one or more intralesional injections of a pharmaceutical composition in an amount sufficient to effect partial disappearance of said common warts at a cumulative dose of 5 unit strength, said pharmaceutical composition comprising a filtered extract of Candida albicans and a secretory antigen.

35. 35. The method of claim 34, wherein said pharmaceutical composition is further capable of reducing the diameter of said common warts by at least 50% at a cumulative dose of one unit strength.

36. 35. The method of claim 32 or 34, wherein the partial disappearance is identified by a reduction in wart diameter.

37. 36. The method of any one of claims 32 to 35, wherein prior to said administering, said common wart is between about 3 mm and about 20 mm in size.

38. The method of any one of claims 32 to 35, wherein said administering comprises providing an intralesional injection to said subject.

39. 39. The method of claim 38, wherein the administration is providing an intralesional injection near the margins of the common wart.

40. 39. The method of claim 38, wherein said administering is providing an intralesional injection at the margins of said common wart.

41. 39. The method of claim 38, wherein said administering is providing an intralesional injection within said common wart.

42. The method of any one of claims 32 to 35, wherein said administering comprises providing two or more intralesional injections to said subject.

43. 43. The method of claim 42, wherein each of the two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

44. 36. The method of any one of claims 32 to 35, wherein the two or more intralesional injections are administered to the subject over a period of time.

45. 45. The method of claim 44, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about two weeks apart.

46. 45. The method of claim 44, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about three weeks apart.

47. 45. The method of claim 44, wherein the two or more intralesional injections are provided to the subject over a period of at least about 18 weeks.

48. 43. The method of claim 42, wherein the two or more intralesional injections are provided in subgroups of two or more intralesional injections over a period of time.

49. 49. The method of claim 48, wherein a subgroup within said two or more intralesional injection subgroups provides a total dose of at least 0.5 unit strength.

50. 50. The method of claim 48 or 49, wherein a pair of subgroups of the two or more intralesional injections is provided to the subject about two weeks apart.

51. 50. The method of claim 48 or 49, wherein a pair of subgroups of the two or more intralesional injections is provided to the subject about three weeks apart.

52. 50. The method of claim 48 or 49, wherein said subgroups of two or more intralesional injections are provided to said subject over a period of at least about 18 weeks.

53. 50. The method of claim 48 or 49, wherein a subgroup in said two or more subgroups comprises two intralesional injections around said common wart.

54. 50. The method of claim 48 or 49, wherein a subgroup in said two or more subgroups comprises three intralesional injections around said common wart.

55. 50. The method of claim 48 or 49, wherein a subgroup in said two or more subgroups comprises four intralesional injections around said common wart.

56. 50. The method of claim 48 or 49, wherein a subgroup within the two or more subgroups comprises five injections around the common wart.

57. 50. The method of claim 48 or 49, wherein a subgroup within said two or more subgroups comprises six intralesional injections around said common wart.

58. 58. The method of any one of claims 52 to 57, wherein the intralesional injections within the subgroups are approximately equally spaced about the margin of the common wart.

59. 58. The method of any one of claims 52 to 57, wherein the intralesional injections within the subgroups are approximately equally spaced around the margin of the common wart.

60. 58. The method of any one of claims 52 to 57, wherein said intralesional injections within said subgroups are administered approximately simultaneously.

61. 1. A method for treating a plurality of common warts in a subject in need thereof, comprising administering to said subject one or more intralesional injections of a pharmaceutical composition in an amount effective for partial disappearance of said plurality of common warts, at a cumulative dose of 5 unit strength, said pharmaceutical composition comprising a filtered extract of Candida albicans and a secretory antigen.

62. 1. A method for treating a plurality of common warts in a subject in need thereof, comprising administering to said subject one or more intralesional injections of a pharmaceutical composition in an amount sufficient to effect partial disappearance of said plurality of common warts at a cumulative dose of 5 unit strength, said pharmaceutical composition comprising a filtered extract of Candida albicans and a secretory antigen.

63. 63. The method of claim 61 or 62, wherein the partial disappearance is identified by a reduction in wart diameter.

64. 63. The method of claim 61 or 62, wherein the plurality of common warts comprises between 3 and 20 common warts.

65. 63. The method of claim 61 or 62, wherein the multiple common warts are in the same anatomical location of the subject.

66. 63. The method of claim 61 or 62, wherein the administering is providing an intralesional injection to the subject.

67. 63. The method of claim 61 or 62, wherein the administering comprises providing two or more intralesional injections to the subject.

68. 68. The method of claim 67, wherein the two or more intralesional injections are administered to the subject over a period of time.

69. 69. The method of claim 68, wherein a pair of intralesional injections of the two or more intralesional injections are provided to the subject about two weeks apart.

70. 69. The method of claim 68, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about three weeks apart.

71. 69. The method of claim 68, wherein the two or more intralesional injections are provided to the subject over a period of at least about 18 weeks.

72. 68. The method of claim 67, wherein each of the two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

73. 63. The method of claim 61 or 62, further comprising identifying a largest common wart within the plurality of common warts.

74. 74. The method of claim 73, wherein prior to said administering, said largest common wart measures between about 3 mm and about 20 mm.

75. 74. The method of claim 73, wherein said administering is providing an intralesional injection at the margin of the largest common wart.

76. 74. The method of claim 73, wherein said administering is providing an intralesional injection near the margin of the largest common wart.

77. 74. The method of claim 73, wherein said administering is providing an intralesional injection within said largest common wart.

78. 74. The method of claim 73, wherein said administering is providing two or more intralesional injections into said largest common wart.

79. 80. The method of claim 78, wherein each of the two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

80. 80. The method of claim 78 or 79, wherein the two or more intralesional injections are administered to the subject over a period of time.

81. 81. The method of claim 80, wherein a pair of intralesional injections of the two or more intralesional injections are provided to the subject about two weeks apart.

82. 81. The method of claim 80, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about three weeks apart.

83. 81. The method of claim 80, wherein the two or more intralesional injections are provided to the subject over a period of at least about 18 weeks.

84. 80. The method of claim 78, wherein the two or more intralesional injections are provided in subgroups of two or more intralesional injections over a period of time.

85. 85. The method of claim 84, wherein a subgroup within said two or more intralesional injection subgroups provides a total dose of at least 0.5 unit strength.

86. 86. The method of claim 84 or 85, wherein a pair of subgroups within said two or more intralesional injections are provided to said subject about two weeks apart.

87. 86. The method of claim 84 or 85, wherein a pair of subgroups of the two or more intralesional injections is provided to the subject about three weeks apart.

88. 86. The method of claim 84 or 85, wherein a subgroup of two or more intralesional injections is provided to the subject over a period of at least about 18 weeks.

89. 86. The method of claim 84 or 85, wherein a subgroup within said two or more subgroups comprises two intralesional injections around the largest common wart.

90. 86. The method of claim 84 or 85, wherein a subgroup within said two or more subgroups comprises three intralesional injections around the largest common wart.

91. 86. The method of claim 84 or 85, wherein a subgroup within said two or more subgroups comprises four intralesional injections around the largest common wart.

92. 86. The method of claim 84 or 85, wherein a subgroup within the two or more subgroups comprises five injections around the largest common wart.

93. 86. The method of claim 84 or 85, wherein a subgroup within said two or more subgroups comprises six intralesional injections around the largest common wart.

94. 94. The method of any one of claims 89-93, wherein the intralesional injections within the subgroup are approximately equally spaced about the margin of the largest common wart.

95. 94. The method of any one of claims 89 to 93, wherein the intralesional injections within the subgroup are approximately equally spaced around the margin of the largest common wart.

96. 94. The method of any one of claims 89 to 93, wherein said intralesional injections within said subgroups are administered approximately simultaneously.

97. 1. A method for treating a plurality of common warts in a subject in need of treatment comprising administering to said subject one or more intralesional injections of a pharmaceutical composition in an amount effective to reduce the diameter of each of said plurality of common warts by at least 50%, at a cumulative dose of one unit strength, said pharmaceutical composition comprising a filtered extract of Candida albicans and a secretor antigen.

98. 1. A method for treating a plurality of common warts in a subject in need thereof, comprising administering to said subject one or more intralesional injections of a pharmaceutical composition in an amount capable of reducing the diameter of each of said plurality of common warts by at least 50% at a cumulative dose of one unit strength, said pharmaceutical composition comprising a filtered extract of Candida albicans and a secretor antigen.

99. 99. The method of claim 97 or 98, wherein the plurality of common warts comprises between 3 and 20 common warts.

100. 99. The method of claim 97 or 98, wherein the multiple common warts are in the same anatomical location of the subject.

101. 99. The method of claim 97 or 98, wherein the administering is providing an intralesional injection to the subject.

102. 99. The method of claim 97 or 98, wherein said administering comprises providing two or more intralesional injections to said subject.

103. 103. The method of claim 102, wherein the two or more intralesional injections are provided to the subject over a period of time.

104. 104. The method of claim 103, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about two weeks apart.

105. 104. The method of claim 103, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about three weeks apart.

106. 103. The method of claim 102, wherein each of the two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

107. 99. The method of claim 97 or 98, further comprising identifying a largest common wart within the plurality of common warts.

108. 108. The method of claim 107, wherein prior to said administering, said largest common wart measures between about 3 mm and about 20 mm.

109. 108. The method of claim 107, wherein said administering is providing an intralesional injection at the margin of the largest common wart.

110. 108. The method of claim 107, wherein said administering is providing an intralesional injection near the margin of the largest common wart.

111. 108. The method of claim 107, wherein said administering is providing an intralesional injection within said largest common wart.

112. 108. The method of claim 107, wherein said administering is providing two or more intralesional injections into said largest common wart.

113. 113. The method of claim 112, wherein each of the two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

114. 114. The method of claim 112 or 113, wherein the two or more intralesional injections are provided to the subject over a period of time.

115. 115. The method of claim 114, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about two weeks apart.

116. 115. The method of claim 114, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about three weeks apart.

117. 113. The method of claim 112, wherein the two or more intralesional injections are provided in subgroups of two or more intralesional injections over a period of time.

118. 118. The method of claim 117, wherein each of the two or more intralesional injection subgroups is provided with a total dose of at least 0.5 unit strength.

119. 119. The method of claim 117 or 118, wherein a pair of subgroups within the two or more intralesional injection subgroups is provided to the subject about two weeks apart.

120. 119. The method of claim 117 or 118, wherein a pair of subgroups of the two or more intralesional injections is provided to the subject about three weeks apart.

121. 119. The method of claim 117 or 118, wherein the subgroup of two or more intralesional injections is administered to the subject over a period of at least about two weeks.

122. 119. The method of claim 117 or 118, wherein a subgroup within said two or more subgroups comprises two intralesional injections around the largest common wart.

123. 119. The method of claim 117 or 118, wherein a subgroup within said two or more subgroups comprises three intralesional injections around the largest common wart.

124. 119. The method of claim 117 or 118, wherein a subgroup within said two or more subgroups comprises four intralesional injections around said largest common wart.

125. 119. The method of claim 117 or 118, wherein a subgroup within the two or more subgroups comprises five injections around the largest common wart.

126. 119. The method of claim 117 or 118, wherein a subgroup within said two or more subgroups comprises six intralesional injections around the largest common wart.

127. 127. The method of any one of claims 122-126, wherein the intralesional injections within the subgroup are approximately equally spaced about the margin of the largest common wart.

128. 127. The method of any one of claims 122-126, wherein the intralesional injections within the subgroup are approximately equally spaced around the margin of the largest common wart.

129. 127. The method of any one of claims 122-126, wherein said intralesional injections within said subgroups are administered approximately simultaneously.

130. 1. A method for treating non-vulgaris warts in a subject in need of treatment, the subject having one or more common warts, comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount effective for complete disappearance of the non-vulgaris warts, at a cumulative dose of 5 unit strength, wherein the pharmaceutical composition comprises a filtered extract of Candida albicans and a secretory antigen.

131. 1. A method for treating non-vulgaris warts in a subject in need of treatment, the subject having one or more common warts, comprising administering to the subject one or more intralesional injections of a pharmaceutical composition in an amount sufficient to effect complete disappearance of the non-vulgaris warts at a cumulative dose of 5 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and a secretory antigen.

132. 132. The method of claim 130 or 131, wherein the non-common wart is a plantar wart.

133. 132. The method of claim 130 or 131, wherein the non-vulgar warts are genital warts.

134. 132. The method of claim 130 or 131, wherein the non-common wart is a facial wart.

135. 132. The method of claim 130 or 131, wherein the non-common wart is a flat wart.

136. 132. The method of claim 130 or 131, wherein the non-vulgar wart is a periungual wart.

137. 132. The method of claim 130 or 131, wherein the non-common wart is in the same anatomical region as the one or more common warts.

138. 132. The method of claim 130 or 131, wherein said complete disappearance is identified by observing that said non-vulgaris wart does not recur at the same site at least 20 weeks after administration of the first intralesional injection.

139. 132. The method of claim 130 or 131, wherein the administering is providing an intralesional injection to the subject.

140. 132. The method of claim 130 or 131, wherein the administering comprises providing two or more intralesional injections to the subject.

141. 141. The method of claim 140, wherein the two or more intralesional injections are provided to the subject over a period of time.

142. 142. The method of claim 141, wherein a pair of intralesional injections of the two or more intralesional injections are administered to the subject two weeks apart.

143. 142. The method of claim 141, wherein a pair of intralesional injections of the two or more intralesional injections are administered to the subject three weeks apart.

144. 142. The method of claim 141, wherein the two or more intralesional injections are administered to the subject over a period of 27 weeks.

145. 141. The method of claim 140, wherein each of the two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

146. 132. The method of claim 130 or 131, wherein the one or more common warts comprises between 3 and 20 common warts.

147. 132. The method of claim 130 or 131, further comprising identifying a largest common wart within the one or more common warts.

148. 148. The method of claim 147, wherein prior to said administration, said largest common wart measures between about 3 mm and about 20 mm.

149. 148. The method of claim 147, wherein said administering is providing an intralesional injection at the margins of the largest common wart.

150. 148. The method of claim 147, wherein the administration is providing an intralesional injection near the margins of the largest common wart.

151. 148. The method of claim 147, wherein said administering is providing an intralesional injection within said largest common wart.

152. 148. The method of claim 147, wherein said administering is providing two or more intralesional injections into said largest common wart.

153. 153. The method of claim 152, wherein each of the two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

154. 154. The method of claim 152 or 153, wherein the two or more intralesional injections are provided to the subject over a period of time.

155. 155. The method of claim 154, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about two weeks apart.

156. 155. The method of claim 154, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about three weeks apart.

157. 155. The method of claim 154, wherein the two or more intralesional injections are provided to the subject over a period of at least about 18 weeks.

158. 153. The method of claim 152, wherein the two or more intralesional injections are provided in subgroups of two or more intralesional injections over a period of time.

159. 159. The method of claim 158, wherein a subgroup within the two or more intralesional injection subgroups is provided with a total dose of at least 0.5 unit strength.

160. 160. The method of claim 158 or 159, wherein a pair of subgroups within said two or more intralesional injections are provided to said subject about two weeks apart.

161. 160. The method of claim 158 or 159, wherein a pair of subgroups within said two or more intralesional injections are provided to said subject about three weeks apart.

162. 160. The method of claim 158 or 159, wherein a subgroup of two or more intralesional injections is provided to the subject over a period of at least about 18 weeks.

163. 160. The method of claim 158 or 159, wherein a subgroup within said two or more subgroups comprises two intralesional injections around the largest common wart.

164. 160. The method of claim 158 or 159, wherein a subgroup within said two or more subgroups comprises three intralesional injections around the largest common wart.

165. 160. The method of claim 158 or 159, wherein a subgroup within said two or more subgroups comprises four intralesional injections around the largest common wart.

166. 160. The method of claim 158 or 159, wherein a subgroup within the two or more subgroups comprises five injections around the largest common wart.

167. 160. The method of claim 158 or 159, wherein a subgroup within said two or more subgroups comprises six intralesional injections around the largest common wart.

168. 168. The method of any one of claims 163 to 167, wherein the intralesional injections within the subgroup are approximately equally spaced around the margin of the largest common wart.

169. 168. The method of any one of claims 163-167, wherein the intralesional injections within the subgroup are approximately equally spaced about the margin of the largest common wart.

170. 168. The method of any one of claims 163-167, wherein said intralesional injections within said subgroups are administered approximately simultaneously.

171. 1. A method for treating a previously treated common wart in a subject in need of treatment comprising administering to said subject one or more intralesional injections of a pharmaceutical composition in an amount effective for complete disappearance of said previously treated common wart, at a cumulative dose of 5 unit strength, said pharmaceutical composition comprising a filtered extract of Candida albicans and a secretor antigen.

172. 1. A method for treating a previously treated common wart in a subject in need of treatment comprising administering to said subject one or more intralesional injections of a pharmaceutical composition in an amount sufficient to effect complete clearance of said previously treated common wart at a cumulative dose of 5 unit strength, said pharmaceutical composition comprising a filtered extract of Candida albicans and a secretory antigen.

173. 173. The method of claim 171 or 172, wherein the previously treated common wart is a common wart previously treated with cryotherapy.

174. 174. The method of claim 173, wherein the previously treated common wart did not respond to the cryotherapy.

175. 174. The method of claim 173, wherein the cryotherapy did not result in complete disappearance of the previously treated common warts.

176. 173. The method of claim 171 or 172, wherein the previously treated common wart is a common wart previously treated with salicylic acid or a related acid.

177. 177. The method of claim 176, wherein the related acid is trichloroacetic acid or bichloroacetic acid.

178. 177. The method of claim 176, wherein the previously treated common wart did not respond to the salicylic acid or related acid.

179. 177. The method of claim 176, wherein the salicylic acid or related acid did not completely eliminate the previously treated common warts.

180. 173. The method of claim 171 or 172, wherein the previously treated common wart is a common wart that has been previously treated with a treatment selected from the group consisting of liquid nitrogen, carbon dioxide, cantharidin, simple occlusion, wart gel, apple cider vinegar, surgery, laser, tea tree oil, freeze wart spray, wart curettage, electrodesiccation, essential oils of lavender and oregano, and imiquimod.

181. 181. The method of claim 180, wherein the previously treated common wart did not respond to the treatment.

182. 181. The method of claim 180, wherein the treatment did not result in complete disappearance of the previously treated common warts.

183. 183. The method of any one of claims 171-182, wherein prior to said administering, said previously treated common warts measure between about 3 mm and about 20 mm.

184. 183. The method of any one of claims 171-182, wherein said complete disappearance is identified by observing that said previously treated common wart does not recur at the same site at least 20 weeks after administration of the first intralesional injection.

185. 183. The method of any one of claims 171 to 182, wherein said complete disappearance is accompanied by the absence of scarring at the location of said previously treated common warts.

186. 183. The method of any one of claims 171 to 182, wherein said complete disappearance is accompanied by a low level of depigmentation at the location of said previously treated common warts.

187. 183. The method of any one of claims 171 to 182, wherein said administering is providing an intralesional injection to said subject.

188. 188. The method of claim 187, wherein said administration is providing an intralesional injection at the margins of said previously treated common wart.

189. 188. The method of claim 187, wherein the administration is providing an intralesional injection near the margins of the previously treated common wart.

190. 188. The method of claim 187, wherein said administration is providing an intralesional injection within said previously treated common wart.

191. 183. The method of any one of claims 171-182, wherein said administering comprises providing two or more intralesional injections to said subject.

192. 192. The method of claim 191, wherein each of the two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

193. 193. The method of claim 191 or 192, wherein the two or more intralesional injections are provided to the subject over a period of time.

194. 194. The method of claim 193, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about two weeks apart.

195. 194. The method of claim 193, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about three weeks apart.

196. 194. The method of claim 193, wherein the two or more intralesional injections are provided to the subject over a period of at least about 18 weeks.

197. 192. The method of claim 191, wherein the two or more intralesional injections are provided in subgroups of two or more intralesional injections over a period of time.

198. 200. The method of claim 197, wherein a subgroup within the two or more intralesional injection subgroups provides a total dose of at least 0.5 unit strength.

199. 200. The method of claim 197 or 198, wherein a pair of subgroups within said two or more intralesional injection subgroups is provided to said subject about two weeks apart.

200. 200. The method of claim 197 or 198, wherein a pair of subgroups of the two or more intralesional injections is provided to the subject about three weeks apart.

201. 200. The method of claim 197 or 198, wherein a subgroup of the two or more intralesional injections is provided to the subject over a period of at least about 18 weeks.

202. 200. The method of claim 197 or 198, wherein a subgroup within said two or more subgroups comprises two intralesional injections around said previously treated common wart.

203. 200. The method of claim 197 or 198, wherein a subgroup within said two or more subgroups comprises three intralesional injections around said previously treated common wart.

204. 200. The method of claim 197 or 198, wherein a subgroup within said two or more subgroups comprises four intralesional injections around said previously treated common wart.

205. 200. The method of claim 197 or 198, wherein a subgroup within the two or more subgroups comprises five injections around the previously treated common wart.

206. 200. The method of claim 197 or 198, wherein a subgroup within said two or more subgroups comprises six intralesional injections around said previously treated common wart.

207. 207. The method of any one of claims 202 to 206, wherein the intralesional injections within the subgroup are approximately equally spaced around the margins of the previously treated common wart.

208. 207. The method of any one of claims 202-206, wherein the intralesional injections within the subgroup are approximately equally spaced about the margins of the previously treated common wart.

209. 207. The method of any one of claims 202-206, wherein said intralesional injections within said subgroups are administered approximately simultaneously.

210. 1. A method for delaying the recurrence of common warts in a subject in need thereof, comprising administering to said subject one or more intralesional injections of a pharmaceutical composition at the time of disappearance of said common warts in an amount effective to delay the reappearance of said common warts, at a cumulative dose of 2.5 unit potency, said pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens.

211. 1. A method for delaying the recurrence of common warts in a subject in need thereof, comprising administering to said subject one or more intralesional injections of a pharmaceutical composition at the time of disappearance of said common warts, in a cumulative dose of 2.5 unit potency, in an amount capable of delaying the reappearance of said common warts, said pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens.

212. 212. The method of claim 210 or 211, wherein the subject does not develop any new common warts within at least 16 weeks following the last of the one or more intralesional injections.

213. 212. The method of claim 210 or 211, wherein the subject does not develop any new common warts within the same anatomical region of the common wart.

214. 212. The method of claim 210 or 211, wherein the subject does not develop any new common warts within the same site of the common wart.

215. 212. The method of claim 210 or 211, wherein prior to said administration, said common wart is between about 3 mm and about 20 mm in size.

216. 212. The method of claim 210 or 211, wherein the administering is providing an intralesional injection to the subject.

217. 217. The method of claim 216, wherein the administration is providing an intralesional injection at the margins of the common wart.

218. 217. The method of claim 216, wherein the administration is providing an intralesional injection near the margins of the common wart.

219. 217. The method of claim 216, wherein the administration is providing an intralesional injection within the common wart.

220. 212. The method of claim 210 or 211, wherein the administering is providing two or more intralesional injections to the subject.

221. 221. The method of claim 220, wherein each of the two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

222. 222. The method of claim 220 or 221, wherein the two or more intralesional injections are provided to the subject over a period of time.

223. 223. The method of claim 222, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about two weeks apart.

224. 223. The method of claim 222, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about three weeks apart.

225. 223. The method of claim 222, wherein the two or more intralesional injections are provided to the subject over a period of at least about eight weeks.

226. 221. The method of claim 220, wherein the two or more intralesional injections are provided in subgroups of two or more intralesional injections over a period of time.

227. 227. The method of claim 226, wherein a subgroup within the two or more intralesional injection subgroups provides a total dose of at least 0.5 unit strength.

228. 228. The method of claim 226 or 227, wherein a pair of subgroups within the two or more intralesional injection subgroups is provided to the subject about two weeks apart.

229. 228. The method of claim 226 or 227, wherein a pair of subgroups within the two or more intralesional injection subgroups is provided to the subject about three weeks apart.

230. 228. The method of claim 226 or 227, wherein a subgroup of the two or more intralesional injections is provided to the subject over a period of at least about eight weeks.

231. 228. The method of claim 226 or 227, wherein a subgroup within said two or more subgroups comprises two intralesional injections around said common wart.

232. 228. The method of claim 226 or 227, wherein a subgroup within said two or more subgroups comprises three intralesional injections around said common wart.

233. 228. The method of claim 226 or 227, wherein a subgroup within said two or more subgroups comprises four intralesional injections around said common wart.

234. 228. The method of claim 226 or 227, wherein a subgroup within the two or more subgroups comprises five injections around the common wart.

235. 228. The method of claim 226 or 227, wherein a subgroup within said two or more subgroups comprises six intralesional injections around said common wart.

236. 236. The method of any one of claims 231 to 235, wherein the intralesional injections within the subgroups are approximately equally spaced around the margin of the common wart.

237. 236. The method of any one of claims 231 to 235, wherein the intralesional injections within the subgroups are approximately equally spaced about the margin of the common wart.

238. 236. The method of any one of claims 231-235, wherein said intralesional injections within said subgroups are administered approximately simultaneously.

239. The method of any one of claims 1 to 238, wherein the pharmaceutical composition comprises at least 80% mannose.

240. The method of any one of claims 1 to 239, wherein the pharmaceutical composition comprises at least 8% glucose.

241. The method of any one of claims 1 to 240, wherein the pharmaceutical composition comprises at least 1% galactose.

242. The method of any one of claims 1 to 240, wherein the antigen has a molecular weight of about 167 kilodaltons.

243. 242. The method of any one of claims 1-241, wherein the subject is between 18 and 65 years of age.

244. 244. The method of any one of claims 1-243, wherein the subject was diagnosed with a first common wart at least 12 weeks prior to receiving the one or more intralesional injections.

245. The method of any one of claims 1 to 244, wherein the subject has not been diagnosed with refractory warts.

246. The method of any one of claims 1-245, wherein the subject has a baseline result of between 5mm and 25mm on a delayed type hypersensitivity test.

247. The method of any one of claims 1 to 246, wherein the subject has not been diagnosed with a systemic disease that impairs immune function.

248. The method of any one of claims 1-246, wherein the subject has not been diagnosed with a localized disease that impairs immune function.

249. The method of any one of claims 1-246, wherein the subject has not been diagnosed with a systemic condition that impairs immune function.

250. The method of any one of claims 1-246, wherein the subject has not been diagnosed with a localized condition that impairs immune function.

251. The method of any one of claims 1-246, wherein the subject has not been diagnosed with psoriasis.

252. The method of any one of claims 1-251, wherein the subject is not undergoing a treatment that results in an immunocompromised state.

253. The method of any one of claims 1 to 252, wherein the subject has not been diagnosed with diabetes.

254. The method of any one of claims 1 to 253, wherein the subject has no history of keloid formation.

255. 255. The method of any one of claims 1-254, wherein the subject does not have a pre-existing dermatological condition in the same anatomical region as the wart being treated.

256. The method of any one of claims 1 to 255, wherein the subject does not have an underlying inflammatory condition.

257. 257. The method of claim 256, wherein the underlying inflammatory condition is an arthritic joint.

258. The method of any one of claims 1 to 257, wherein the subject has not received one or more treatments selected from the group consisting of liquid nitrogen, carbon dioxide, electrodesiccation, laser, surgery, simple occlusion, salicylic acid, trichloroacetic acid, bichloroacetic acid, over-the-counter medications, and cantharidin within four weeks prior to said administering.

259. The method of any one of claims 1-258, wherein the subject has not received one or more immunotherapies selected from the group consisting of diphenylcyclopropenone (DPCP), dinitrochlorobenzene (DNCB), imiquimod, 5-fluorouracil, bleomycin, and podophyllin within 12 weeks prior to said administering.

260. The method of any one of claims 1 to 259, wherein the subject has not received, within 12 weeks prior to said administering, one or more systemic therapies selected from the group consisting of cimetidine, zinc supplements at doses greater than 20 mg elemental zinc per day, azathioprine, 6-mercaptopurine, methotrexate, infliximab, adalimumab, etanercept, and steroids.

261. The method of any one of claims 1-260, wherein the subject has not received any investigational drug within 30 days prior to said administering.

262. 261. The method of any one of claims 1-260, wherein the subject has not received any investigational agent within 5 half-lives of the investigational agent prior to said administration.

263. A pharmaceutical product comprising a filtered extract of Candida albicans and secretory antigens, formulated to effect complete eradication of common warts at a cumulative dose of 2.5 unit strength.

264. A pharmaceutical product comprising a filtered extract of Candida albicans and secretory antigens, formulated to partially clear common warts at a cumulative dose of 5 unit strength.

265. A pharmaceutical comprising a filtered extract of Candida albicans and secretory antigens, formulated to reduce the diameter of common warts by at least 50% at a cumulative dose of one unit strength.

266. A pharmaceutical product comprising a filtered extract of Candida albicans and secretory antigens, formulated to partially clear multiple common warts at a cumulative dose of 5 unit strength.

267. A pharmaceutical product comprising a filtered extract of Candida albicans and secretory antigens, formulated to reduce the diameter of multiple common warts by at least 50% at a cumulative dose of one unit strength.

268. A pharmaceutical product comprising a filtered extract of Candida albicans and secretory antigens, formulated to effect complete eradication of non-common warts at a cumulative dose of 5 unit strength.

269. A pharmaceutical product comprising a filtered extract of Candida albicans and secretory antigens, formulated to cause complete disappearance of previously treated common warts at a cumulative dose of 5 unit strength.

270. 1. A pharmaceutical product comprising a filtered extract of Candida albicans and secretory antigens, formulated to delay the reappearance of common warts upon their disappearance at a cumulative dose of 2.5 unit strength.

271. 271. The pharmaceutical product of any one of claims 263 to 270, wherein the pharmaceutical product comprises at least 80% mannose.

272. 271. The pharmaceutical product of any one of claims 263 to 270, wherein the pharmaceutical product comprises at least 8% glucose.

273. 271. The pharmaceutical product of any one of claims 263 to 270, wherein the pharmaceutical product comprises at least 1% galactose.

274. 271. The pharmaceutical product of any one of claims 263 to 270, wherein the antigen has a molecular weight of about 167 kilodaltons.

275. 275. The pharmaceutical product of any one of claims 263 to 274, wherein the pharmaceutical product is formulated in a vial.

276. The pharmaceutical product of claim 275, wherein the vial is a multi-dose storage vial.

277. The pharmaceutical product of claim 275, wherein the vial is a single-dose, non-retention vial.

278. The pharmaceutical product of claim 275, wherein the vial is a glass vial.

279. The pharmaceutical product of claim 278, wherein the glass vial is a 2 mL vial.

280. 274. The pharmaceutical product of any one of claims 263 to 273, wherein the pharmaceutical product is formulated in a pre-filled syringe.

281. The pharmaceutical product of claim 280, wherein the prefilled syringe has a volume of 0.5 mL.

282. 1. A method for reducing the level of IL-23 in a subject diagnosed with common warts, comprising administering to the subject one or more intralesional injections of a quantity of a pharmaceutical composition at a cumulative dose of one unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens.

283. The method of claim 282, wherein the level of IL-23 in the subject upon receiving said cumulative doses is reduced by at least about 15% compared to the level of IL-23 measured in the subject prior to said administration.

284. 1. A method for completely eliminating common warts in a subject in need thereof, comprising reducing the level of IL-23 by at least about 35% in a subject in need thereof.

285. The method of claim 284, wherein the reduction is achieved by administering to the subject one or more intralesional injections of a quantity of a pharmaceutical composition at a cumulative dose of 3 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens.

286. 285. The method of claim 284, wherein said complete disappearance is identified by observing that said common wart does not recur at the same site at least 20 weeks after said reduction.

287. 1. A method for reducing the level of IL-7 in a subject diagnosed with common warts, comprising administering to the subject one or more intralesional injections of a quantity of a pharmaceutical composition at a cumulative dose of 0.6 unit potency, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens.

288. The method of claim 287, wherein upon receiving said cumulative doses, the level of IL-7 in the subject is reduced by at least about 10% compared to the level of IL-7 measured in the subject prior to said administering.

289. 1. A method for reducing the level of IL-7 in a subject diagnosed with common warts, comprising administering to the subject one or more intralesional injections of an amount of a pharmaceutical composition at a cumulative dose of 3 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens.

290. The method of claim 289, wherein upon receiving said cumulative doses, the level of IL-7 in the subject is reduced by at least about 20% compared to the level of IL-7 measured in the subject prior to said administering.

291. 1. A method for reducing the level of IP-10 in a subject diagnosed with common warts, comprising administering to the subject one or more intralesional injections of a quantity of a pharmaceutical composition at a cumulative dose of 3 unit strength, the pharmaceutical composition comprising a filtered extract of Candida albicans and secretory antigens.

292. The method of claim 291, wherein the level of IP-10 in the subject upon receiving the cumulative dose is reduced by at least about 5% compared to the level of IP-10 measured in the subject prior to said administering.

293. 30. The method of any one of claims 282, 283, and 285-292, wherein said administering is providing an intralesional injection to said subject.

294. 294. The method of claim 293, wherein the administration is providing an intralesional injection near the margins of the common wart.

295. 294. The method of claim 293, wherein the administration is providing an intralesional injection at the margins of the common wart.

296. 294. The method of claim 293, wherein the administration is providing an intralesional injection within the common wart.

297. 30. The method of any one of claims 282, 283, and 285-292, wherein said administering comprises providing two or more intralesional injections to said subject.

298. 300. The method of claim 297, wherein each of the two or more intralesional injections is provided in a dose of at least 0.5 unit strength.

299. 30. The method of any one of claims 282, 283, 285-292, wherein the two or more intralesional injections are administered to the subject over a period of time.

300. 300. The method of claim 299, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about two weeks apart.

301. 300. The method of claim 299, wherein a pair of intralesional injections of the two or more intralesional injections is provided to the subject about three weeks apart.

302. 300. The method of claim 299, wherein the two or more intralesional injections are provided to the subject over a period of at least about eight weeks.

303. 300. The method of claim 297, wherein the two or more intralesional injections are provided in subgroups of two or more intralesional injections over a period of time.

304. The method of claim 303, wherein a subgroup within the two or more intralesional injection subgroups provides a total dose of at least 0.5 unit strength.

305. 305. The method of claim 303 or 304, wherein a pair of subgroups within said two or more intralesional injection subgroups is provided to said subject about two weeks apart.

306. 305. The method of claim 303 or 304, wherein a pair of subgroups within said two or more intralesional injection subgroups is provided to said subject about three weeks apart.

307. 305. The method of claim 303 or 304, wherein a subgroup of the two or more intralesional injections is provided to the subject over a period of at least about eight weeks.

308. 305. The method of claim 303 or 304, wherein a subgroup within said two or more subgroups comprises two intralesional injections around said common wart.

309. 305. The method of claim 303 or 304, wherein a subgroup within said two or more subgroups comprises three intralesional injections around said common wart.

310. 305. The method of claim 303 or 304, wherein a subgroup within said two or more subgroups comprises four intralesional injections around said common wart.

311. 305. The method of claim 303 or 304, wherein a subgroup within the two or more subgroups comprises five injections around the common wart.

312. 305. The method of claim 303 or 304, wherein a subgroup within said two or more subgroups comprises six intralesional injections around said common wart.

313. 313. The method of any one of claims 308-312, wherein the intralesional injections within the subgroups are approximately equally spaced about the margin of the common wart.

314. 313. The method of any one of claims 308 to 312, wherein the intralesional injections within the subgroups are approximately equally spaced around the margin of the common wart.

315. 313. The method of any one of claims 308-312, wherein said intralesional injections within said subgroups are administered approximately simultaneously.

316. The method of any one of claims 1 to 262 and 282 to 315, wherein the pharmaceutical composition comprises a filtered extract of two strains and secretory antigens of Candida albicans.

317. 317. The method of claim 316, wherein a representative sample of a first of said two strains of Candida albicans has been deposited with the ATCC under ATCC Accession No. PTA-126019.

318. 317. The method of claim 316, wherein a representative sample of a first of said two strains of Candida albicans has been deposited with the ATCC under ATCC Accession No. ATCC-10231.

319. The method of any one of claims 316-318, wherein a representative sample of the second of said two strains of Candida albicans has been deposited with the ATCC under ATCC Accession No. PTA-126020.

320. 282. The pharmaceutical product of any one of claims 263 to 281, wherein the filtered extract of Candida albicans comprises two strains of Candida albicans.

321. The method of claim 320, wherein a representative sample of the first of said two strains of Candida albicans has been deposited with the ATCC under ATCC Accession No. PTA-126019.

322. The method of claim 320, wherein a representative sample of the first of said two strains of Candida albicans has been deposited with the ATCC under ATCC Accession No. ATCC-10231.

323. The pharmaceutical product of any one of claims 320-322, wherein a representative sample of the second of said two strains of Candida albicans has been deposited with the ATCC under ATCC Accession No. PTA-126020.

Citation Information

Patent Citations

  • human papillomavirus therapeutic vaccine

    JP2016538333A